Document and Entity Information
Document and Entity Information - USD ($) | 12 Months Ended | ||
Jan. 03, 2016 | Feb. 25, 2016 | Jun. 26, 2015 | |
Document and Entity Information [Abstract] | |||
Document Type | 10-K | ||
Amendment Flag | false | ||
Document Fiscal Year Focus | 2,015 | ||
Document Fiscal Period Focus | FY | ||
Entity Registrant Name | PERKINELMER INC | ||
Entity Central Index Key | 31,791 | ||
Current Fiscal Year End Date | --01-03 | ||
Document Period End Date | Jan. 3, 2016 | ||
Entity Filer Category | Large Accelerated Filer | ||
Entity Common Stock, Shares Outstanding | 109,789,094 | ||
Entity Well-known Seasoned Issuer | Yes | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Public Float | $ 6,101,934,638 |
Consolidated Statements of Oper
Consolidated Statements of Operations - USD ($) $ in Thousands | 12 Months Ended | ||
Jan. 03, 2016 | Dec. 28, 2014 | Dec. 29, 2013 | |
Revenue | |||
Product revenue | $ 1,552,638 | $ 1,540,075 | $ 1,498,070 |
Service revenue | 709,721 | 697,144 | 659,516 |
Total revenue | 2,262,359 | 2,237,219 | 2,157,586 |
Cost of product revenue | 793,728 | 805,345 | 783,584 |
Cost of service revenue | 444,131 | 427,266 | 397,860 |
Selling, general and administrative expenses | 598,848 | 659,335 | 581,898 |
Research and development expenses | 125,928 | 121,141 | 132,400 |
Restructuring and contract termination charges, net | 13,590 | 13,390 | 33,892 |
Asset impairment | 0 | 0 | 158 |
Operating income from continuing operations | 286,134 | 210,742 | 227,794 |
Interest and other expense, net | 42,119 | 41,139 | 64,110 |
Income from continuing operations before income taxes | 244,015 | 169,603 | 163,684 |
Provision for (benefit from) income taxes | 31,327 | 8,437 | (10,583) |
Income from continuing operations | 212,688 | 161,166 | 174,267 |
Loss from discontinued operations before income taxes | (3) | (4,959) | (10,352) |
Loss on disposition of discontinued operations before income taxes | (28) | (260) | (1,810) |
Provision for (benefit from) income taxes on discontinued operations and dispositions | 232 | (1,831) | (5,107) |
Loss on discontinued operations and dispositions | (263) | (3,388) | (7,055) |
Net income | $ 212,425 | $ 157,778 | $ 167,212 |
Basic earnings per share: | |||
Income from continuing operations | $ 1.89 | $ 1.43 | $ 1.55 |
Loss on discontinued operations and dispositions | 0 | (0.03) | (0.06) |
Net income | 1.89 | 1.40 | 1.49 |
Diluted earnings per share: | |||
Income from continuing operations | 1.88 | 1.42 | 1.54 |
Loss on discontinued operations and dispositions | 0 | (0.03) | (0.06) |
Net income | $ 1.87 | $ 1.39 | $ 1.47 |
Consolidated Statements of Comp
Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands | 12 Months Ended | ||
Jan. 03, 2016 | Dec. 28, 2014 | Dec. 29, 2013 | |
Net income | $ 212,425 | $ 157,778 | $ 167,212 |
Other comprehensive income (loss) | |||
Foreign currency translation adjustments | (70,178) | (52,951) | 8,756 |
Unrecognized prior service costs, net of tax | (316) | 146 | (658) |
Reclassification adjustments for losses on derivatives included in net income, net of tax | 0 | 0 | 2,892 |
Unrealized (losses) gains on securities, net of tax | (262) | 14 | 8 |
Other comprehensive (loss) income | (70,756) | (52,791) | 10,998 |
Comprehensive income | $ 141,669 | $ 104,987 | $ 178,210 |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Thousands | Jan. 03, 2016 | Dec. 28, 2014 |
Current assets: | ||
Cash and cash equivalents | $ 237,932 | $ 174,821 |
Accounts receivable, net | 439,015 | 470,563 |
Inventories | 288,028 | 285,457 |
Other current assets | 68,186 | 137,710 |
Total current assets | 1,033,161 | 1,068,551 |
Property, plant and equipment, net | 167,029 | 176,194 |
Marketable securities and investments | 1,586 | 1,568 |
Intangible assets, net | 490,811 | 490,265 |
Goodwill | 2,276,149 | 2,284,077 |
Other assets, net | 197,559 | 106,921 |
Total assets | 4,166,295 | 4,127,576 |
Current liabilities: | ||
Current portion of long-term debt | 1,123 | 1,075 |
Accounts payable | 152,726 | 173,953 |
Accrued restructuring and contract termination costs | 17,090 | 17,124 |
Accrued expenses and other current liabilities | 388,446 | 403,021 |
Current liabilities of discontinued operations | 2,100 | 2,137 |
Total current liabilities | 561,485 | 597,310 |
Long-term debt | 1,011,762 | 1,045,393 |
Long-term liabilities | 482,607 | 442,771 |
Total liabilities | $ 2,055,854 | $ 2,085,474 |
Commitments and contingencies (see Notes 13 and 16) | ||
Stockholders' equity: | ||
Preferred stock—$1 par value per share, authorized 1,000,000 shares; none issued or outstanding | $ 0 | $ 0 |
Common stock—$1 par value per share, authorized 300,000,000 shares; issued and outstanding 112,034,000 and 112,481,000 shares at January 3, 2016 and December 28, 2014, respectively | 112,034 | 112,481 |
Capital in excess of par value | 52,932 | 94,276 |
Retained earnings | 1,991,431 | 1,810,545 |
Accumulated other comprehensive income | (45,956) | 24,800 |
Total stockholders' equity | 2,110,441 | 2,042,102 |
Total liabilities and stockholders' equity | $ 4,166,295 | $ 4,127,576 |
Consolidated Balance Sheet Pare
Consolidated Balance Sheet Parenthetical - $ / shares | Jan. 03, 2016 | Dec. 28, 2014 |
Balance Sheet Parenthetical [Abstract] | ||
Preferred stock, par value | $ 1 | $ 1 |
Preferred stock, authorized | 1,000,000 | 1,000,000 |
Preferred stock, issued | 0 | 0 |
Preferred stock, outstanding | 0 | 0 |
Common stock, par value | $ 1 | $ 1 |
Common stock, authorized | 300,000,000 | 300,000,000 |
Common stock, issued | 112,034,000 | 112,481,000 |
Common stock, outstanding | 112,034,000 | 112,481,000 |
Consolidated Statements of Stoc
Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands | Total | Common Stock Amount [Member] | Capital In Excess of Par Value [Member] | Retained Earnings [Member] | Accumulated Other Comprehensive Income (Loss) [Member] |
Beginning Balance at Dec. 30, 2012 | $ 1,939,812 | $ 115,036 | $ 209,610 | $ 1,548,573 | $ 66,593 |
Net income | 167,212 | 167,212 | |||
Other comprehensive income (loss) | 10,998 | 10,998 | |||
Dividends | (31,421) | (31,421) | |||
Exercise of employee stock options and related income tax benefits | 19,842 | 947 | 18,895 | ||
Issuance of common stock for employee benefit plans | 2,732 | 90 | 2,642 | ||
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations | 127,398 | 3,728 | 123,670 | ||
Issuance of common stock for long-term incentive program | 8,257 | 281 | 7,976 | ||
Stock compensation | 4,453 | 0 | 4,453 | 0 | 0 |
Ending Balance at Dec. 29, 2013 | 1,994,487 | 112,626 | 119,906 | 1,684,364 | 77,591 |
Net income | 157,778 | 157,778 | |||
Other comprehensive income (loss) | (52,791) | (52,791) | |||
Dividends | (31,597) | (31,597) | 0 | ||
Exercise of employee stock options and related income tax benefits | 24,455 | 1,024 | 23,431 | ||
Issuance of common stock for employee benefit plans | 2,539 | 61 | 2,478 | ||
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations | 65,529 | 1,448 | 64,081 | ||
Issuance of common stock for long-term incentive program | 7,880 | 218 | 7,662 | ||
Stock compensation | 4,880 | 0 | 4,880 | 0 | 0 |
Ending Balance at Dec. 28, 2014 | 2,042,102 | 112,481 | 94,276 | 1,810,545 | 24,800 |
Net income | 212,425 | 212,425 | |||
Other comprehensive income (loss) | (70,756) | (70,756) | |||
Dividends | (31,539) | (31,539) | |||
Exercise of employee stock options and related income tax benefits | 17,340 | 849 | 16,491 | ||
Issuance of common stock for employee benefit plans | 3,686 | 78 | 3,608 | ||
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations | 76,439 | 1,595 | 74,844 | ||
Issuance of common stock for long-term incentive program | 9,319 | 221 | 9,098 | ||
Stock compensation | 4,303 | 0 | 4,303 | 0 | 0 |
Ending Balance at Jan. 03, 2016 | $ 2,110,441 | $ 112,034 | $ 52,932 | $ 1,991,431 | $ (45,956) |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 12 Months Ended | ||
Jan. 03, 2016 | Dec. 28, 2014 | Dec. 29, 2013 | |
Operating activities: | |||
Net income | $ 212,425 | $ 157,778 | $ 167,212 |
Loss from discontinued operations and dispositions, net of income taxes | 263 | 3,388 | 7,055 |
Income from continuing operations | 212,688 | 161,166 | 174,267 |
Adjustments to reconcile net income from continuing operations to net cash provided by continuing operations: | |||
Restructuring and contract termination charges, net | 13,590 | 13,390 | 33,892 |
Depreciation and amortization | 112,007 | 116,736 | 126,879 |
Stock-based compensation | 17,719 | 14,464 | 14,053 |
Pension and other postretirement expense (income) | 9,420 | 77,669 | (18,176) |
Deferred taxes | (6,571) | (33,351) | (29,907) |
Contingencies and prior year tax matters | (5,342) | (7,605) | (34,455) |
Amortization of deferred debt issuance costs, interest rate hedge and accretion of discounts | 1,496 | 1,434 | 6,502 |
Losses (gains) on dispositions, net | 0 | 108 | (1,566) |
Amortization of acquired inventory revaluation | 7,275 | 2,425 | 203 |
Asset impairment | 0 | 0 | 158 |
Excess tax benefit from exercise of common stock options | (2,435) | 0 | 0 |
Changes in assets and liabilities which (used) provided cash, excluding effects from companies purchased and divested: | |||
Accounts receivable, net | 6,760 | (16,989) | (14,071) |
Inventories, net | (28,700) | (24,642) | (14,171) |
Accounts payable | (16,082) | 8,103 | (1,083) |
Accrued expenses and other | (34,244) | (30,640) | (85,277) |
Net cash provided by operating activities of continuing operations | 287,581 | 282,268 | 157,248 |
Net cash (used in) provided by operating activities of discontinued operations | (483) | (671) | 1,343 |
Net cash provided by operating activities | 287,098 | 281,597 | 158,591 |
Investing activities: | |||
Capital expenditures | (29,632) | (29,072) | (38,981) |
Proceeds from dispositions of property, plant and equipment, net | 0 | 2,531 | 52,202 |
Changes in restricted cash balances | 59 | 0 | 0 |
Proceeds from surrender of life insurance policies | 757 | 490 | 783 |
Activity related to acquisitions and investments, net of cash and cash equivalents acquired | (72,040) | (271,477) | (15,699) |
Net cash used in investing activities of continuing operations | (100,856) | (297,528) | (1,695) |
Net cash provided by investing activities of discontinued operations | 0 | 1,631 | 484 |
Net cash used in investing activities | (100,856) | (295,897) | (1,211) |
Financing activities: | |||
Payments on revolving credit facility | (485,000) | (356,000) | (538,000) |
Proceeds from revolving credit facility | 451,000 | 475,000 | 677,000 |
Prepayment of long-term debt | 0 | 0 | (150,000) |
Premium on prepayment of long-term debt | 0 | 0 | (11,119) |
Payments of debt financing costs | 0 | (1,845) | 0 |
Net (payments on) proceeds from other credit facilities | (1,072) | (12,675) | 5,281 |
Settlement of cash flow hedges | 18,706 | 0 | 1,363 |
Payments for acquisition-related contingent consideration | (103) | (855) | 0 |
Excess tax benefit from exercise of common stock options | 2,435 | 0 | 0 |
Proceeds from issuance of common stock under stock plans | 14,905 | 24,455 | 20,313 |
Purchases of common stock | (76,439) | (65,529) | (127,398) |
Dividends paid | (31,571) | (31,620) | (31,600) |
Net cash (used in) provided by financing activities | (107,139) | 30,931 | (154,160) |
Effect of exchange rate changes on cash and cash equivalents | (15,992) | (15,052) | (1,422) |
Net increase in cash and cash equivalents | 63,111 | 1,579 | 1,798 |
Cash and cash equivalents at beginning of year | 174,821 | 173,242 | 171,444 |
Cash and cash equivalents at end of year | 237,932 | 174,821 | 173,242 |
Supplemental disclosures of cash flow information | |||
Interest | 31,741 | 30,320 | 39,904 |
Income taxes | $ 49,275 | $ 40,638 | $ 36,675 |
Nature of Operations and Accoun
Nature of Operations and Accounting Policies | 12 Months Ended |
Jan. 03, 2016 | |
Accounting Policies [Abstract] | |
Nature of Operations and Accounting Policies | Nature of Operations and Accounting Policies Nature of Operations: PerkinElmer, Inc. is a leading provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. Through its advanced technologies, solutions and services, critical issues are addressed that help to improve the health and safety of people and their environment. The results are reported within two reporting segments: Human Health and Environmental Health. The consolidated financial statements include the accounts of PerkinElmer, Inc. and its subsidiaries (the “Company”). All intercompany balances and transactions have been eliminated in consolidation. The Company has two operating segments; Human Health and Environmental Health. The Company’s Human Health segment concentrates on developing diagnostics, tools and applications to help detect diseases earlier and more accurately and to accelerate the discovery and development of critical new therapies. Within the Human Health segment, the Company serves both the diagnostics and research markets. The Company’s Environmental Health segment provides products, services and solutions to facilitate the creation of safer food and consumer products, more secure surroundings and efficient energy resources. The Environmental Health segment serves the environmental, industrial and laboratory services markets. The Company realigned its organization at the beginning of fiscal year 2015. OneSource, the Company's multivendor laboratory service business that serves the life sciences end market, was moved from the Environmental Health segment into the Human Health segment. The results reported for fiscal year 2015 reflect this new alignment of the Company's operating segments. Financial information in this report relating to fiscal years 2014 and 2013 has been retrospectively adjusted to reflect this change to the Company's operating segments. The Company's fiscal year ends on the Sunday nearest December 31. The Company reports fiscal years under a 52/53 week format and as a result, certain fiscal years will contain 53 weeks. The fiscal year ended January 3, 2016 included 53 weeks. The additional week in fiscal year 2015 has been reflected in the Company's third quarter. Each of the fiscal years ended December 28, 2014 and December 29, 2013 included 52 weeks. The fiscal year ending January 1, 2017 will include 52 weeks. The Company has evaluated subsequent events from January 3, 2016 through the date of the issuance of these consolidated financial statements and has determined that other than the events the Company has disclosed within the notes to the consolidated financial statements, no material subsequent events have occurred that would affect the information presented in these consolidated financial statements. Accounting Policies and Estimates: The preparation of consolidated financial statements in accordance with United States (“U.S.”) Generally Accepted Accounting Principles (“GAAP”) requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. Revenue Recognition: The Company’s product revenue is recorded when persuasive evidence of an arrangement exists, delivery has occurred, the price to the buyer is fixed or determinable, and collectability is reasonably assured. For products that include installation, and if the installation meets the criteria to be considered a separate element, product revenue is recognized upon delivery, and installation revenue is recognized when the installation is complete. For revenue that includes customer-specified acceptance criteria, revenue is recognized after the acceptance criteria have been met. Certain of the Company’s products require specialized installation. Revenue for these products is deferred until installation is completed. Revenue from services is deferred and recognized over the contractual period, or as services are rendered. In limited circumstances, the Company has arrangements that include multiple elements that are delivered at different points of time, such as revenue from products and services with a remaining service or storage component, including cord blood processing and storage. For these arrangements, the revenue is allocated to each of the deliverables based upon their relative selling prices as determined by a selling-price hierarchy. A deliverable in an arrangement qualifies as a separate unit of accounting if the delivered item has value to the customer on a stand-alone basis. A delivered item that does not qualify as a separate unit of accounting is combined with the other undelivered items in the arrangement and revenue is recognized for those combined deliverables as a single unit of accounting. The selling price used for each deliverable is based upon vendor-specific objective evidence ("VSOE") if such evidence is available, third-party evidence ("TPE") if VSOE is not available, and management's best estimate of selling price ("BESP") if neither VSOE nor TPE are available. TPE is the price of the Company's or any competitor's largely interchangeable products or services in stand-alone sales to similarly-situated customers. BESP is the price at which the Company would sell the deliverable if it were sold regularly on a stand-alone basis, considering market conditions and entity-specific factors. Revenue from software licenses and services was 5% of the Company's total revenue for each of fiscal years 2015, 2014 and 2013 . The Company sells its software licenses with maintenance services and, in some cases, also with consulting services. For the undelivered elements, the Company determines VSOE of fair value to be the price charged when the undelivered element is sold separately. The Company determines VSOE for maintenance sold in connection with a software license based on the amount that will be separately charged for the maintenance renewal period. The Company determines VSOE for consulting services by reference to the amount charged for similar engagements when a software license sale is not involved. The Company recognizes revenue from software licenses sold together with maintenance and/or consulting services upon shipment using the residual method, provided that the above criteria have been met. If VSOE of fair value for the undelivered elements cannot be established, the Company defers all revenue from the arrangement until the earlier of the point at which such sufficient VSOE does exist or all elements of the arrangement have been delivered, or if the only undelivered element is maintenance, then the Company recognizes the entire fee ratably over the maintenance period. The Company recognizes revenue from the grant of certain intellectual property rights for patented technologies it owns. These rights typically include a combination of the following: the grant of a non-exclusive, retroactive and future license to patented technologies, a covenant-not-to-sue, the release of the licensee from certain claims, and the dismissal of any pending litigation. The intellectual property rights granted may be perpetual in nature, extending until the expiration of the related patents, or can be granted for a defined timeframe. For these arrangements, the revenue is allocated to each of the deliverables based upon their relative selling prices as determined by the selling-price hierarchy. In the case where the agreement includes the dismissal of any pending litigation, the Company allocates between revenue and litigation settlement using the residual method. The Company recognizes revenue when the earnings process is complete and upon the execution of the agreement, when collectability is reasonably assured, or upon receipt of the minimum upfront fee for term agreement renewals, and when all other revenue recognition criteria have been met. Service revenues represent the Company’s service offerings including service contracts, field service including related time and materials, diagnostic testing, cord blood processing and storage, and training. Service revenues are recognized as the service is performed. Revenues for service contracts and storage contracts are recognized over the contract period. The Company sells products and accessories predominantly through its direct sales force. As a result, the use of distributors is generally limited to geographic regions where the Company has no direct sales force. The Company does not offer product return or exchange rights (other than those relating to defective goods under warranty) or price protection allowances to its customers, including its distributors. Payment terms granted to distributors are the same as those granted to end-user customers and payments are not dependent upon the distributors’ receipt of payment from their end-user customers. Sales incentives related to distributor revenue are also the same as those for end-user customers. Warranty Costs : The Company provides for estimated warranty costs for products at the time of their sale. Warranty liabilities are estimated using expected future repair costs based on historical labor and material costs incurred during the warranty period. Shipping and Handling Costs: The Company reports shipping and handling revenue in revenue, to the extent they are billed to customers, and the associated costs in cost of product revenue. Inventories : Inventories, which include material, labor and manufacturing overhead, are valued at the lower of cost or market. Inventories are accounted for using the first-in, first-out method of determining inventory costs. Inventory quantities on-hand are regularly reviewed, and where necessary, provisions for excess and obsolete inventory are recorded based primarily on the Company’s estimated forecast of product demand and production requirements. Income Taxes: The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases. This method also requires the recognition of future tax benefits such as net operating loss carryforwards, to the extent that realization of such benefits is more likely than not. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the fiscal years in which those temporary differences are expected to be recovered or settled. A valuation allowance is established for any deferred tax asset for which realization is not more likely than not. With respect to earnings expected to be indefinitely reinvested offshore, the Company does not accrue tax for the repatriation of such foreign earnings. The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions and other issues. These reserves are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is more likely than not to be realized following resolution of any potential contingencies present related to the tax benefit. Potential interest and penalties associated with such uncertain tax positions is recorded as a component of income tax expense. See Note 6, below, for additional details. Property, Plant and Equipment: The Company depreciates property, plant and equipment using the straight-line method over its estimated useful lives, which generally fall within the following ranges: buildings- 10 to 40 years; leasehold improvements-estimated useful life or remaining term of lease, whichever is shorter; and machinery and equipment- 3 to 7 years. Certain tooling costs are capitalized and amortized over a 3 -year life, while repairs and maintenance costs are expensed. Asset Retirement Obligations : The Company records obligations associated with its lease obligations, the retirement of tangible long-lived assets and the associated asset retirement costs in accordance with authoritative guidance on asset retirement obligations. The Company reviews legal obligations associated with the retirement of long-lived assets that result from contractual obligations or the acquisition, construction, development and/or normal use of the assets. If it is determined that a legal obligation exists, regardless of whether the obligation is conditional on a future event, the fair value of the liability for an asset retirement obligation is recognized in the period in which it is incurred, if a reasonable estimate of fair value can be made. The fair value of the liability is added to the carrying amount of the associated asset, and this additional carrying amount is depreciated over the life of the asset. The difference between the gross expected future cash flow and its present value is accreted over the life of the related lease as interest expense. The amounts recorded in the consolidated financial statements are not material to any year presented. Pension and Other Postretirement Benefits: The Company sponsors both funded and unfunded U.S. and non-U.S. defined benefit pension plans and other postretirement benefits. The Company immediately recognizes actuarial gains and losses in operating results in the year in which the gains and losses occur. Actuarial gains and losses are measured annually as of the calendar month-end that is closest to the Company's fiscal year end and accordingly will be recorded in the fourth quarter, unless the Company is required to perform an interim remeasurement. The remaining components of pension expense, primarily service and interest costs and assumed return on plan assets, are recorded on a quarterly basis. The Company’s funding policy provides that payments to the U.S. pension trusts shall at least be equal to the minimum funding requirements of the Employee Retirement Income Security Act of 1974. Non-U.S. plans are accrued for, but generally not fully funded, and benefits are paid from operating funds. Translation of Foreign Currencies: For foreign operations, asset and liability accounts are translated at current exchange rates; income and expenses are translated using weighted average exchange rates for the reporting period. Resulting translation adjustments, as well as translation gains and losses from certain intercompany transactions considered permanent in nature, are reported in accumulated other comprehensive (loss) income, a separate component of stockholders’ equity. Gains and losses arising from transactions and translation of period-end balances denominated in currencies other than the functional currency are included in other expense, net. Business Combinations: Business combinations are accounted for at fair value. Acquisition costs are expensed as incurred and recorded in selling, general and administrative expenses; previously held equity interests are valued at fair value upon the acquisition of a controlling interest; in-process research and development (“IPR&D”) is recorded at fair value as an intangible asset at the acquisition date; restructuring costs associated with a business combination are expensed subsequent to the acquisition date; and changes in deferred tax asset valuation allowances and income tax uncertainties after the acquisition date affect income tax expense. Measurement period adjustments are made in the period in which the amounts are determined and the current period income effect of such adjustments will be calculated as if the adjustments had been completed as of the acquisition date. All changes that do not qualify as measurement period adjustments are also included in current period earnings. The accounting for business combinations requires estimates and judgment as to expectations for future cash flows of the acquired business, and the allocation of those cash flows to identifiable intangible assets, in determining the estimated fair value for assets acquired and liabilities assumed. The fair values assigned to tangible and intangible assets acquired and liabilities assumed, including contingent consideration, are based on management’s estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. If the actual results differ from the estimates and judgments used in these estimates, the amounts recorded in the financial statements could result in a possible impairment of the intangible assets and goodwill, require acceleration of the amortization expense of finite-lived intangible assets, or the recognition of additional consideration which would be expensed. Goodwill and Other Intangible Assets: The Company’s intangible assets consist of (i) goodwill, which is not being amortized; (ii) indefinite lived intangibles, which consist of a trade name that is not subject to amortization; and (iii) amortizing intangibles, which consist of patents, trade names and trademarks, licenses, customer relationships, and purchased technologies, which are being amortized over their estimated useful lives. The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of a two-step process. The first step is the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. The second step measures the amount of an impairment loss, and is only performed if the carrying value exceeds the fair value of the reporting unit. This annual impairment assessment is performed by the Company on the later of January 1 or the first day of each fiscal year. This same impairment test will be performed at other times during the course of the year, should an event occur which suggests that the recoverability of goodwill should be reconsidered. Non-amortizing intangibles are also subject to an annual impairment test. The impairment test consists of a comparison of the fair value of the non-amortizing intangible asset with its carrying amount. If the carrying amount of a non-amortizing intangible asset exceeds its fair value, an impairment loss in an amount equal to that excess is recognized . In addition, the Company evaluates the remaining useful life of its non-amortizing intangible assets at least annually to determine whether events or circumstances continue to support an indefinite useful life. If events or circumstances indicate that the useful lives of non-amortizing intangible assets are no longer indefinite, the assets will be tested for impairment. These intangible assets will then be amortized prospectively over their estimated remaining useful life and accounted for in the same manner as other intangible assets that are subject to amortization. Recoverability of amortizing intangible assets is assessed only when events have occurred that may give rise to impairment. When a potential impairment has been identified, forecasted undiscounted net cash flows of the operations to which the asset relates are compared to the current carrying value of the long-lived assets present in that operation. If such cash flows are less than such carrying amounts, long-lived assets, including such intangibles, are written down to their respective fair values. See Note 12, below, for additional details. Stock-Based Compensation: The Company accounts for stock-based compensation expense based on estimated grant date fair value, generally using the Black-Scholes option-pricing model. The fair value is recognized, net of estimated forfeitures, as expense in the consolidated financial statements over the requisite service period. The determination of fair value and the timing of expense using option pricing models such as the Black-Scholes model require the input of highly subjective assumptions, including the expected term and the expected price volatility of the underlying stock. The Company estimates the expected term assumption based on historical experience. In determining the Company’s expected stock price volatility assumption, the Company reviews both the historical and implied volatility of the Company’s common stock, with implied volatility based on the implied volatility of publicly traded options on the Company’s common stock. The Company has one stock-based compensation plan from which it makes grants, which is described more fully in Note 18, below. Marketable Securities and Investments: The cost of securities sold is based on the specific identification method. If securities are classified as available for sale, the Company records these investments at their fair values with unrealized gains and losses included in accumulated other comprehensive (loss) income. Under the cost method of accounting, equity investments in private companies are carried at cost and are adjusted for other-than-temporary declines in fair value, additional investments or distributions. Cash and Cash Equivalents: The Company considers all highly liquid unrestricted instruments with a purchased maturity of three months or less to be cash equivalents. The carrying amount of cash equivalents approximates fair value due to the short maturities of these instruments. Environmental Matters: The Company accrues for costs associated with the remediation of environmental pollution when it is probable that a liability has been incurred and the Company’s proportionate share of the amount can be reasonably estimated. The recorded liabilities have not been discounted. Research and Development: Research and development costs are expensed as incurred. The fair value of acquired IPR&D costs are recorded at fair value as an intangible asset at the acquisition date and amortized once the product is ready for sale or expensed if abandoned. Restructuring Charges: In recent fiscal years, the Company has undertaken a series of restructuring actions related to the impact of acquisitions and divestitures, the alignment of its operations with its growth strategy, the integration of its business units and productivity initiatives. In connection with these initiatives, the Company has recorded restructuring charges, as more fully described in Note 4, below. Generally, costs associated with an exit or disposal activity are recognized when the liability is incurred. Prior to recording restructuring charges for employee separation agreements, the Company notifies all employees of termination. Costs related to employee separation arrangements requiring future service beyond a specified minimum retention period are recognized over the service period. Costs related to lease terminations are recorded at the fair value of the liability based on the remaining lease rental payments, reduced by estimated sublease rentals that could be reasonably obtained for the property, at the date the Company ceases use. Comprehensive Income: Comprehensive income is defined as net income or loss and other changes in stockholders’ equity from transactions and other events from sources other than stockholders. Comprehensive income is reflected in the consolidated statements of comprehensive income. Derivative Instruments and Hedging: Derivatives are recorded on the consolidated balance sheets at fair value. Accounting for gains or losses resulting from changes in the values of those derivatives depends on the use of the derivative instrument and whether it qualifies for hedge accounting. For a cash flow hedge, the effective portion of the derivative’s gain or loss is initially reported as a component of other comprehensive income and subsequently amortized into net earnings when the hedged exposure affects net earnings. Cash flow hedges related to anticipated transactions are designated and documented at the inception of each hedge by matching the terms of the contract to the underlying transaction. The Company classifies the cash flows from hedging transactions in the same categories as the cash flows from the respective hedged items. Once established, cash flow hedges are generally recorded in other comprehensive income, unless an anticipated transaction is no longer likely to occur, and subsequently amortized into net earnings when the hedged exposure affects net earnings. Discontinued or dedesignated cash flow hedges are immediately settled with counterparties, and the related accumulated derivative gains or losses are recognized into net earnings on the consolidated financial statements. Settled cash flow hedges related to forecasted transactions that remain probable are recorded as a component of other comprehensive (loss) income and are subsequently amortized into net earnings when the hedged exposure affects net earnings. Forward contract effectiveness for cash flow hedges is calculated by comparing the fair value of the contract to the change in value of the anticipated transaction using forward rates on a monthly basis. The Company also has entered into other foreign currency forward contracts that are not designated as hedging instruments for accounting purposes. These contracts are recorded at fair value, with the changes in fair value recognized into interest and other expense, net on the consolidated financial statements. Recently Issued Accounting Pronouncements: From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (the "FASB") and are adopted by the Company as of the specified effective dates. Unless otherwise discussed, such pronouncements did not have or will not have a significant impact on the Company’s consolidated financial position, results of operations and cash flows or do not apply to the Company’s operations. In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases . The provisions of this guidance are effective for annual periods beginning after December 15, 2018, and interim periods within those years, with early adoption permitted. The Company is evaluating the requirements of this guidance and has not yet determined the impact of the adoption on its consolidated financial position, results of operations and cash flows. In November 2015, the FASB issued Accounting Standards Update No. 2015-17, Balance Sheet Classification of Deferred Taxes ("ASU No. 2015-17"). Under this new guidance, companies are required to present deferred tax assets and deferred tax liabilities, and any related valuation allowances, as noncurrent on the company's consolidated balance sheet. The provisions of this guidance can be applied prospectively or retrospectively and are effective for interim and annual periods beginning after December 15, 2016, with early adoption permitted. During fiscal year 2015, the Company early adopted the new guidance on a prospective basis and has presented all deferred tax assets and deferred tax liabilities as noncurrent in the consolidated balance sheet at January 3, 2016. If the Company elected to adopt the standard on a retrospective basis, current deferred tax assets of $62.0 million would have been classified as noncurrent at December 28, 2014 . In September 2015, the FASB issued Accounting Standards Update No. 2015-16, Simplifying the Accounting for Measurement-Period Adjustments ("ASU No. 2015-16"). Under this new guidance, an acquirer should recognize adjustments to provisional amounts for items in a business combination that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. The acquirer should record, in the same period’s financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting had been completed at the acquisition date. The provisions of this guidance are to be applied prospectively and are effective for interim and annual periods beginning after December 15, 2015, with early adoption permitted. During the third quarter of fiscal year 2015, the Company early adopted the new guidance and adjusted the provisional amounts recorded for acquisitions in which the purchase accounting allocations were preliminary. During fiscal year 2015, there was an immaterial impact on the current period net income as a result of the change to the provisional amounts for items that would have been recognized in previous periods if the adjustments to provisional amounts had been recognized as of the acquisition date. See Note 2, below, for additional details. In July 2015, the FASB issued Accounting Standards Update No. 2015-11, Simplifying the Measurement of Inventory . Under this new guidance, companies that use inventory measurement methods other than last-in, first-out or the retail inventory method should measure inventory at the lower of cost and net realizable value. The provisions of this guidance are to be applied prospectively and are effective for interim and annual periods beginning after December 15, 2016, with early adoption permitted. The Company is evaluating the requirements of this guidance. The adoption is not expected to have a material impact on the Company’s consolidated financial position, results of operations and cash flows. In April 2015, the FASB issued Accounting Standards Update No. 2015-04, Practical Expedient for the Measurement Date of an Employer’s Defined Benefit Obligation and Plan Assets . Under this new guidance, an entity with a fiscal year-end that does not coincide with a calendar month-end (for example an entity that has a 52/53 week fiscal year) has the ability, as a practical expedient, to measure its defined benefit retirement obligations and related plan assets as of the month-end that is closest to its fiscal year end. The provisions of this guidance should be applied prospectively. During fiscal year 2015, the Company early adopted the new guidance. The adoption did not have a material impact on the Company's consolidated financial position, results of operations or cash flows. In April 2015, the FASB issued Accounting Standards Update No. 2015-03, Interest - Imputation of Interest - Simplifying the Presentation of Debt Issuance Costs . Under this new guidance, debt issuance costs related to a recognized debt liability should be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The provisions of this guidance are to be applied retrospectively and are effective for interim and annual periods beginning after December 15, 2015, with early adoption permitted. The Company early adopted this guidance in the fourth quarter of fiscal year 2015. The consolidated balance sheet as of December 28, 2014, included in these consolidated financial statements, reflects a restatement to reclassify unamortized debt issuance costs of $6.5 million from other long-term assets to long-term debt. For debt issuance costs paid to secure revolving credit facilities, the Company made a policy election to present such costs as a direct deduction from the debt liability on the consolidated balance sheet. In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers . Under this new guidance, an entity should use a five-step process to recognize revenue, depicting the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard also requires new disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. Subsequent to the issuance of the standard, the FASB decided to defer the effective date for one year to annual periods beginning after December 15, 2017, with early adoption permitted for annual periods beginning after December 15, 2016. The standard may be adopted either using a full retrospective approach or a modified retrospective approach. The Company is evaluating the requirements of this guidance and has not yet determined the transition method to use or the i |
Business Combinations and Asset
Business Combinations and Asset Purchases | 12 Months Ended |
Jan. 03, 2016 | |
Business Combinations [Abstract] | |
Business Combinations and Asset Purchases | Business Combinations Acquisitions in fiscal year 2015 During fiscal year 2015, the Company completed the acquisition of five businesses for a total consideration of $77.1 million in cash. The acquired businesses included Vanadis Diagnostics AB (“Vanadis”), which was acquired for total consideration of $35.1 million in cash, as further described in Note 21 below, and other acquisitions for an aggregate consideration of $42.0 million in cash. The Company has a potential obligation to pay the shareholders of Vanadis additional contingent consideration of up to $93.0 million , which at closing had an estimated fair value of $56.9 million . The excess of the purchase prices over the fair values of each of the acquired businesses' net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforce acquired, and has been allocated to goodwill, of which $9.2 million is tax deductible. The Company has reported the operations for all of these acquisitions within the results of the Company’s Human Health and Environmental Health segments from the acquisition dates. Identifiable definite-lived intangible assets, such as core technology and trade names, acquired as part of this acquisition had weighted average amortization periods of 9 years . The total purchase price for the acquisitions in fiscal year 2015 has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: 2015 Acquisitions (Preliminary) (In thousands) Fair value of business combination: Cash payments $ 75,285 Contingent consideration 56,878 Working capital and other adjustments 1,832 Less: cash acquired (3,864 ) Total $ 130,131 Identifiable assets acquired and liabilities assumed: Current assets $ 2,551 Property, plant and equipment 998 Identifiable intangible assets: Core technology 15,759 Trade names 200 Licenses 116 Customer relationships 3,073 IPR&D 75,700 Goodwill 51,356 Deferred taxes (16,772 ) Liabilities assumed (2,850 ) Total $ 130,131 Acquisitions in fiscal year 2014 Acquisition of Perten Instruments Group AB. In December 2014, the Company acquired all of the outstanding stock of Perten Instruments Group AB ("Perten"). Perten is a provider of analytical instruments and services for quality control of food, grain, flour and feed. The Company expects this acquisition to enhance its industrial, environmental and safety business by expanding the Company's product offerings to the academic and industrial end markets. The Company paid the shareholders of Perten $269.9 million in cash for the stock of Perten. The excess of the purchase price over the fair value of the acquired net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforce acquired, and has been allocated to goodwill, none of which is tax deductible. The Company has reported the operations for this acquisition within the results of the Company’s Environmental Health segment from the acquisition date. Identifiable definite-lived intangible assets, such as core technology, customer relationships and trade names, acquired as part of this acquisition had weighted average amortization periods of approximately 5 to 10 years . Other acquisitions in fiscal year 2014. In addition to the Perten acquisition, the Company completed the acquisition of two businesses in fiscal year 2014 for total consideration of $17.6 million in cash and $4.3 million of assumed debt. The excess of the purchase price over the fair value of each of the acquired businesses' net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforce acquired, and has been allocated to goodwill, none of which is tax deductible. The Company reported the operations for these acquisitions within the results of the Human Health and Environmental Health segments from the acquisition dates. The total purchase price for the acquisitions in fiscal year 2014 has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: Perten 2014 Other Acquisitions (In thousands) Fair value of business combination: Cash payments $ 269,937 $ 17,898 Working capital and other adjustments — (294 ) Less: cash acquired (16,732 ) (124 ) Total $ 253,205 $ 17,480 Identifiable assets acquired and liabilities assumed: Current assets $ 32,578 $ 1,935 Property, plant and equipment 1,485 125 Other assets — 364 Identifiable intangible assets: Core technology 17,000 1,705 Trade names 8,000 — Customer relationships 87,000 6,800 IPR&D — 1,266 Goodwill 160,776 15,518 Deferred taxes (28,612 ) (3,072 ) Deferred revenue — (589 ) Liabilities assumed (17,422 ) (2,285 ) Debt assumed (7,600 ) (4,287 ) Total $ 253,205 $ 17,480 Acquisitions in fiscal year 2013 During fiscal year 2013, the Company completed the acquisition of four businesses for total consideration of $11.4 million , in cash. As of the closing dates, the Company potentially had to pay additional contingent consideration for the four acquired businesses of up to $2.2 million , which at closing had an estimated fair value of $1.1 million . During fiscal year 2014, the Company paid $0.4 million in additional deferred consideration for one of these acquisitions. The excess of the purchase price over the fair value of each of the acquired businesses' net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforce acquired, and has been allocated to goodwill, none of which is tax deductible. The Company reported the operations for these acquisitions within the results of the Human Health and Environmental Health segments from the acquisition dates. The Company does not consider the acquisitions completed during fiscal years 2015, 2014 and 2013 to be material to its consolidated results of operations; therefore, the Company is not presenting pro forma financial information of operations. During fiscal year 2015 , the Company recognized $65.7 million of revenue for Perten. The Company has determined that the presentation of the results of operations for each of the other acquisitions, from the date of acquisition, is impracticable due to the integration of the operations upon acquisition. As of January 3, 2016 , the allocations of purchase prices for acquisitions completed in fiscal years 2014 and 2013 were final. The preliminary allocations of the purchase prices for acquisitions completed in fiscal year 2015 were based upon initial valuations. The Company's estimates and assumptions underlying the initial valuations are subject to the collection of information necessary to complete its valuations within the measurement periods, which are up to one year from the respective acquisition dates. The primary areas of the preliminary purchase price allocations that are not yet finalized relate to the fair value of certain tangible and intangible assets acquired and liabilities assumed, assets and liabilities related to income taxes and related valuation allowances, and residual goodwill. The Company expects to continue to obtain information to assist in determining the fair values of the net assets acquired at the acquisition dates during the measurement periods. During the measurement periods, the Company will adjust assets or liabilities if new information is obtained about facts and circumstances that existed as of the acquisition dates that, if known, would have resulted in the recognition of those assets and liabilities as of those dates. With the Company's adoption of ASU No. 2015-16 during fiscal year 2015, these adjustments will be made in the periods in which the amounts are determined and the cumulative effect of such adjustments will be calculated as if the adjustments had been completed as of the acquisition dates. The portion of the adjustment which relates to a prior period should either be presented separately on the consolidated statement of operations or disclosed in the notes to the consolidated financial statements. All changes that do not qualify as adjustments made during the measurement periods are also included in current period earnings. During fiscal year 2015 , the Company obtained information to assist in determining the fair values of certain tangible and intangible assets acquired and liabilities assumed as part of its acquisitions and adjusted its purchase price allocations. Based on this information, for acquisitions completed during fiscal year 2015, the Company recognized a decrease in deferred taxes of $0.5 million , with a corresponding decrease in goodwill. For the Perten acquisition, the Company recognized increases in intangible assets of $2.0 million and liabilities assumed of $1.2 million , which were offset by a decrease in goodwill of $3.4 million , deferred taxes of $2.8 million , and other current assets of $0.2 million . For other acquisitions completed during fiscal year 2014, the Company recognized a decrease in working capital and other adjustments of $0.5 million with a corresponding decrease in goodwill. In addition, during the third quarter of fiscal year 2015 , in connection with updating the provisional purchase accounting for the Perten acquisition, the Company adjusted goodwill and intangible assets which had been preliminarily recorded in U.S. dollars to Swedish Krona. This resulted in a decrease in intangible assets and goodwill of $21.4 million and a corresponding increase in other comprehensive loss through increased foreign currency translation adjustments as a result of the change in the exchange rate between the acquisition date and June 28, 2015. Of the $21.4 million decrease, $8.2 million related to changes in the exchange rate from the acquisition date through December 28, 2014. During fiscal year 2015 , there was an immaterial impact on the current period net income as a result of the change to the provisional amounts for items that would have been recognized in previous periods if the adjustments to provisional amounts had been recognized as of the acquisition date. Allocations of the purchase price for acquisitions are based on estimates of the fair value of the net assets acquired and are subject to adjustment upon finalization of the purchase price allocations. The accounting for business combinations requires estimates and judgments as to expectations for future cash flows of the acquired business, and the allocation of those cash flows to identifiable intangible assets, in determining the estimated fair values for assets acquired and liabilities assumed. The fair values assigned to tangible and intangible assets acquired and liabilities assumed, including contingent consideration, are based on management’s estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. Contingent consideration is measured at fair value at the acquisition date, based on the probability that revenue thresholds or product development milestones will be achieved during the earnout period, with changes in the fair value after the acquisition date affecting earnings to the extent it is to be settled in cash. Increases or decreases in the fair value of contingent consideration liabilities primarily result from changes in the estimated probabilities of achieving revenue thresholds or product development milestones during the earnout period. As of January 3, 2016 , the Company may have to pay contingent consideration, related to acquisitions with open contingency periods, of up to $95.4 million . As of January 3, 2016 , the Company has recorded contingent consideration obligations of $57.4 million , of which $9.4 million was recorded in accrued expenses and other current liabilities, and $48.0 million was recorded in long-term liabilities. As of December 28, 2014 , the Company has recorded contingent consideration obligations of $0.1 million , which was recorded in accrued expenses and other current liabilities. The expected maximum earnout period for acquisitions with open contingency periods does not exceed 6 years from the respective acquisition dates, and the remaining weighted average expected earnout period at January 3, 2016 was 2 years. If the actual results differ from the estimates and judgments used in these fair values, the amounts recorded in the consolidated financial statements could result in a possible impairment of the intangible assets and goodwill, require acceleration of the amortization expense of definite-lived intangible assets or the recognition of additional contingent consideration which would be recognized as a component of operating expenses from continuing operations. In connection with the purchase price allocations for acquisitions, the Company estimates the fair value of deferred revenue assumed with its acquisitions. The estimated fair value of deferred revenue is determined by the legal performance obligation at the date of acquisition, and is generally based on the nature of the activities to be performed and the related costs to be incurred after the acquisition date. The fair value of an assumed liability related to deferred revenue is estimated based on the current market cost of fulfilling the obligation, plus a normal profit margin thereon. The estimated costs to fulfill the deferred revenue are based on the historical direct costs related to providing the services. The Company does not include any costs associated with selling effort, research and development, or the related margins on these costs. In most acquisitions, profit associated with selling effort is excluded because the acquired businesses would have concluded the selling effort on the support contracts prior to the acquisition date. The estimated research and development costs are not included in the fair value determination, as these costs are not deemed to represent a legal obligation at the time of acquisition. The sum of the costs and operating income approximates, in theory, the amount that the Company would be required to pay a third-party to assume the obligation. Total transaction costs related to acquisition activities for fiscal years 2015, 2014 and 2013 were $0.7 million , $3.1 million and $0.1 million , respectively. These transaction costs were expensed as incurred and recorded in selling, general and administrative expenses in the Company's consolidated statements of operations. |
Discontinued Operations
Discontinued Operations | 12 Months Ended |
Jan. 03, 2016 | |
Discontinued Operations and Disposal Groups [Abstract] | |
Discontinued Operations | Discontinued Operations As part of the Company’s continuing efforts to focus on higher growth opportunities, the Company has discontinued certain businesses. The Company has accounted for these businesses as discontinued operations and, accordingly, has presented the results of operations and related cash flows as discontinued operations for all periods presented. Any remaining assets and liabilities of these businesses have been presented separately, and are reflected within assets and liabilities from discontinued operations in the accompanying consolidated balance sheets as of January 3, 2016 and December 28, 2014 . In May 2014, the Company’s management approved the shutdown of its microarray-based diagnostic testing laboratory in the United States, which had been reported within the Human Health segment. The Company determined that, with the lack of adequate reimbursement from health care payers, the microarray-based diagnostic testing laboratory in the United States would need significant investment in its operations to reduce costs in order to effectively compete in the market. The shutdown of the microarray-based diagnostic testing laboratory in the United States resulted in a $0.1 million net pre-tax loss primarily related to the disposal of fixed assets, which was partially offset by the sale of a building in fiscal year 2014. In August 1999, the Company sold the assets of its Technical Service business. The Company recorded pre-tax losses of $0.03 million in fiscal year 2015 , $0.2 million in fiscal year 2014 and $2.1 million in fiscal year 2013 for a contingency related to this business. These losses were recognized as a loss on disposition of discontinued operations before income taxes. During fiscal year 2013, the Company settled various commitments related to the divestiture of other discontinued operations and recognized a pre-tax gain of $0.3 million . This gain was recognized as a gain on disposition of discontinued operations before income taxes. Summary pre-tax operating results of the discontinued operations, which include the periods prior to disposition and a $1.0 million pre-tax restructuring charge related to workforce reductions in the microarray-based diagnostic testing laboratory in the United States during fiscal year 2014, were as follows during the three fiscal years ended: January 3, December 28, December 29, (In thousands) Revenue $ 98 $ 348 $ 8,646 Costs and expenses 101 5,307 18,998 Loss from discontinued operations before income taxes $ (3 ) $ (4,959 ) $ (10,352 ) The Company recorded a tax provision of $0.2 million on discontinued operations and dispositions in fiscal year 2015 , a tax benefit of $1.8 million on discontinued operations and dispositions in fiscal year 2014 and a tax benefit of $5.1 million on discontinued operations and dispositions in fiscal year 2013 . |
Restructuring and Contract Term
Restructuring and Contract Termination Charges, Net | 12 Months Ended |
Jan. 03, 2016 | |
Restructuring and Related Activities [Abstract] | |
Restructuring and Contract Termination Charges, Net | Restructuring and Contract Termination Charges, Net The Company's management has approved a series of restructuring actions related to the impact of acquisitions and divestitures, the alignment of the Company's operations with its growth strategy, the integration of its business units and productivity initiatives. The current portion of restructuring and contract termination charges is recorded in accrued restructuring and contract termination charges and the long-term portion of restructuring and contract termination charges is recorded in long-term liabilities. The activities associated with these plans have been reported as restructuring and contract termination charges, net, and are included as a component of operating expenses from continuing operations. The Company implemented restructuring plans in the fourth quarter of fiscal year 2015, the second and first quarters of fiscal year 2014, and the first quarter of fiscal year 2013 consisting of workforce reductions and the closure of excess facility space principally intended to focus resources on higher growth end markets (the "Q4 2015 Plan", "Q2 2014 Plan", "Q1 2014 Plan" and "Q1 2013 Plan", respectively). The Company implemented restructuring plans in the second quarter of fiscal year 2015 and the third quarter of fiscal year 2014 consisting of workforce reductions principally intended to realign resources to emphasize growth initiatives (the "Q2 2015 Plan" and "Q3 2014 Plan", respectively). The Company implemented restructuring plans in the fourth and third quarters of fiscal year 2013 consisting of workforce reductions and the closure of excess facility space principally intended to shift certain of the Company's research and development resources into the Company's newly opened Center for Innovation (the "Q4 2013 Plan" and "Q3 2013 Plan", respectively). The Company implemented a restructuring plan in the second quarter of fiscal year 2013 consisting of workforce reductions and the closure of excess facility space principally intended to shift certain of the Company's operations into a newly established shared service center, as well as realign operations, research and development resources, and production resources as a result of previous acquisitions (the "Q2 2013 Plan"). All other previous restructuring plans were workforce reductions or the closure of excess facility space principally intended to integrate the Company's businesses in order to realign operations, reduce costs, achieve operational efficiencies and shift resources into geographic regions and end markets that are more consistent with the Company's growth strategy (the "Previous Plans"). The following table summarizes the number of employees reduced, the initial restructuring or contract termination charges by operating segment, and the dates by which payments were substantially completed, or the expected dates by which payments will be substantially completed, for restructuring actions implemented during fiscal years 2015, 2014 and 2013 : Workforce Reductions Closure of Excess Facility Total (Expected) Date Payments Substantially Completed by Headcount Reduction Human Health Environmental Health Human Health Environmental Health Severance Excess Facility (In thousands, except headcount data) Q4 2015 Plan 174 $ 2,230 $ 9,065 $ 285 $ — $ 11,580 Q1 FY2017 Q4 FY2017 Q2 2015 Plan 97 1,850 4,160 — — 6,010 Q2 FY2016 — Q3 2014 Plan 152 7,126 5,925 — — 13,051 Q4 FY2015 — Q2 2014 Plan 22 545 190 — — 735 Q2 FY2015 — Q1 2014 Plan 17 370 197 — — 567 Q4 FY2014 — Q4 2013 Plan 73 955 2,953 7,271 — 11,179 Q4 FY2014 Q1 FY2019 Q3 2013 Plan 29 394 — 138 — 532 Q1 FY2014 Q4 FY2013 Q2 2013 Plan (1) 264 9,523 8,609 522 50 18,704 Q4 FY2014 Q3 FY2014 Q1 2013 Plan 62 2,340 245 — — 2,585 Q3 FY2013 — ____________________________ (1) Subsequent to the initial charge, during fiscal year 2013, the Company recorded an additional $0.6 million pre-tax restructuring charge in the Human Health segment for the Q2 2013 Plan for services that were provided for one-time termination benefits in which the employee was required to render service beyond the legal notification period. The Company expects to make payments under the Previous Plans for remaining residual lease obligations, with terms varying in length, through fiscal year 2022 . The Company also has terminated various contractual commitments in connection with certain disposal activities and has recorded charges, to the extent applicable, for the costs of terminating these contracts before the end of their terms and the costs that will continue to be incurred for the remaining terms without economic benefit to the Company. The Company recorded additional pre-tax charges of $0.1 million , $1.5 million and $0.7 million in the Environmental Health segment during fiscal years 2015, 2014 and 2013 , respectively, as a result of these contract terminations. At January 3, 2016 , the Company had $22.2 million recorded for accrued restructuring and contract termination charges, of which $17.1 million was recorded in short-term accrued restructuring and $5.1 million was recorded in long-term liabilities. At December 28, 2014 , the Company had $23.8 million recorded for accrued restructuring and contract termination charges, of which $17.1 million was recorded in short-term accrued restructuring and $6.7 million was recorded in long-term liabilities. The following table summarizes the Company's restructuring accrual balances and related activity by restructuring plan, as well as contract termination accrual balances and related activity, during fiscal years 2015, 2014 and 2013 : Balance at December 30, 2012 2013 Charges and Changes in Estimates, Net 2013 Amounts Paid Balance at December 29, 2013 2014 Charges and Changes in Estimates, Net 2014 Amounts Paid Balance at December 28, 2014 2015 Charges and Changes in Estimates, Net 2015 Amounts Paid Balance at January 3, 2016 (In thousands) Severance: Q4 2015 Plan $ — $ — $ — $ — $ — $ — $ — $ 11,295 $ (925 ) $ 10,370 Q2 2015 Plan (1) — — — — — — — 5,471 (4,322 ) 1,149 Q3 2014 Plan (2) — — — — 13,051 (2,992 ) 10,059 (3,064 ) (5,460 ) 1,535 Q2 2014 Plan (3) — — — — 735 (484 ) 251 (179 ) (13 ) 59 Q1 2014 Plan (4) — — — — 567 (475 ) 92 (92 ) — — Facility: Q4 2015 Plan — — — — — — — 285 (26 ) 259 Previous Plans including 2013 plans (5) 27,151 33,196 (25,112 ) 35,235 (2,508 ) (19,603 ) 13,124 (209 ) (4,222 ) 8,693 Restructuring 27,151 33,196 (25,112 ) 35,235 11,845 (23,554 ) 23,526 13,507 (14,968 ) 22,065 Contract Termination 596 696 (992 ) 300 1,545 (1,541 ) 304 83 (255 ) 132 Total Restructuring and Contract Termination $ 27,747 $ 33,892 $ (26,104 ) $ 35,535 $ 13,390 $ (25,095 ) $ 23,830 $ 13,590 $ (15,223 ) $ 22,197 ____________________________ (1) During fiscal year 2015 , the Company recognized pre-tax restructuring reversals of $0.2 million in the Human Health segment and $0.3 million in the Environmental Health segment related to lower than expected costs associated with workforce reductions for the Q2 2015 Plan. (2) During fiscal year 2015 , the Company recognized pre-tax restructuring reversals of $1.2 million in the Human Health segment and $1.9 million in the Environmental Health segment related to lower than expected costs associated with workforce reductions for the Q3 2014 Plan. (3) During fiscal year 2015 , the Company recognized pre-tax restructuring reversals of $0.1 million in each of the Human Health and Environmental Health segments related to lower than expected costs associated with workforce reductions for the Q2 2014 Plan. (4) During fiscal year 2015 , the Company recognized a pre-tax restructuring reversal of $0.1 million in the Human Health segment related to lower than expected costs associated with workforce reductions for the Q1 2014 Plan. (5) During fiscal year 2015 , the Company recognized a pre-tax restructuring charge of $1.4 million in the Human Health segment primarily related to higher than expected costs associated with the closure of the excess facility space, which was offset by a pre-tax restructuring reversal of $1.6 million in the Environmental Health segment primarily related to lower than expected costs associated with workforce reductions for the previous restructuring plans. During fiscal year 2014 , the Company recognized pre-tax restructuring reversals of $0.8 million in the Human Health segment and $1.7 million in the Environmental Health segment primarily related to lower than expected costs associated with workforce reductions, which was partially offset by higher than expected costs associated with the closure of the excess facility space for the previous restructuring plans. |
Interest and Other Expense (Inc
Interest and Other Expense (Income), Net | 12 Months Ended |
Jan. 03, 2016 | |
Other Income and Expenses [Abstract] | |
Interest and Other Expense (Income), Net | Interest and Other Expense, Net Interest and other expense, net, consisted of the following for the fiscal years ended: January 3, December 28, December 29, (In thousands) Interest income $ (673 ) $ (667 ) $ (650 ) Interest expense 37,997 36,270 49,924 Other expense, net 4,795 5,536 14,836 Total interest and other expense, net $ 42,119 $ 41,139 $ 64,110 In December 2013, the Company redeemed all of its 6% senior unsecured notes due in 2015 (the “2015 Notes”) for a redemption price that included the outstanding principal amount of $150.0 million and a prepayment premium of $11.1 million , which is included in other expense, net. The transaction also resulted in the write-off of $2.8 million for the remaining unamortized derivative losses for previously settled cash flow hedges and the write-off of $0.2 million for the remaining deferred debt issuance costs. Both of these amounts are included in interest expense. Foreign currency transaction losses were $25.5 million , $5.5 million and $4.7 million in fiscal years 2015, 2014 and 2013 , respectively. Net gains from forward currency hedge contracts were $20.8 million , $0.2 million and $1.4 million in fiscal years 2015, 2014 and 2013 , respectively. These amounts were included in other expense, net. |
Income Taxes
Income Taxes | 12 Months Ended |
Jan. 03, 2016 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Income Taxes The Company regularly reviews its tax positions in each significant taxing jurisdiction in the process of evaluating its unrecognized tax benefits. The Company makes adjustments to its unrecognized tax benefits when: (i) facts and circumstances regarding a tax position change, causing a change in management’s judgment regarding that tax position; (ii) a tax position is effectively settled with a tax authority at a differing amount; and/or (iii) the statute of limitations expires regarding a tax position. The tabular reconciliation of the total amounts of unrecognized tax benefits is as follows for the fiscal years ended: January 3, December 28, December 29, (In thousands) Unrecognized tax benefits, beginning of year $ 32,342 $ 39,410 $ 58,110 Gross increases—tax positions in prior periods 325 — 325 Gross decreases—tax positions in prior periods (2,305 ) (1,809 ) (10,539 ) Gross increases—current-period tax positions — 239 2,222 Settlements (441 ) (1,400 ) (3,643 ) Lapse of statute of limitations (1,077 ) (4,129 ) (6,495 ) Foreign currency translation adjustments (701 ) 31 (570 ) Unrecognized tax benefits, end of year $ 28,143 $ 32,342 $ 39,410 The Company classifies interest and penalties as a component of income tax expense. At January 3, 2016 , the Company had accrued interest and penalties of $2.1 million and $0.1 million , respectively. At December 28, 2014 , the Company had accrued interest and penalties of $3.4 million and $0.2 million , respectively. During fiscal year 2015 , the Company recognized a net benefit of $1.5 million for interest and a benefit of $0.1 million for penalties in its total tax provision primarily due to settlements and statutes of limitations that had lapsed. During fiscal year 2014 , the Company recognized a net benefit of $0.7 million for interest and a benefit of $0.2 million for penalties in its total tax provision primarily due to settlements and statutes of limitations that had lapsed. During fiscal year 2013 , the Company recognized a benefit of $3.9 million for interest and a benefit of $3.7 million for penalties in its total tax provision due to settlements and statutes of limitations that had lapsed. At January 3, 2016 , the Company had gross tax effected unrecognized tax benefits of $28.1 million , of which $24.3 million , if recognized, would affect the continuing operations effective tax rate. The remaining amount, if recognized, would affect discontinued operations. The Company believes that it is reasonably possible that approximately $5.7 million of its uncertain tax positions at January 3, 2016 , including accrued interest and penalties, and net of tax benefits, may be resolved over the next twelve months as a result of lapses in applicable statutes of limitations and potential settlements. Various tax years after 2009 remain open to examination by certain jurisdictions in which the Company has significant business operations, such as Finland, Germany, Italy, Netherlands, Singapore, the United Kingdom and the United States. The tax years under examination vary by jurisdiction. During fiscal years 2015, 2014 and 2013 , the Company recorded net discrete income tax benefits of $7.2 million , $7.0 million and $24.0 million , respectively, primarily for reversals of uncertain tax position reserves and resolution of other tax matters. The components of income (loss) from continuing operations before income taxes were as follows for the fiscal years ended: January 3, December 28, December 29, (In thousands) U.S. $ 3,160 $ (37,758 ) $ (71,901 ) Non-U.S. 240,855 207,361 235,585 Total $ 244,015 $ 169,603 $ 163,684 On a U.S. income tax basis, the Company has reported significant taxable income over the three year period ended January 3, 2016 . The Company has utilized tax attributes to minimize cash taxes paid on that taxable income. The components of the provision for (benefit from) income taxes for continuing operations were as follows: Current Expense (Benefit) Deferred Expense (Benefit) Total (In thousands) Fiscal year ended January 3, 2016 Federal $ (5,532 ) $ (1,799 ) $ (7,331 ) State 3,112 (2,492 ) 620 Non-U.S. 40,318 (2,280 ) 38,038 Total $ 37,898 $ (6,571 ) $ 31,327 Fiscal year ended December 28, 2014 Federal $ (262 ) $ (19,169 ) $ (19,431 ) State 2,416 (3,842 ) (1,426 ) Non-U.S. 39,634 (10,340 ) 29,294 Total $ 41,788 $ (33,351 ) $ 8,437 Fiscal year ended December 29, 2013 Federal $ 2,331 $ (29,961 ) $ (27,630 ) State 1,968 (2,147 ) (179 ) Non-U.S. 15,025 2,201 17,226 Total $ 19,324 $ (29,907 ) $ (10,583 ) The total provision for (benefit from) income taxes included in the consolidated financial statements is as follows for the fiscal years ended: January 3, December 28, December 29, (In thousands) Continuing operations $ 31,327 $ 8,437 $ (10,583 ) Discontinued operations 232 (1,831 ) (5,107 ) Total $ 31,559 $ 6,606 $ (15,690 ) A reconciliation of income tax expense at the U.S. federal statutory income tax rate to the recorded tax provision is as follows for the fiscal years ended: January 3, December 28, December 29, (In thousands) Tax at statutory rate $ 85,405 $ 59,361 $ 57,289 Non-U.S. rate differential, net (51,814 ) (36,616 ) (36,377 ) U.S. taxation of multinational operations 1,732 2,367 3,658 State income taxes, net 649 1,970 (1,762 ) Prior year tax matters (7,202 ) (7,009 ) (23,534 ) Federal tax credits (2,295 ) (3,399 ) (5,452 ) Change in valuation allowance 2,593 (7,679 ) (4,675 ) Other, net 2,259 (558 ) 270 Total $ 31,327 $ 8,437 $ (10,583 ) The Company’s provision for (benefit from) income taxes for fiscal years 2015, 2014 and 2013 included $8.3 million , $7.1 million and $7.4 million , respectively, of benefits derived from tax holidays in China and Singapore. The tax holidays in China and Singapore are scheduled to expire in fiscal years 2017 and 2018 , respectively. The tax effects of temporary differences and attributes that gave rise to deferred income tax assets and liabilities as of January 3, 2016 and December 28, 2014 were as follows: January 3, December 28, (In thousands) Deferred tax assets: Inventory $ 9,887 $ 9,041 Reserves and accruals 29,137 30,641 Accrued compensation 23,620 22,915 Net operating loss and credit carryforwards 100,336 106,020 Accrued pension 34,736 44,342 Restructuring reserve 6,362 7,522 Deferred revenue 40,065 46,413 All other, net — 824 Total deferred tax assets 244,143 267,718 Deferred tax liabilities: Postretirement health benefits (4,202 ) (4,472 ) Depreciation and amortization (140,091 ) (176,043 ) Total deferred tax liabilities (144,293 ) (180,515 ) Valuation allowance (67,400 ) (55,460 ) Net deferred tax assets $ 32,450 $ 31,743 At January 3, 2016 , for income tax return purposes the Company had U.S. federal net operating loss carryforwards of $36.3 million , state net operating loss carryforwards of $226.4 million , foreign net operating loss carryforwards of $199.5 million , state tax credit carryforwards of $10.7 million , general business tax credit carryforwards of $32.1 million , and foreign tax credit carryforwards of $13.0 million . These are subject to expiration in years ranging from 2016 to 2034 , and without expiration for certain foreign net operating loss carryforwards and certain state credit carryforwards. U.S. federal tax credits of $15.0 million created by excess tax benefits from the exercise of stock options or the vesting of RSUs are not recorded as deferred income tax assets. To the extent such tax attributes are utilized, the benefit realized will increase stockholders’ equity. At January 3, 2016 , excess tax benefits from the exercise of stock options of $2.4 million was recognized in stockholders’ equity. Valuation allowances take into consideration limitations imposed upon the use of the tax attributes and reduce the value of such items to the likely net realizable amount. The Company regularly evaluates positive and negative evidence available to determine if valuation allowances are required or if existing valuation allowances are no longer required. Valuation allowances have been provided on state net operating loss and state tax credit carryforwards and on certain foreign tax attributes that the Company has determined are not more likely than not to be realized. The increase in the valuation allowance in fiscal year 2015 is primarily due to an increase in tax attributes that the Company does not expect to realize for two of its non-U.S. subsidiaries. During fiscal year 2015, the Company adopted ASU No. 2015-17 and has presented all deferred tax assets and deferred tax liabilities as noncurrent in the consolidated balance sheet at January 3, 2016. The financial position for the period ending December 28, 2014 has not been retrospectively adjusted. Current deferred tax assets of $62.0 million were included in other current assets at December 28, 2014 . The components of net deferred tax assets (liabilities) as of January 3, 2016 and December 28, 2014 were as follows: January 3, December 28, (In thousands) U.S. $ 54,411 $ 44,073 Non-U.S. (21,961 ) (12,330 ) Total $ 32,450 $ 31,743 Taxes have not been provided on unremitted earnings of international subsidiaries that the Company considers indefinitely reinvested because the Company plans to keep these amounts indefinitely reinvested overseas except for instances where the Company can remit such earnings to the U.S. without an associated net tax cost. The Company's indefinite reinvestment determination is based on the future operational and capital requirements of its U.S. and non-U.S. operations. As of January 3, 2016 , the amount of foreign earnings that the Company has the intent and ability to keep invested outside the U.S. indefinitely and for which no U.S. tax cost has been provided was approximately $859.0 million . It is not practical to calculate the unrecognized deferred tax liability on those earnings. |
Earnings Per Share
Earnings Per Share | 12 Months Ended |
Jan. 03, 2016 | |
Earnings Per Share [Abstract] | |
Earnings Per Share | Earnings Per Share Basic earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding during the period less restricted unvested shares. Diluted earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding plus all potentially dilutive common stock equivalents, primarily shares issuable upon the exercise of stock options using the treasury stock method. The following table reconciles the number of shares utilized in the earnings per share calculations for the fiscal years ended: January 3, December 28, December 29, (In thousands) Number of common shares—basic 112,507 112,593 112,254 Effect of dilutive securities: Stock options 621 922 982 Restricted stock awards 187 224 267 Number of common shares—diluted 113,315 113,739 113,503 Number of potentially dilutive securities excluded from calculation due to antidilutive impact 607 475 485 Antidilutive securities include outstanding stock options with exercise prices and average unrecognized compensation cost in excess of the average fair market value of common stock for the related period. Antidilutive options were excluded from the calculation of diluted net income per share and could become dilutive in the future. |
Accounts Receivable, Net
Accounts Receivable, Net | 12 Months Ended |
Jan. 03, 2016 | |
Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract] | |
Accounts Receivable, Net | Accounts Receivable, Net Accounts receivable were net of reserves for doubtful accounts of $29.9 million and $32.9 million as of January 3, 2016 and December 28, 2014 , respectively. |
Inventories, Net
Inventories, Net | 12 Months Ended |
Jan. 03, 2016 | |
Inventory Disclosure [Abstract] | |
Inventories, Net | Inventories Inventories as of January 3, 2016 and December 28, 2014 consisted of the following: January 3, December 28, (In thousands) Raw materials $ 98,984 $ 96,169 Work in progress 17,858 18,783 Finished goods 171,186 170,505 Total inventories $ 288,028 $ 285,457 |
Property, Plant and Equipment,
Property, Plant and Equipment, Net | 12 Months Ended |
Jan. 03, 2016 | |
Property, Plant and Equipment, Net [Abstract] | |
Property, Plant and Equipment, Net | Property, Plant and Equipment, Net Property, plant and equipment, at cost, as of January 3, 2016 and December 28, 2014 , consisted of the following: January 3, December 28, (In thousands) Land $ 802 $ 906 Building and leasehold improvements 177,587 175,040 Machinery and equipment 316,567 316,868 Total property, plant and equipment 494,956 492,814 Accumulated depreciation (327,927 ) (316,620 ) Total property, plant and equipment, net $ 167,029 $ 176,194 Depreciation expense on property, plant and equipment for the fiscal years ended January 3, 2016 , December 28, 2014 and December 29, 2013 was $33.4 million , $33.3 million and $37.6 million , respectively. |
Marketable Securities and Inves
Marketable Securities and Investments | 12 Months Ended |
Jan. 03, 2016 | |
Marketable Securities [Abstract] | |
Marketable Securities and Investments | Marketable Securities and Investments Investments as of January 3, 2016 and December 28, 2014 consisted of the following: January 3, December 28, (In thousands) Marketable securities $ 1,586 $ 1,568 Marketable securities include equity and fixed-income securities held to meet obligations associated with the Company’s supplemental executive retirement plan and other deferred compensation plans. The Company has, accordingly, classified these securities as long-term. The net unrealized holding gain and loss on marketable securities, net of deferred income taxes, reported as a component of other comprehensive (loss) income in stockholders’ equity, was a $0.3 million loss in fiscal year 2015 and a $0.01 million gain in fiscal year 2014 . The proceeds from the sales of securities and the related gains and losses are not material for any period presented. Marketable securities classified as available for sale as of January 3, 2016 and December 28, 2014 consisted of the following: Market Gross Unrealized Holding Value Cost Gains (Losses) (In thousands) January 3, 2016 Equity securities $ 908 $ 1,299 $ — $ (391 ) Fixed-income securities 57 57 — — Other 621 822 — (201 ) $ 1,586 $ 2,178 $ — $ (592 ) December 28, 2014 Equity securities $ 1,002 $ 1,110 $ 7 $ (115 ) Fixed-income securities 88 88 — — Other 478 541 — (63 ) $ 1,568 $ 1,739 $ 7 $ (178 ) |
Goodwill and Intangible Assets,
Goodwill and Intangible Assets, Net | 12 Months Ended |
Jan. 03, 2016 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Goodwill and Intangible Assets, Net | Goodwill and Intangible Assets, Net The Company tests goodwill and non-amortizing intangible assets at least annually for possible impairment. Accordingly, the Company completes the annual testing of impairment for goodwill and non-amortizing intangible assets on the later of January 1 or the first day of each fiscal year. In addition to its annual test, the Company regularly evaluates whether events or circumstances have occurred that may indicate a potential impairment of goodwill or non-amortizing intangible assets. The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of a two-step process. The first step is the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. The second step measures the amount of an impairment loss, and is only performed if the carrying value exceeds the fair value of the reporting unit. The Company performed its annual impairment testing for its reporting units as of January 1, 2015 , its annual impairment date for fiscal year 2015 . The Company concluded based on the first step of the process that there was no goodwill impairment, and the fair value exceeded the carrying value by more than 20.0% for each reporting unit, with the exception of the Perten reporting unit in which its fair value approximated carrying value, as expected based on the recent acquisition date. The long-term terminal growth rate for the Company’s reporting units was 3.0% for the fiscal year 2015 impairment analysis. The range for the discount rates for the reporting units was 9.5% to 12.5% . Keeping all other variables constant, a 10.0% change in any one of the input assumptions for the various reporting units would still allow the Company to conclude, based on the first step of the process, that there was no impairment of goodwill. As discussed in Note 23, the Company realigned its organization at the beginning of fiscal year 2015, which resulted in a change in the composition of the Company's reportable segments. OneSource, the Company's multivendor laboratory service business that serves the life sciences end market, was moved from the Environmental Health segment into the Human Health segment. As a result of the realignment, the Company reallocated goodwill from the Environmental Health segment to the Human Health segment based on the relative fair value, determined using the income approach, of the OneSource laboratory service business within the historical Environmental Health segment. The realignment resulted in $41.2 million of goodwill being reallocated from the Environmental Health segment to the Human Health segment, as of December 28, 2014. The Company has consistently employed the income approach to estimate the current fair value when testing for impairment of goodwill. A number of significant assumptions and estimates are involved in the application of the income approach to forecast operating cash flows, including markets and market share, sales volumes and prices, costs to produce, tax rates, capital spending, discount rates and working capital changes. Cash flow forecasts are based on approved business unit operating plans for the early years’ cash flows and historical relationships in later years. The income approach is sensitive to changes in long-term terminal growth rates and the discount rates. The long-term terminal growth rates are consistent with the Company’s historical long-term terminal growth rates, as the current economic trends are not expected to affect the long-term terminal growth rates of the Company. The Company corroborates the income approach with a market approach. The Company has consistently employed the relief from royalty model to estimate the current fair value when testing for impairment of non-amortizing intangible assets. The impairment test consists of a comparison of the fair value of the non-amortizing intangible asset with its carrying amount. If the carrying amount of a non-amortizing intangible asset exceeds its fair value, an impairment loss in an amount equal to that excess is recognized . In addition, the Company evaluates the remaining useful lives of its non-amortizing intangible assets at least annually to determine whether events or circumstances continue to support an indefinite useful life. If events or circumstances indicate that the useful lives of non-amortizing intangible assets are no longer indefinite, the assets will be tested for impairment. These intangible assets will then be amortized prospectively over their estimated remaining useful lives and accounted for in the same manner as other intangible assets that are subject to amortization. The Company performed its annual impairment testing as of January 1, 2015 , and concluded that there was no impairment of non-amortizing intangible assets. An assessment of the recoverability of amortizing intangible assets takes place when events have occurred that may give rise to an impairment. During fiscal year 2013, the Company recorded a charge of $0.2 million for the impairment of certain long-lived assets within the Human Health segment, as the carrying amounts of the long-lived assets were not recoverable and exceeded their fair value. These non-cash impairments of long-lived assets, including intangible assets, have been recorded as a separate component of operating expenses. The changes in the carrying amount of goodwill for fiscal years 2015 and 2014 are as follows: Human Health Environmental Health Consolidated (In thousands) Balance at December 29, 2013 $ 1,689,492 $ 453,628 $ 2,143,120 Foreign currency translation (29,145 ) (8,741 ) (37,886 ) Acquisitions, earnouts and other 2,408 176,435 178,843 Balance at December 28, 2014 1,662,755 621,322 2,284,077 Foreign currency translation (28,368 ) (27,066 ) (55,434 ) Acquisitions, earnouts and other 38,104 9,402 47,506 Balance at January 3, 2016 $ 1,672,491 $ 603,658 $ 2,276,149 Identifiable intangible asset balances at January 3, 2016 by category and by business segment were as follows: Human Health Environmental Health Consolidated (In thousands) Patents $ 37,111 $ 2,800 $ 39,911 Less: Accumulated amortization (27,466 ) (2,322 ) (29,788 ) Net patents 9,645 478 10,123 Trade names and trademarks 32,887 7,362 40,249 Less: Accumulated amortization (19,810 ) (876 ) (20,686 ) Net trade names and trademarks 13,077 6,486 19,563 Licenses 58,969 — 58,969 Less: Accumulated amortization (45,286 ) — (45,286 ) Net licenses 13,683 — 13,683 Core technology 181,807 125,435 307,242 Less: Accumulated amortization (121,262 ) (90,567 ) (211,829 ) Net core technology 60,545 34,868 95,413 Customer relationships 298,978 92,588 391,566 Less: Accumulated amortization (177,730 ) (13,925 ) (191,655 ) Net customer relationships 121,248 78,663 199,911 IPR&D 80,748 4,931 85,679 Less: Accumulated amortization (1,378 ) (2,767 ) (4,145 ) Net IPR&D 79,370 2,164 81,534 Net amortizable intangible assets 297,568 122,659 420,227 Non-amortizable intangible assets: Trade name — 70,584 70,584 Total $ 297,568 $ 193,243 $ 490,811 Identifiable intangible asset balances at December 28, 2014 by category and business segment were as follows: Human Health Environmental Health Consolidated (In thousands) Patents $ 37,153 $ 2,800 $ 39,953 Less: Accumulated amortization (25,018 ) (2,182 ) (27,200 ) Net patents 12,135 618 12,753 Trade names and trademarks 33,069 7,000 40,069 Less: Accumulated amortization (16,878 ) (58 ) (16,936 ) Net trade names and trademarks 16,191 6,942 23,133 Licenses 59,631 — 59,631 Less: Accumulated amortization (41,792 ) — (41,792 ) Net licenses 17,839 — 17,839 Core technology 171,163 127,328 298,491 Less: Accumulated amortization (100,050 ) (84,647 ) (184,697 ) Net core technology 71,113 42,681 113,794 Customer relationships 301,371 100,814 402,185 Less: Accumulated amortization (149,917 ) (7,077 ) (156,994 ) Net customer relationships 151,454 93,737 245,191 IPR&D 5,079 5,024 10,103 Less: Accumulated amortization (998 ) (2,134 ) (3,132 ) Net IPR&D 4,081 2,890 6,971 Net amortizable intangible assets 272,813 146,868 419,681 Non-amortizable intangible assets: Trade name — 70,584 70,584 Total $ 272,813 $ 217,452 $ 490,265 Total amortization expense related to definite-lived intangible assets was $78.6 million in fiscal year 2015 , $83.4 million in fiscal year 2014 and $89.3 million in fiscal year 2013 . Estimated amortization expense related to definite-lived intangible assets for each of the next five years is $71.8 million in fiscal year 2016 , $62.5 million in fiscal year 2017 , $60.7 million in fiscal year 2018 , $48.7 million in fiscal year 2019 , and $40.1 million in fiscal year 2020 . The Company entered into a strategic agreement in fiscal year 2012 under which it acquired certain intangible assets and received a license to certain core technology for an analytics and data discovery platform, as well as the exclusive right to distribute the platform in certain scientific research and development markets. During fiscal year 2012, the Company paid $6.8 million for net intangible assets and $25.0 million for prepaid royalties. During fiscal year 2013, the Company extended the existing agreement for an additional year. In addition, the Company entered into a new agreement to expand the distribution rights to the clinical and other related markets and acquired additional intangible assets. During fiscal year 2013, the Company paid $7.0 million for net intangible assets and $40.3 million for prepaid royalties. During fiscal year 2015 , the Company paid $9.8 million for additional prepaid royalties. The prepaid royalties have been recorded primarily as other long-term assets. The Company expects to pay $10.0 million of additional prepaid royalties within the next twelve months. The Company expenses royalties as revenue is recognized. These intangible assets are being amortized over their estimated useful lives. The Company has reported the amortization of these intangible assets within the results of the Company's Human Health segment from the execution date. |
Debt
Debt | 12 Months Ended |
Jan. 03, 2016 | |
Debt Disclosure [Abstract] | |
Debt | Debt Senior Unsecured Revolving Credit Facility. On January 8, 2014, the Company refinanced its debt held under a previous senior unsecured revolving credit facility and entered into a new senior unsecured revolving credit facility. The Company's senior unsecured revolving credit facility provides for $700.0 million of revolving loans and has an initial maturity of January 8, 2019 . As of January 3, 2016 , undrawn letters of credit in the aggregate amount of $11.5 million were treated as issued and outstanding when calculating the borrowing availability under the senior unsecured revolving credit facility. As of January 3, 2016 , the Company had $206.5 million available for additional borrowing under the facility. The Company uses the senior unsecured revolving credit facility for general corporate purposes, which may include working capital, refinancing existing indebtedness, capital expenditures, share repurchases, acquisitions and strategic alliances. The interest rates under the senior unsecured revolving credit facility are based on the Eurocurrency rate or the base rate at the time of borrowing, plus a margin. The base rate is the higher of (i) the rate of interest in effect for such day as publicly announced from time to time by JP Morgan Chase Bank, N.A. as its "prime rate," (ii) the Federal Funds rate plus 50 basis points or (iii) one-month Libor plus 1.00%. At January 3, 2016 , borrowings under the senior unsecured revolving credit facility were accruing interest primarily based on the Eurocurrency rate. The Eurocurrency margin as of January 3, 2016 was 108 basis points. The weighted average Eurocurrency interest rate as of January 3, 2016 was 0.36% , resulting in a weighted average effective Eurocurrency rate, including the margin, of 1.44% . As of January 3, 2016 , the senior unsecured revolving credit facility had an aggregated carrying value of $479.6 million , which was net of $2.4 million unamortized debt issuance costs. As of December 28, 2014 , the senior unsecured revolving credit facility had an aggregate carrying value of $512.8 million , which was net of $3.2 million unamortized debt issuance costs. The credit agreement for the facility contains affirmative, negative and financial covenants and events of default similar to those contained in the credit agreement for the Company's previous facility. The financial covenants in the Company's senior unsecured revolving credit facility include a debt-to-capital ratio, and two contingent covenants, a maximum consolidated leverage ratio and a minimum consolidated interest coverage ratio, applicable if the Company's credit rating is downgraded below investment grade. 5% Senior Unsecured Notes due in 2021. On October 25, 2011, the Company issued $500.0 million aggregate principal amount of senior unsecured notes due in 2021 in a registered public offering and received $496.9 million of net proceeds from the issuance. The 2021 Notes were issued at 99.372% of the principal amount, which resulted in a discount of $3.1 million . As of January 3, 2016 , the 2021 Notes had an aggregate carrying value of $495.1 million , net of $2.0 million of unamortized original issue discount and $2.9 million of unamortized debt issuance costs. As of December 28, 2014 , the 2021 Notes had an aggregate carrying value of $494.4 million , net of $2.3 million of unamortized original issue discount and $3.3 million of unamortized debt issuance costs. The 2021 Notes mature in November 2021 and bear interest at an annual rate of 5% . Interest on the 2021 Notes is payable semi-annually on May 15th and November 15th each year. Prior to August 15, 2021 (three months prior to their maturity date), the Company may redeem the 2021 Notes in whole or in part, at its option, at a redemption price equal to the greater of (i) 100% of the principal amount of the 2021 Notes to be redeemed, plus accrued and unpaid interest, or (ii) the sum of the present values of the remaining scheduled payments of principal and interest in respect to the 2021 Notes being redeemed, discounted on a semi-annual basis, at the Treasury Rate plus 45 basis points, plus accrued and unpaid interest. At any time on or after August 15, 2021 (three months prior to their maturity date), the Company may redeem the 2021 Notes, at its option, at a redemption price equal to 100% of the principal amount of the 2021 Notes to be redeemed plus accrued and unpaid interest. Upon a change of control (as defined in the indenture governing the 2021 Notes) and a contemporaneous downgrade of the 2021 Notes below investment grade, each holder of 2021 Notes will have the right to require the Company to repurchase such holder's 2021 Notes for 101% of their principal amount, plus accrued and unpaid interest. Financing Lease Obligations. In fiscal year 2012, the Company entered into agreements with the lessors of certain buildings that the Company is currently occupying and leasing to expand those buildings. The Company provided a portion of the funds needed for the construction of the additions to the buildings, and as a result the Company was considered the owner of the buildings during the construction period. At the end of the construction period, the Company was not reimbursed by the lessors for all of the construction costs. The Company is therefore deemed to have continuing involvement and the leases qualify as financing leases under sale-leaseback accounting guidance, representing debt obligations for the Company and non-cash investing and financing activities. As a result, the Company capitalized $29.3 million in property, plant and equipment, net, representing the fair value of the buildings with a corresponding increase to debt. The Company has also capitalized $11.5 million in additional construction costs necessary to complete the renovations to the buildings, which were funded by the lessors, with a corresponding increase to debt. At January 3, 2016 , the Company had $38.2 million recorded for these financing lease obligations, of which $1.1 million was recorded as short-term debt and $37.1 million was recorded as long-term debt. At December 28, 2014 , the Company had $39.3 million recorded for these financing lease obligations, of which $1.1 million was recorded as short-term debt and $38.2 million was recorded as long-term debt. The buildings are being depreciated on a straight-line basis over the terms of the leases to their estimated residual values, which will equal the remaining financing obligation at the end of the lease term. At the end of the lease term, the remaining balances in property, plant and equipment, net and debt will be reversed against each other. The following table summarizes the maturities of the Company’s indebtedness as of January 3, 2016 : Sr. Unsecured Revolving Credit Facility Maturing 2019 5.0% Sr. Notes Maturing 2021 Financing Lease Obligations Total (In thousands) 2016 $ — $ — $ 1,123 $ 1,123 2017 — — 1,169 1,169 2018 — — 1,367 1,367 2019 482,000 — 1,532 483,532 2020 — — 1,597 1,597 2021 and thereafter — 500,000 31,409 531,409 Total before unamortized discount 482,000 500,000 38,197 1,020,197 Unamortized discount and debt issuance costs (2,384 ) (4,928 ) — (7,312 ) Total $ 479,616 $ 495,072 $ 38,197 $ 1,012,885 |
Accrued Expenses and Other Curr
Accrued Expenses and Other Current Liabilities | 12 Months Ended |
Jan. 03, 2016 | |
Accounts Payable and Accrued Liabilities, Current [Abstract] | |
Accrued Expenses and Other Current Liabilities | Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities as of January 3, 2016 and December 28, 2014 consisted of the following: January 3, December 28, (In thousands) Payroll and incentives $ 62,813 $ 61,018 Employee benefits 33,446 40,318 Deferred revenue 163,167 168,928 Federal, non-U.S. and state income taxes 2,882 9,801 Other accrued operating expenses 126,138 122,956 Total accrued expenses and other current liabilities $ 388,446 $ 403,021 |
Employee Benefit Plans
Employee Benefit Plans | 12 Months Ended |
Jan. 03, 2016 | |
Compensation and Retirement Disclosure [Abstract] | |
Employee Benefit Plans | Employee Benefit Plans Savings Plan: The Company has a 401(k) Savings Plan for the benefit of all qualified U.S. employees, with such employees receiving matching contributions in the amount equal to 100.0% of the first 5.0% of eligible compensation up to applicable Internal Revenue Service limits. Savings plan expense was $12.8 million in fiscal year 2015 , $12.2 million in fiscal year 2014 and $12.8 million in fiscal year 2013 . Pension Plans: The Company has a defined benefit pension plan covering certain U.S. employees and non-U.S. pension plans for certain non-U.S. employees. The principal U.S. defined benefit pension plan was closed to new hires effective January 31, 2001, and benefits for those employed by the Company’s former Life Sciences businesses were frozen as of that date. Plan benefits were frozen as of March 2003 for those employed by the Company’s former Analytical Instruments business and corporate employees. Plan benefits were frozen as of January 31, 2011 for all remaining employees that were still actively accruing in the plan. The plans provide benefits that are based on an employee’s years of service and compensation near retirement. Net periodic pension cost (credit) for U.S. and non-U.S. plans included the following components for fiscal years ended: January 3, December 28, December 29, (In thousands) Service cost $ 4,332 $ 4,070 $ 3,664 Interest cost 20,696 23,475 21,334 Expected return on plan assets (26,021 ) (25,007 ) (25,106 ) Curtailment gain (907 ) — — Actuarial loss (gain) 12,953 71,700 (16,464 ) Amortization of prior service cost (238 ) (281 ) (267 ) Net periodic pension cost (credit) $ 10,815 $ 73,957 $ (16,839 ) During fiscal year 2014, the Company notified certain employees of its intention to terminate their employment as part of the Q3 2014 restructuring plan. During fiscal year 2015, the termination of these participants decreased the expected future service lives in excess of the curtailment limit for one of the Company's pension plans, which resulted in a curtailment gain. The Company recorded the curtailment gain of $0.8 million during fiscal year 2015. As part of the curtailment, the Company remeasured the assets and liabilities of the plan that had the curtailment based upon current discount rates and the fair value of the pension plan's assets as of the curtailment date, which resulted in an actuarial loss of $0.8 million . The following table sets forth the changes in the funded status of the principal U.S. pension plan and the principal non-U.S. pension plans and the amounts recognized in the Company’s consolidated balance sheets as of January 3, 2016 and December 28, 2014 . January 3, 2016 December 28, 2014 Non-U.S. U.S. Non-U.S. U.S. (In thousands) Actuarial present value of benefit obligations: Accumulated benefit obligations $ 267,862 $ 301,416 $ 291,640 $ 327,632 Change in benefit obligations: Projected benefit obligations at beginning of year $ 303,809 $ 327,632 $ 288,216 $ 279,299 Service cost 2,532 1,800 2,670 1,400 Interest cost 7,695 13,001 10,575 12,900 Benefits paid and plan expenses (11,100 ) (24,127 ) (12,280 ) (19,282 ) Participants’ contributions 343 — 394 — Plan curtailments (759 ) — — — Plan settlements (1,401 ) — — — Actuarial loss (gain) 131 (16,890 ) 42,095 53,315 Effect of exchange rate changes (24,290 ) — (27,861 ) — Projected benefit obligations at end of year $ 276,960 $ 301,416 $ 303,809 $ 327,632 Change in plan assets: Fair value of plan assets at beginning of year $ 156,767 $ 256,254 $ 143,704 $ 249,756 Actual return on plan assets 3,745 (7,434 ) 22,939 25,780 Benefits paid and plan expenses (11,100 ) (24,127 ) (12,280 ) (19,282 ) Employer’s contributions 10,908 20,000 11,195 — Participants’ contributions 343 — 394 — Plan settlements (1,401 ) — — — Effect of exchange rate changes (8,368 ) — (9,185 ) — Fair value of plan assets at end of year 150,894 244,693 156,767 256,254 Net liabilities recognized in the consolidated balance sheets $ (126,066 ) $ (56,723 ) $ (147,042 ) $ (71,378 ) Net amounts recognized in the consolidated balance sheets consist of: Noncurrent assets $ 12,135 $ — $ 9,825 $ — Current liabilities (6,261 ) — (6,786 ) — Noncurrent liabilities (131,940 ) (56,723 ) (150,081 ) (71,378 ) Net liabilities recognized in the consolidated balance sheets $ (126,066 ) $ (56,723 ) $ (147,042 ) $ (71,378 ) Net amounts recognized in accumulated other comprehensive income consist of: Prior service cost $ (932 ) $ — $ (1,371 ) $ — Net amounts recognized in accumulated other comprehensive income $ (932 ) $ — $ (1,371 ) $ — Actuarial assumptions as of the year-end measurement date: Discount rate 2.88 % 4.25 % 2.75 % 4.08 % Rate of compensation increase 3.26 % None 3.07 % None Actuarial assumptions used to determine net periodic pension cost during the year were as follows: January 3, 2016 December 28, 2014 December 29, 2013 Non-U.S. U.S. Non-U.S. U.S. Non-U.S. U.S. Discount rate 2.75 % 4.08 % 3.77 % 4.77 % 3.62 % 3.92 % Rate of compensation increase 3.28 % None 3.23 % None 2.88 % None Expected rate of return on assets 4.60 % 7.25 % 5.30 % 7.25 % 5.50 % 7.50 % The following table provides a breakdown of the non-U.S. benefit obligations and fair value of assets for pension plans that have benefit obligations in excess of plan assets: January 3, December 28, (In thousands) Pension Plans with Projected Benefit Obligations in Excess of Plan Assets Projected benefit obligations $ 138,201 $ 156,867 Fair value of plan assets — — Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets Accumulated benefit obligations $ 134,858 $ 153,239 Fair value of plan assets — — Assets of the defined benefit pension plans are primarily equity and debt securities. Asset allocations as of January 3, 2016 and December 28, 2014 , and target asset allocations for fiscal year 2016 are as follows: Target Allocation Percentage of Plan Assets at January 1, 2017 January 3, 2016 December 28, 2014 Asset Category Non-U.S. U.S. Non-U.S. U.S. Non-U.S. U.S. Equity securities 45-55% 40-50% 49 % 42 % 49 % 39 % Debt securities 45-55% 50-60% 50 % 58 % 50 % 61 % Other 0-5% 0-5% 1 % — % 1 % — % Total 100 % 100 % 100 % 100 % 100 % 100 % The Company maintains target allocation percentages among various asset classes based on investment policies established for the pension plans which are designed to maximize the total rate of return (income and appreciation) after inflation within the limits of prudent risk taking, while providing for adequate near-term liquidity for benefit payments. The Company’s expected rate of return on assets assumptions are derived from management’s estimates, as well as other information compiled by management, including studies that utilize customary procedures and techniques. The studies include a review of anticipated future long-term performance of individual asset classes and consideration of the appropriate asset allocation strategy given the anticipated requirements of the plans to determine the average rate of earnings expected on the funds invested to provide for the pension plans benefits. While the study gives appropriate consideration to recent fund performance and historical returns, the assumption is primarily a long-term, prospective rate. The Company's discount rate assumptions are derived from a range of factors, including a yield curve for certain plans, composed of the rates of return on high-quality fixed-income corporate bonds available at the measurement date and the related expected duration for the obligations, and a bond matching approach for certain plans. For the plans in the United States, as of December 28, 2014 the Company adopted a new mortality base table, RP-2014, with projection scale, MP-2014, that was published by the Society of Actuaries in 2014. The adoption of the new mortality base table resulted in a $32.1 million increase to the projected benefit obligation as of December 28, 2014. During fiscal year 2015, the Society of Actuaries issued an updated mortality improvement scale that reflects smaller improvements in longevity than predicted by its MP-2014 scale. The Company adopted the updated projection scale, MP-2015, as of January 3, 2016. The adoption of the updated projection scale resulted in a $6.8 million decrease to the projected benefit obligation at January 3, 2016. The changes to the projected benefit obligations due to the adoption of the mortality base table and projection scale are included within "Actuarial loss (gain)" in the Change in Benefit Obligations for fiscal years 2015 and 2014 above . The target allocations for plan assets are listed in the above table. Equity securities primarily include investments in large-cap and mid-cap companies located in the United States and abroad, and equity index funds. Debt securities include corporate bonds of companies from diversified industries, high-yield bonds, and U.S. government securities. Other types of investments include investments in non-U.S. government index linked bonds, multi-strategy hedge funds and venture capital funds that follow several different strategies. The fair values of the Company’s pension plan assets as of January 3, 2016 and December 28, 2014 by asset category, classified in the three levels of inputs described in Note 21 to the consolidated financial statements are as follows: Fair Value Measurements at January 3, 2016 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Cash $ 2,890 $ 2,890 $ — $ — Equity Securities: U.S. large-cap 30,357 30,357 — — International large-cap value 26,686 26,686 — — Emerging markets growth 10,600 10,600 — — Equity index funds 74,974 — 74,974 — Domestic real estate funds 2,735 2,735 — — Commodity funds 8,128 8,128 — — Fixed income securities: Non-U.S. Treasury Securities 21,531 — 21,531 — Corporate and U.S. debt instruments 137,117 28,746 108,371 — Corporate bonds 23,871 — 23,871 — High yield bond funds 3,324 3,324 — — Other types of investments: Multi-strategy hedge funds 23,415 — — 23,415 Venture capital funds 1 — — 1 Non-U.S. government index linked bonds 29,958 — 29,958 — Total assets measured at fair value $ 395,587 $ 113,466 $ 258,705 $ 23,416 Fair Value Measurements at December 28, 2014 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Cash $ 4,971 $ 4,971 $ — $ — Equity Securities: U.S. large-cap 28,602 28,602 — — International large-cap value 25,202 25,202 — — Emerging markets growth 13,010 13,010 — — Equity index funds 77,432 — 77,432 — Domestic real estate funds 2,860 2,860 — — Commodity funds 7,423 7,423 — — Fixed income securities: Non-U.S. Treasury Securities 22,025 — 22,025 — Corporate and U.S. debt instruments 147,834 53,813 94,021 — Corporate bonds 25,164 — 25,164 — High yield bond funds 3,614 3,614 — — Other types of investments: Multi-strategy hedge funds 23,332 — — 23,332 Venture capital funds 1 — — 1 Non-U.S. government index linked bonds 31,551 — 31,551 — Total assets measured at fair value $ 413,021 $ 139,495 $ 250,193 $ 23,333 Valuation Techniques: Valuation techniques utilized need to maximize the use of observable inputs and minimize the use of unobservable inputs. There have been no changes in the methodologies utilized at January 3, 2016 compared to December 28, 2014 . The following is a description of the valuation techniques utilized to measure the fair value of the assets shown in the table above. Equity Securities: Shares of registered investment companies that are publicly traded are categorized as Level 1 assets; they are valued at quoted market prices that represent the net asset value of the fund. These instruments have active markets. Equity index funds are mutual funds that are not publicly traded and are comprised primarily of underlying equity securities that are publicly traded on exchanges. Price quotes for the assets held by these funds are readily observable and available. Equity index funds are categorized as Level 2 assets. Fixed Income Securities: Fixed income mutual funds that are publicly traded are valued at quoted market prices that represent the net asset value of securities held by the fund and are categorized as Level 1 assets. Fixed income index funds that are not publicly traded are stated at net asset value as determined by the issuer of the fund based on the fair value of the underlying investments and are categorized as Level 2 assets. Individual fixed income bonds are categorized as Level 2 assets except where sufficient quoted prices exist in active markets, in which case such securities are categorized as Level 1 assets. These securities are valued using third-party pricing services. These services may use, for example, model-based pricing methods that utilize observable market data as inputs. Broker dealer bids or quotes of securities with similar characteristics may also be used. Other Types of Investments: Non-U.S. government index link bond funds are not publicly traded and are stated at net asset value as determined by the issuer of the fund based on the fair value of the underlying investments. Underlying investments consist of bonds in which payment of income on the principal is related to a specific price index and are categorized as Level 2 assets. Hedge funds, private equity funds and venture capital funds are valued at fair value by using the net asset values provided by the investment managers and are updated, if necessary, using analytical procedures, appraisals, public market data and/or inquiry of the investment managers. The net asset values are determined based upon the fair values of the underlying investments in the funds. These other investments invest primarily in readily available marketable securities and allocate gains, losses, and expense to the investor based on the ownership percentage as described in the fund agreements. They are categorized as Level 3 assets. The Company's policy is to recognize significant transfers between levels at the actual date of the event. A reconciliation of the beginning and ending Level 3 assets for fiscal years 2015, 2014 and 2013 is as follows: Fair Value Measurements Using Significant Unobservable Inputs (Level 3): Common Collective Trusts/Private Funds Venture Capital Funds Multi-strategy Hedge Funds Total (In thousands) Balance at December 30, 2012 $ 162 $ 7 $ 20,262 $ 20,431 Realized losses 7 — — 7 Unrealized (losses) gains (19 ) 1 2,427 2,409 Issuances, sales and settlements (150 ) — — (150 ) Balance at December 29, 2013 — 8 22,689 22,697 Unrealized (losses) gains — (7 ) 643 636 Balance at December 28, 2014 — 1 23,332 23,333 Unrealized gains — — 83 83 Balance at January 3, 2016 $ — $ 1 $ 23,415 $ 23,416 With respect to plans outside of the United States, the Company expects to contribute $9.3 million in the aggregate during fiscal year 2016. During fiscal year 2015 , the Company contributed $14.9 million , in the aggregate, to pension plans outside of the United States and $20.0 million to its defined benefit pension plan in the United States. During fiscal year 2014, the Company made contributions of $11.2 million , in the aggregate, to plans outside of the United States. During fiscal year 2013, the Company made contributions of $37.0 million for the 2012 plan year to its defined benefit pension plan in the United States. During fiscal year 2013, the Company contributed $20.2 million , in the aggregate, to plans outside of the United States, which includes an additional contribution of $10.0 million to its defined benefit pension plan in the United Kingdom. The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows: Non-U.S. U.S. (In thousands) 2016 $ 10,490 $ 17,950 2017 11,051 18,018 2018 11,466 18,289 2019 11,855 18,469 2020 12,473 18,683 2021-2025 67,253 95,733 The Company also sponsors a supplemental executive retirement plan to provide senior management with benefits in excess of normal pension benefits. Effective July 31, 2000, this plan was closed to new entrants. At January 3, 2016 and December 28, 2014 , the projected benefit obligations were $21.5 million and $24.5 million , respectively. Assets with a fair value of $0.6 million and $0.5 million , segregated in a trust (which is included in marketable securities and investments on the consolidated balance sheets), were available to meet this obligation as of January 3, 2016 and December 28, 2014 , respectively. Pension income and expenses for this plan netted to income of $1.6 million in fiscal year 2015 , expense of $4.8 million in fiscal year 2014 and income of $0.4 million in fiscal year 2013 . Postretirement Medical Plans: The Company provides healthcare benefits for eligible retired U.S. employees under a comprehensive major medical plan or under health maintenance organizations where available. Eligible U.S. employees qualify for retiree health benefits if they retire directly from the Company and have at least ten years of service. Generally, the major medical plan pays stated percentages of covered expenses after a deductible is met and takes into consideration payments by other group coverage and by Medicare. The plan requires retiree contributions under most circumstances and has provisions for cost-sharing charges. Effective January 1, 2000, this plan was closed to new hires. For employees retiring after 1991, the Company has capped its medical premium contribution based on employees’ years of service. The Company funds the amount allowable under a 401(h) provision in the Company’s defined benefit pension plan. Assets of the plan are primarily equity and debt securities and are available only to pay retiree health benefits. Net periodic postretirement medical benefit cost (credit) included the following components for the fiscal years ended: January 3, December 28, December 29, (In thousands) Service cost $ 108 $ 95 $ 106 Interest cost 143 155 135 Expected return on plan assets (1,062 ) (964 ) (965 ) Actuarial loss (gain) 971 (384 ) (182 ) Net periodic postretirement medical benefit cost (credit) $ 160 $ (1,098 ) $ (906 ) The following table sets forth the changes in the postretirement medical plan’s funded status and the amounts recognized in the Company’s consolidated balance sheets as of January 3, 2016 and December 28, 2014 . January 3, December 28, (In thousands) Actuarial present value of benefit obligations: Retirees $ 1,033 $ 1,159 Active employees eligible to retire 424 388 Other active employees 2,119 1,795 Accumulated benefit obligations at beginning of year 3,576 3,342 Service cost 108 95 Interest cost 143 155 Benefits paid (158 ) (157 ) Actuarial (gain) loss (308 ) 141 Change in accumulated benefit obligations during the year (215 ) 234 Retirees 907 1,033 Active employees eligible to retire 423 424 Other active employees 2,031 2,119 Accumulated benefit obligations at end of year 3,361 3,576 Change in plan assets: Fair value of plan assets at beginning of year 14,728 13,396 Actual return on plan assets (375 ) 1,332 Fair value of plan assets at end of year 14,353 14,728 Net assets recognized in the consolidated balance sheets $ 10,992 $ 11,152 Net amounts recognized in the consolidated balance sheets consist of: Noncurrent assets $ 10,992 $ 11,152 Net assets recognized in the consolidated balance sheets $ 10,992 $ 11,152 Net amounts recognized in accumulated other comprehensive income consist of: Prior service cost $ — $ — Net amounts recognized in accumulated other comprehensive income $ — $ — Actuarial assumptions as of the year-end measurement date: Discount rate 4.34 % 4.10 % Actuarial assumptions used to determine net cost during the year are as follows: January 3, December 28, December 29, Discount rate 4.10 % 4.77 % 3.86 % Expected rate of return on assets 7.25 % 7.25 % 7.50 % The Company maintains a master trust for plan assets related to the U.S. defined benefit plans and the U.S. postretirement medical plan. Accordingly, investment policies, target asset allocations and actual asset allocations are the same as those disclosed for the U.S. defined benefit plans. The fair values of the Company’s plan assets at January 3, 2016 and December 28, 2014 by asset category, classified in the three levels of inputs described in Note 21, are as follows: Fair Value Measurements at January 3, 2016 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Cash $ 133 $ 133 $ — $ — Equity Securities: U.S. large-cap 1,781 1,781 — — International large-cap value 1,566 1,566 — — Emerging markets growth 622 622 — — Domestic real estate funds 160 160 — — Commodity funds 477 477 — — Fixed income securities: Corporate debt instruments 8,045 1,687 6,358 — High yield bond funds 195 195 — — Other types of investments: Multi-strategy hedge funds 1,374 — — 1,374 Total assets measured at fair value $ 14,353 $ 6,621 $ 6,358 $ 1,374 Fair Value Measurements at December 28, 2014 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Cash $ 248 $ 248 $ — $ — Equity Securities: U.S. large-cap 1,644 1,644 — — International large-cap value 1,449 1,449 — — Emerging markets growth 748 748 — — Domestic real estate funds 164 164 — — Commodity funds 427 427 — — Fixed income securities: Corporate debt instruments 8,499 3,094 5,405 — High yield bond funds 208 208 — — Other types of investments: Multi-strategy hedge funds 1,341 — — 1,341 Total assets measured at fair value $ 14,728 $ 7,982 $ 5,405 $ 1,341 Valuation Techniques: Valuation techniques are the same as those disclosed for the U.S. defined benefit plans above. A reconciliation of the beginning and ending Level 3 assets for fiscal years 2015, 2014 and 2013 is as follows: Fair Value Measurements Using Significant Unobservable Inputs (Level 3): Common Collective Trusts/Private Funds Venture Capital Funds Multi-strategy Hedge Funds Total (In thousands) Balance at December 30, 2012 $ 9 $ 1 $ 1,184 $ 1,194 Unrealized (losses) gains (1 ) (1 ) 33 31 Issuances, sales and settlements (8 ) — — (8 ) Balance at December 29, 2013 — — 1,217 1,217 Unrealized gains — — 124 124 Balance at December 28, 2014 — — 1,341 1,341 Unrealized gains — — 33 33 Balance at January 3, 2016 $ — $ — $ 1,374 $ 1,374 The Company does no t expect to make any contributions to the postretirement medical plan during fiscal year 2016 . The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows: Postretirement Medical Plan (In thousands) 2016 $ 162 2017 171 2018 179 2019 189 2020 197 2021-2025 1,154 Deferred Compensation Plans: During fiscal year 1998, the Company implemented a nonqualified deferred compensation plan that provides benefits payable to officers and certain key employees or their designated beneficiaries at specified future dates, or upon retirement or death. The plan was amended to eliminate deferral elections, with the exception of Company 401(k) excess contributions for eligible participants, for plan years beginning January 1, 2011. Benefit payments under the plan are funded by contributions from participants, and for certain participants, contributions by the Company. The obligations related to the deferred compensation plan totaled $1.2 million and $1.0 million at January 3, 2016 and December 28, 2014 , respectively. |
Contingencies
Contingencies | 12 Months Ended |
Jan. 03, 2016 | |
Commitments and Contingencies Disclosure [Abstract] | |
Contingencies | Contingencies The Company is conducting a number of environmental investigations and remedial actions at current and former locations of the Company and, along with other companies, has been named a potentially responsible party (“PRP”) for certain waste disposal sites. The Company accrues for environmental issues in the accounting period that the Company's responsibility is established and when the cost can be reasonably estimated. The Company has accrued $11.8 million and $12.3 million as of January 3, 2016 and December 28, 2014 , respectively, which represents its management’s estimate of the cost of the remediation of known environmental matters, and does not include any potential liability for related personal injury or property damage claims. During fiscal year 2014, the Company recorded a benefit of $2.3 million for cost reimbursements related to a particular site for monitoring and mitigation activities. During fiscal year 2013, the Company accrued an additional $5.7 million related to a particular site for increased monitoring and mitigation activities. The Company's environmental accrual is not discounted and does not reflect the recovery of any material amounts through insurance or indemnification arrangements. The cost estimates are subject to a number of variables, including the stage of the environmental investigations, the magnitude of the possible contamination, the nature of the potential remedies, possible joint and several liability, the time period over which remediation may occur, and the possible effects of changing laws and regulations. For sites where the Company has been named a PRP, management does not currently anticipate any additional liability to result from the inability of other significant named parties to contribute. The Company expects that the majority of such accrued amounts could be paid out over a period of up to ten years. As assessment and remediation activities progress at each individual site, these liabilities are reviewed and adjusted to reflect additional information as it becomes available. There have been no environmental problems to date that have had, or are expected to have, a material adverse effect on the Company’s consolidated financial statements. While it is possible that a loss exceeding the amounts recorded in the consolidated financial statements may be incurred, the potential exposure is not expected to be materially different from those amounts recorded. The Company is subject to various claims, legal proceedings and investigations covering a wide range of matters that arise in the ordinary course of its business activities. Although the Company has established accruals for potential losses that it believes are probable and reasonably estimable, in the opinion of the Company’s management, based on its review of the information available at this time, the total cost of resolving these contingencies at January 3, 2016 should not have a material adverse effect on the Company’s consolidated financial statements. However, each of these matters is subject to uncertainties, and it is possible that some of these matters may be resolved unfavorably to the Company. |
Warranty Reserves
Warranty Reserves | 12 Months Ended |
Jan. 03, 2016 | |
Product Warranties Disclosures [Abstract] | |
Warranty Reserves | Warranty Reserves The Company provides warranty protection for certain products usually for a period of one year beyond the date of sale. The majority of costs associated with warranty obligations include the replacement of parts and the time for service personnel to respond to repair and replacement requests. A warranty reserve is recorded based upon historical results, supplemented by management’s expectations of future costs. Warranty reserves are included in “Accrued expenses and other current liabilities” on the consolidated balance sheets. A summary of warranty reserve activity for the fiscal years ended January 3, 2016 , December 28, 2014 and December 29, 2013 is as follows: (In thousands) Balance at December 30, 2012 $ 11,003 Provision charged to income 17,291 Payments (17,116 ) Adjustments to previously provided warranties, net (693 ) Foreign currency translation and acquisitions 49 Balance at December 29, 2013 10,534 Provision charged to income 17,447 Payments (16,750 ) Adjustments to previously provided warranties, net 73 Foreign currency translation and acquisitions (521 ) Balance at December 28, 2014 10,783 Provision charged to income 16,904 Payments (16,204 ) Adjustments to previously provided warranties, net (60 ) Foreign currency translation and acquisitions (501 ) Balance at January 3, 2016 $ 10,922 |
Stock Plans
Stock Plans | 12 Months Ended |
Jan. 03, 2016 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |
Stock Plans | Stock Plans Stock-Based Compensation: In addition to the Company’s Employee Stock Purchase Plan, the Company utilizes one stock-based compensation plan, the 2009 Incentive Plan (the “2009 Plan”). Under the 2009 Plan, 10.7 million shares of the Company's common stock are authorized for stock option grants, restricted stock awards, performance units and stock grants as part of the Company’s compensation programs. In addition to shares of the Company’s common stock originally authorized for issuance under the 2009 Plan, the 2009 Plan includes shares of the Company’s common stock previously granted under the Amended and Restated 2001 Incentive Plan and the 2005 Incentive Plan that were canceled or forfeited without the shares being issued. The following table summarizes total pre-tax compensation expense recognized related to the Company’s stock options, restricted stock, restricted stock units, performance units and stock grants, net of estimated forfeitures, included in the Company’s consolidated statements of operations for fiscal years 2015, 2014 and 2013 : January 3, December 28, December 29, (In thousands) Cost of product and service revenue $ 1,339 $ 1,456 $ 1,304 Research and development expenses 600 546 853 Selling, general and administrative expenses 15,780 12,462 11,896 Total stock-based compensation expense $ 17,719 $ 14,464 $ 14,053 The total income tax benefit recognized in the consolidated statements of operations for stock-based compensation was $5.8 million in fiscal year 2015 , $5.4 million in fiscal year 2014 and $4.4 million in fiscal year 2013 . Stock-based compensation costs capitalized as part of inventory were $0.2 million and $0.3 million as of January 3, 2016 and December 28, 2014 , respectively. The excess tax benefit recognized from stock compensation, classified as a financing cash activity, was $2.4 million in fiscal year 2015 , and zero in both fiscal years 2014 and 2013. Stock Options: The Company has granted options to purchase common shares at prices equal to the market price of the common shares on the date the option is granted. Conditions of vesting are determined at the time of grant. Options are generally exercisable in equal annual installments over a period of three years, and will generally expire seven years after the date of grant. Options replaced in association with business combination transactions are generally issued with the same terms of the respective plans under which they were originally issued. The fair value of each option grant is estimated using the Black-Scholes option pricing model. The fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility was calculated based on the historical and implied volatility of the Company’s stock. The average expected life was based on the contractual term of the option and historic exercise experience. The risk-free interest rate is based on United States Treasury zero-coupon issues with a remaining term equal to the expected life assumed at the date of grant. Forfeitures are estimated based on voluntary termination behavior, as well as an analysis of actual option forfeitures. The Company’s weighted-average assumptions used in the Black-Scholes option pricing model were as follows for the fiscal years ended: January 3, December 28, December 29, Risk-free interest rate 1.3 % 1.5 % 0.9 % Expected dividend yield 0.6 % 0.7 % 0.8 % Expected lives 5 years 5 years 5 years Expected stock volatility 26.5 % 30.9 % 38.5 % The following table summarizes stock option activity for the three fiscal years ended January 3, 2016 : January 3, 2016 December 28, 2014 December 29, 2013 Number of Shares Weighted- Average Exercise Price Number of Shares Weighted- Average Exercise Price Number of Shares Weighted- Average Exercise Price (Shares in thousands) Outstanding at beginning of year 2,828 $ 26.11 3,494 $ 23.34 4,266 $ 21.64 Granted 502 46.36 520 43.12 518 33.62 Exercised (849 ) 17.56 (1,024 ) 23.89 (947 ) 21.45 Canceled (4 ) 20.20 (4 ) 20.97 (8 ) 22.88 Forfeited (105 ) 33.90 (158 ) 35.33 (335 ) 23.04 Outstanding at end of year 2,372 $ 33.12 2,828 $ 26.11 3,494 $ 23.34 Exercisable at end of year 1,500 $ 27.01 1,900 $ 21.13 2,392 $ 20.66 The aggregate intrinsic value for stock options outstanding at January 3, 2016 was $42.7 million with a weighted-average remaining contractual term of 3.6 years. The aggregate intrinsic value for stock options exercisable at January 3, 2016 was $36.2 million with a weighted-average remaining contractual term of 2.5 years. At January 3, 2016 , there were 2.3 million stock options that were vested, and expected to vest in the future, with an aggregate intrinsic value of $42.1 million and a weighted-average remaining contractual term of 3.6 years. The weighted-average per-share grant-date fair value of options granted during fiscal years 2015, 2014 and 2013 was $11.02 , $11.86 , and $10.82 , respectively. The total intrinsic value of options exercised during fiscal years 2015, 2014 and 2013 was $25.9 million , $22.0 million , and $13.8 million , respectively. Cash received from option exercises for fiscal years 2015, 2014 and 2013 was $14.9 million , $24.5 million , and $20.3 million , respectively. The total compensation expense recognized related to the Company’s outstanding options was $4.2 million in fiscal year 2015 , $5.0 million in fiscal year 2014 and $4.4 million in fiscal year 2013 . There was $5.7 million of total unrecognized compensation cost, net of estimated forfeitures, related to nonvested stock options granted as of January 3, 2016 . This cost is expected to be recognized over a weighted-average period of 1.8 years, and will be adjusted for any future changes in estimated forfeitures. Restricted Stock Awards: The Company has awarded shares of restricted stock and restricted stock units to certain employees and non-employee directors at no cost to them, which cannot be sold, assigned, transferred or pledged during the restriction period. The restricted stock and restricted stock units vest through the passage of time, assuming continued employment. The fair value of the award at the time of the grant is expensed on a straight line basis primarily in selling, general and administrative expenses over the vesting period, which is generally three years. These awards were granted under the Company’s 2009 Plan. Recipients of the restricted stock have the right to vote such shares and receive dividends. The following table summarizes restricted stock award activity for the three fiscal years ended January 3, 2016 : January 3, 2016 December 28, 2014 December 29, 2013 Number of Shares Weighted- Average Grant- Date Fair Value Number of Shares Weighted- Average Grant- Date Fair Value Number of Shares Weighted- Average Grant- Date Fair Value (Shares in thousands) Nonvested at beginning of year 558 $ 35.51 649 $ 29.24 781 $ 24.71 Granted 245 46.86 261 42.61 289 33.87 Vested (249 ) 31.11 (258 ) 27.64 (346 ) 22.98 Forfeited (52 ) 40.71 (94 ) 33.58 (75 ) 28.76 Nonvested at end of year 502 $ 42.61 558 $ 35.51 649 $ 29.24 The fair value of restricted stock awards vested during fiscal years 2015, 2014 and 2013 was $7.8 million , $7.1 million , and $8.0 million , respectively. The total compensation expense recognized related to the restricted stock awards was $8.7 million in fiscal year 2015 , $7.1 million in fiscal year 2014 and $7.5 million in fiscal year 2013 . As of January 3, 2016 , there was $10.8 million of total unrecognized compensation cost, net of forfeitures, related to nonvested restricted stock awards. That cost is expected to be recognized over a weighted-average period of 1.3 years. Performance Units: The Company’s performance unit program provides a cash award based on the achievement of specific performance criteria. A target number of units are granted at the beginning of a three-year performance period. The number of units earned at the end of the performance period is determined by multiplying the number of units granted by a performance factor ranging from 0% to 200% . Awards are determined by multiplying the number of units earned by the stock price at the end of the performance period, and are paid in cash and accounted for as a liability based award. The compensation expense associated with these units is recognized over the period that the performance targets are expected to be achieved. The Company granted 66,509 performance units, 79,463 performance units, and 98,056 performance units during fiscal years 2015, 2014 and 2013 , respectively. The weighted-average per-share grant-date fair value of performance units granted during fiscal years 2015, 2014 and 2013 was $46.83 , $42.84 , and $34.06 , respectively. During fiscal years 2015, 2014 and 2013 , 8,860 , 35,954 and 28,515 performance units were forfeited, respectively. The total compensation expense related to performance units was $4.0 million , $1.6 million , and $1.4 million for fiscal years 2015, 2014 and 2013 , respectively. As of January 3, 2016 , there were 201,415 performance units outstanding subject to forfeiture, with a corresponding liability of $5.9 million recorded in accrued expenses and long-term liabilities. Stock Awards: The Company’s stock award program provides non-employee directors an annual equity award. For fiscal years 2015, 2014 and 2013 the award equaled the number of shares of the Company’s common stock which has an aggregate fair market value of $100,000 on the date of the award. The stock award is prorated for non-employee directors who serve for only a portion of the year. The compensation expense associated with these stock awards is recognized when the stock award is granted. In fiscal years 2015, 2014 and 2013 , each non-employee director was awarded 1,953 shares, 2,373 shares, and 3,263 shares, respectively. The Company also granted 544 shares to a new non-employee director during fiscal year 2015. The weighted-average per-share grant-date fair value of stock awards granted during fiscal years 2015, 2014 and 2013 was $51.01 , $42.14 , and $30.65 , respectively. In each of fiscal years 2015, 2014 and 2013 , the total compensation expense recognized related to these stock awards was $0.7 million . Employee Stock Purchase Plan: In April 1999, the Company’s shareholders approved the 1998 Employee Stock Purchase Plan. In April 2005, the Compensation and Benefits Committee of the Board voted to amend the Employee Stock Purchase Plan, effective July 1, 2005, whereby participating employees have the right to purchase common stock at a price equal to 95% of the closing price on the last day of each six-month offering period. The number of shares which an employee may purchase, subject to certain aggregate limits, is determined by the employee’s voluntary contribution, which may not exceed 10% of the employee’s base compensation. During fiscal year 2015 , the Company issued 78,294 shares of common stock under the Company’s Employee Stock Purchase Plan at a weighted-average price of $47.08 per share. During fiscal year 2014 , the Company issued 60,870 shares under this plan at a weighted-average price of $41.71 per share. During fiscal year 2013 , the Company issued 89,521 shares under this plan at a weighted-average price of $30.51 per share. At January 3, 2016 there remains available for sale to employees an aggregate of 1.0 million shares of the Company’s common stock out of the 5.0 million shares authorized by shareholders for issuance under this plan. |
Stockholders' Equity
Stockholders' Equity | 12 Months Ended |
Jan. 03, 2016 | |
Stockholders' Equity Note [Abstract] | |
Stockholders' Equity | Stockholders’ Equity Comprehensive Income: The components of accumulated other comprehensive (loss) income consisted of the following: Foreign Currency Translation Adjustment, net of tax Unrecognized Prior Service Costs, net of tax Unrealized (Losses) Gains on Securities, net of tax Unrealized and Realized (Losses) Gains on Derivatives, net of tax Accumulated Other Comprehensive Income (Loss) (In thousands) Balance, December 30, 2012 $ 67,527 $ 2,087 $ (129 ) $ (2,892 ) $ 66,593 Current year change 8,756 (658 ) 8 2,892 10,998 Balance, December 29, 2013 76,283 1,429 (121 ) — 77,591 Current year change (52,951 ) 146 14 — (52,791 ) Balance, December 28, 2014 23,332 1,575 (107 ) — 24,800 Current year change (70,178 ) (316 ) (262 ) — (70,756 ) Balance, January 3, 2016 $ (46,846 ) $ 1,259 $ (369 ) $ — $ (45,956 ) During fiscal year 2013, pre-tax losses of $4.8 million were reclassified from accumulated other comprehensive income into interest and other expense, net, related to previously settled cash flow hedges, which includes $2.8 million for the remaining unamortized derivative losses that were reclassified when the Company redeemed all of its 2015 Notes. The Company recognized a tax provision of $1.9 million related to these amounts reclassified out of accumulated other comprehensive income for fiscal year 2013. During fiscal years 2015, 2014 and 2013 , pre-tax income of $0.3 million , pre-tax expense of $0.1 million , and pre-tax income of $0.7 million , respectively, were reclassified from accumulated other comprehensive income into selling, general and administrative expenses as a component of net periodic benefit cost. Stock Repurchase Program: On October 23, 2014, the Board of Directors (the "Board") authorized the Company to repurchase up to 8.0 million shares of common stock under a stock repurchase program (the "Repurchase Program"). The Repurchase Program will expire on October 23, 2016 unless terminated earlier by the Board, and may be suspended or discontinued at any time. On October 24, 2012, the Board authorized the Company to repurchase up to 6.0 million shares of common stock under a stock repurchase program (the "Former Repurchase Program"). The Former Repurchase Program expired on October 24, 2014. During fiscal year 2015 , the Company repurchased 1.5 million shares of common stock in the open market at an aggregate cost of $72.0 million , including commissions, under the Repurchase Program. During fiscal year 2014 , the Company repurchased 1.4 million shares of common stock in the open market at an aggregate cost of $61.3 million , including commissions, under the Repurchase Program and the Former Repurchase Program. During fiscal year 2013 , the Company repurchased 3.6 million shares of common stock in the open market at an aggregate cost of $123.0 million , including commissions, under the Former Repurchase Program. As of January 3, 2016 , 5.9 million shares remained available for repurchase under the Repurchase Program. From January 4, 2016 through February 25, 2016 , the Company repurchased 2.4 million shares of common stock in the open market at an aggregate cost of $109.7 million , including commissions, under the Repurchase Program. The Board has authorized the Company to repurchase shares of common stock to satisfy minimum statutory tax withholding obligations in connection with the vesting of restricted stock awards and restricted stock unit awards granted pursuant to the Company’s equity incentive plans and to satisfy obligations related to the exercise of stock options made pursuant to the Company's equity incentive plans. During fiscal year 2015 , the Company repurchased 95,129 shares of common stock for this purpose at an aggregate cost of $4.4 million . During fiscal year 2014 , the Company repurchased 98,269 shares of common stock for this purpose at an aggregate cost of $4.3 million . During fiscal year 2013 , the Company repurchased 127,544 shares of common stock for this purpose at an aggregate cost of $4.4 million . The repurchased shares have been reflected as additional authorized but unissued shares, with the payments reflected in common stock and capital in excess of par value. Dividends: The Board declared a regular quarterly cash dividend of $0.07 per share in each quarter of fiscal years 2015 and 2014 . At January 3, 2016 , the Company has accrued $7.8 million for dividends declared on October 29, 2015 for the fourth quarter of fiscal year 2015 that was paid in February 2016 . On January 28, 2016 , the Company announced that the Board had declared a quarterly dividend of $0.07 per share for the first quarter of fiscal year 2016 that will be payable in May 2016 . In the future, the Board may determine to reduce or eliminate the Company’s common stock dividend in order to fund investments for growth, repurchase shares or conserve capital resources. |
Derivatives And Hedging Activit
Derivatives And Hedging Activities | 12 Months Ended |
Jan. 03, 2016 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Derivatives and Hedging Activities | Derivatives and Hedging Activities The Company uses derivative instruments as part of its risk management strategy only, and includes derivatives utilized as economic hedges that are not designated as hedging instruments. By nature, all financial instruments involve market and credit risks. The Company enters into derivative instruments with major investment grade financial institutions and has policies to monitor the credit risk of those counterparties. The Company does not enter into derivative contracts for trading or other speculative purposes, nor does the Company use leveraged financial instruments. Approximately 60% of the Company’s business is conducted outside of the United States, generally in foreign currencies. As a result, fluctuations in foreign currency exchange rates can increase the costs of financing, investing and operating the business. In the ordinary course of business, the Company enters into foreign exchange contracts for periods consistent with its committed exposures to mitigate the effect of foreign currency movements on transactions denominated in foreign currencies. The intent of these economic hedges is to offset gains and losses that occur on the underlying exposures from these currencies, with gains and losses resulting from the forward currency contracts that hedge these exposures. Transactions covered by hedge contracts include intercompany and third-party receivables and payables. The contracts are primarily in European and Asian currencies, have maturities that do not exceed 12 months , have no cash requirements until maturity, and are recorded at fair value on the Company’s consolidated balance sheets. The unrealized gains and losses on the Company’s foreign currency contracts are recognized immediately in interest and other expense, net. The cash flows related to the settlement of these hedges are included in cash flows from operating activities within the Company’s consolidated statement of cash flows. Principal hedged currencies include the British Pound, Euro, Japanese Yen and Singapore Dollar. The Company held forward foreign exchange contracts, designated as economic hedges, with U.S. dollar equivalent notional amounts totaling $127.3 million at January 3, 2016 , $95.0 million at December 28, 2014 , and $138.4 million at December 29, 2013 , and the fair value of these foreign currency derivative contracts was insignificant. The gains and losses realized on these foreign currency derivative contracts are not material. The duration of these contracts was generally 30 days or less during each of fiscal years 2015, 2014 and 2013 . In addition, in connection with certain intercompany loan agreements utilized to finance its acquisitions, the Company enters into forward foreign exchange contracts intended to hedge movements in foreign exchange rates prior to settlement of such intercompany loans denominated in foreign currencies. The Company records these hedges at fair value on the Company’s consolidated balance sheets. The unrealized gains and losses on these hedges, as well as the gains and losses associated with the remeasurement of the intercompany loans, are recognized immediately in interest and other expense, net. The cash flows related to the settlement of these hedges are included in cash flows from financing activities within the Company’s consolidated statement of cash flows. During fiscal year 2014, the Company entered into five forward foreign exchange contracts, designated as economic hedges, with settlement dates in fiscal year 2015 and combined Euro denominated notional amounts of €238.2 million outstanding as of December 28, 2014 , designated as economic hedges, that were intended to hedge movements in foreign exchange rates prior to settlement of certain intercompany loan agreements. During fiscal year 2015, the Company settled several of these forward exchange contracts. During fiscal year 2015, the Company also entered into new forward foreign exchange contracts that settled in fiscal year 2015 or will settle in fiscal year 2016. The combined Euro denominated notional amounts of these outstanding hedges was €107.4 million and €238.2 million as of January 3, 2016 and December 28, 2014 , respectively. The net gains and losses on these derivatives, combined with the gains and losses on the remeasurement of the hedged intercompany loans, were not material for fiscal years 2015 and 2014 . During fiscal year 2015 , the Company received $18.7 million as a result of the settlement of these hedges. In May 2008 , the Company settled forward interest rate contracts with notional amounts totaling $150.0 million upon the issuance of its 2015 Notes, and recognized $8.4 million , net of taxes of $5.4 million , of accumulated derivative losses in other comprehensive (loss) income. During fiscal year 2013, the Company amortized a pre-tax loss of $2.0 million into interest and other expense, net. In addition, during fiscal year 2013, the Company redeemed all of its 2015 Notes and recognized a pre-tax loss of $2.8 million for the remaining unamortized derivative losses into interest and other expense, net. The Company does no t expect any material net pre-tax gains or losses to be reclassified from accumulated other comprehensive (loss) income into interest and other expense, net within the next twelve months. |
Fair Value Measurements
Fair Value Measurements | 12 Months Ended |
Jan. 03, 2016 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | Fair Value Measurements Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents, derivatives, marketable securities and accounts receivable. The Company believes it had no significant concentrations of credit risk as of January 3, 2016 . The Company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during fiscal years 2015 and 2014 . The Company’s financial assets and liabilities carried at fair value are primarily comprised of marketable securities, derivative contracts used to hedge the Company’s currency risk, and acquisition related contingent consideration. The Company has not elected to measure any additional financial instruments or other items at fair value. Valuation Hierarchy: The following summarizes the three levels of inputs required to measure fair value. For Level 1 inputs, the Company utilizes quoted market prices as these instruments have active markets. For Level 2 inputs, the Company utilizes quoted market prices in markets that are not active, broker or dealer quotations, or utilizes alternative pricing sources with reasonable levels of price transparency. For Level 3 inputs, the Company utilizes unobservable inputs based on the best information available, including estimates by management primarily based on information provided by third-party fund managers, independent brokerage firms and insurance companies. A financial asset’s or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The following tables show the assets and liabilities carried at fair value measured on a recurring basis as of January 3, 2016 and December 28, 2014 classified in one of the three classifications described above: Fair Value Measurements at January 3, 2016 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Marketable securities $ 1,586 $ 1,586 $ — $ — Foreign exchange derivative assets 2,659 — 2,659 — Foreign exchange derivative liabilities (442 ) — (442 ) — Contingent consideration (57,350 ) — — (57,350 ) Fair Value Measurements at December 28, 2014 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Marketable securities $ 1,568 $ 1,568 $ — $ — Foreign exchange derivative assets 3,205 — 3,205 — Foreign exchange derivative liabilities, net (302 ) — (302 ) — Contingent consideration (91 ) — — (91 ) Level 1 and Level 2 Valuation Techniques: The Company’s Level 1 and Level 2 assets and liabilities are comprised of investments in equity and fixed-income securities as well as derivative contracts. For financial assets and liabilities that utilize Level 1 and Level 2 inputs, the Company utilizes both direct and indirect observable price quotes, including common stock price quotes, foreign exchange forward prices and bank price quotes. Below is a summary of valuation techniques for Level 1 and Level 2 financial assets and liabilities. Marketable securities: Include equity and fixed-income securities measured at fair value using the quoted market prices in active markets at the reporting date. Foreign exchange derivative assets and liabilities: Include foreign exchange derivative contracts that are valued using quoted forward foreign exchange prices at the reporting date. The Company’s foreign exchange derivative contracts are subject to master netting arrangements that allow the Company and its counterparties to net settle amounts owed to each other. Derivative assets and liabilities that can be net settled under these arrangements have been presented in the Company's consolidated balance sheet on a net basis and are recorded in other assets. As of both January 3, 2016 and December 28, 2014 , none of the master netting arrangements involved collateral. Level 3 Valuation Techniques: The Company’s Level 3 liabilities are comprised of contingent consideration related to acquisitions. For liabilities that utilize Level 3 inputs, the Company uses significant unobservable inputs. Below is a summary of valuation techniques for Level 3 liabilities. Contingent consideration: Contingent consideration is measured at fair value at the acquisition date using projected milestone dates, discount rates, probabilities of success and projected revenues (for revenue-based considerations). Projected risk-adjusted contingent payments are discounted back to the current period using a discounted cash flow model. During fiscal year 2015, the Company acquired certain assets and assumed certain liabilities from Vanadis. Under the terms of the acquisition, the initial purchase consideration was $32.0 million , net of cash and the Company will be obligated to make potential future milestone payments, based on completion of a proof of concept, regulatory approvals and product sales, of up to $93.0 million ranging from 2016 to 2019. The key assumptions used to determine the fair value of the contingent consideration included projected milestone dates of 2016 to 2019 , discount rates ranging from 3.1% to 11.3% , conditional probabilities of success of each individual milestone ranging from 85% to 95% and cumulative probabilities of success for each individual milestone ranging from 53% to 90% . The fair value of the contingent consideration as of the acquisition date was estimated at $56.9 million . A significant delay in the product development (including projected regulatory milestone) achievement date in isolation could result in a significantly lower fair value measurement; a significant acceleration in the product development (including projected regulatory milestone) achievement date in isolation would not have a material impact on the fair value measurement; a significant change in the discount rate in isolation would not have a material impact on the fair value measurement; and a significant change in the probabilities of success in isolation could result in a significant change in fair value measurement. The fair values of contingent consideration are calculated on a quarterly basis based on a collaborative effort of the Company’s regulatory, research and development, operations, finance and accounting groups, as appropriate. Potential valuation adjustments are made as additional information becomes available, including the progress towards achieving proof of concept, regulatory approvals and revenue targets as compared to initial projections, the impact of market competition and market landscape shifts from non-invasive prenatal testing products, with the impact of such adjustments being recorded in the consolidated statements of operations. As of January 3, 2016 , the Company may have to pay contingent consideration, related to acquisitions with open contingency periods, of up to $95.4 million . The expected maximum earnout period for acquisitions with open contingency periods does not exceed 6 years from the respective acquisition dates, and the remaining weighted average expected earnout period at January 3, 2016 was 2 years. A reconciliation of the beginning and ending Level 3 net liabilities for contingent consideration is as follows: (In thousands) Balance at December 30, 2012 $ (3,017 ) Additions (1,100 ) Amounts paid and foreign currency translation 135 Change in fair value (included within selling, general and administrative expenses) (944 ) Balance at December 29, 2013 (4,926 ) Additions — Amounts paid and foreign currency translation 2,074 Change in fair value (included within selling, general and administrative expenses) 2,761 Balance at December 28, 2014 (91 ) Additions (57,353 ) Amounts paid and foreign currency translation 113 Change in fair value (included within selling, general and administrative expenses) (19 ) Balance at January 3, 2016 $ (57,350 ) The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term maturities of these assets and liabilities. If measured at fair value, cash and cash equivalents would be classified as Level 1. As of January 3, 2016 , the Company’s senior unsecured revolving credit facility, which provides for $700.0 million of revolving loans, had borrowings outstanding of $482.0 million , which excluded $2.4 million unamortized debt issuance costs and letters of credit. As of December 28, 2014 , the senior unsecured revolving credit facility had $516.0 million of borrowings outstanding, which excluded $3.2 million unamortized debt issuance costs and letters of credit. The interest rate on the Company’s senior unsecured revolving credit facility is reset at least monthly to correspond to variable rates that reflect currently available terms and conditions for similar debt. The Company had no change in credit standing during fiscal year 2015 . Consequently, the borrowing value of the current year and prior year credit facilities approximate fair value and would be classified as Level 2. The Company's 2021 Notes, with a face value of $500.0 million , had an aggregate carrying value of $495.1 million , net of $2.0 million of unamortized original issue discount and $2.9 million of unamortized debt issuance costs as of January 3, 2016 . The 2021 Notes had an aggregate carrying value of $494.4 million , net of $2.3 million of unamortized original issue discount and $3.3 million of unamortized debt issuance costs as of December 28, 2014 . The 2021 Notes had a fair value of $518.9 million and $542.7 million as of January 3, 2016 and December 28, 2014 , respectively. The fair value of the 2021 Notes is estimated using market quotes from brokers and is based on current rates offered for similar debt. The Company's financing lease obligations had an aggregate carrying value of $38.2 million and $39.3 million as of January 3, 2016 and December 28, 2014 , respectively. The carrying values of the Company's financing lease obligations approximated their fair value as there has been minimal change in the Company's incremental borrowing rate. As of January 3, 2016 , the 2021 Notes and financing lease obligations were classified as Level 2. As of January 3, 2016 , there has not been any significant impact to the fair value of the Company’s derivative liabilities due to credit risk. Similarly, there has not been any significant adverse impact to the Company’s derivative assets based on the evaluation of its counterparties’ credit risks. |
Leases
Leases | 12 Months Ended |
Jan. 03, 2016 | |
Leases [Abstract] | |
Leases | Leases The Company leases certain property and equipment under operating leases. Rental expense charged to continuing operations for fiscal years 2015, 2014 and 2013 amounted to $54.4 million , $54.8 million , and $52.6 million , respectively. Minimum rental commitments under noncancelable operating leases are as follows: $51.0 million in fiscal year 2016 , $34.1 million in fiscal year 2017 , $25.9 million in fiscal year 2018 , $20.2 million in fiscal year 2019 , $16.4 million in fiscal year 2020 and $48.7 million in fiscal year 2021 and thereafter . On August 22, 2013 , the Company sold one of its facilities located in Boston, Massachusetts for net proceeds of $47.6 million . Simultaneously with the closing of the sale of the property, the Company entered into a lease agreement to lease back the property for its continued use. The lease has an initial term of 15 years and the Company has the right to extend the term of the lease for two additional periods of ten years each. The lease is accounted for as an operating lease and at the transaction date the Company had deferred $26.5 million of gains which are being amortized in operating expenses over the initial lease term of 15 years . During fiscal years 2015, 2014 and 2013 , the Company amortized $1.8 million , $1.8 million and $0.6 million , respectively, of deferred gains related to the lease. The deferred gains remaining to be amortized were $22.3 million at January 3, 2016 , of which $1.8 million was recorded in accrued expenses and other current liabilities, and $20.5 million was recorded in long-term liabilities. The deferred gains remaining to be amortized were $24.1 million at December 28, 2014 , of which $1.8 million was recorded in accrued expenses and other current liabilities, and $22.3 million was recorded in long-term liabilities. |
Industry Segment and Geographic
Industry Segment and Geographic Area Information | 12 Months Ended |
Jan. 03, 2016 | |
Segment Reporting [Abstract] | |
Industry Segment Information | Industry Segment and Geographic Area Information The Company discloses information about its operating segments based on the way that management organizes the segments within the Company for making operating decisions and assessing financial performance. The Company evaluates the performance of its operating segments based on revenue and operating income. Intersegment revenue and transfers are not significant. The Company’s management reviews the results of the Company’s operations by the Human Health and Environmental Health operating segments. The accounting policies of the operating segments are the same as those described in Note 1. The Company realigned its organization at the beginning of fiscal year 2015 to enable the Company to both deliver complete solutions targeted towards certain end markets and develop value-added applications and solutions to foster further expansion of those markets. OneSource, the Company's multivendor laboratory service business that serves the life sciences end market, was moved from the Environmental Health segment into the Human Health segment. The results reported for fiscal year 2015 reflect this new alignment of the Company's operating segments. Financial information in this report relating to fiscal years 2014 and 2013 has been retrospectively adjusted to reflect this change to the Company's operating segments. The principal products and services of the Company's two operating segments are: • Human Health . Develops diagnostics, tools and applications to help detect diseases earlier and more accurately and to accelerate the discovery and development of critical new therapies. The Human Health segment serves both the diagnostics and research markets. • Environmental Health . Provides products, services and solutions to facilitate the creation of safer food and consumer products, more secure surroundings and efficient energy resources. The Environmental Health segment serves the environmental, industrial and laboratory services markets. The Company has included the expenses for its corporate headquarters, such as legal, tax, audit, human resources, information technology, and other management and compliance costs, as well as the activity related to the mark-to-market adjustment on postretirement benefit plans, as “Corporate” below. The Company has a process to allocate and recharge expenses to the reportable segments when these costs are administered or paid by the corporate headquarters based on the extent to which the segment benefited from the expenses. These amounts have been calculated in a consistent manner and are included in the Company’s calculations of segment results to internally plan and assess the performance of each segment for all purposes, including determining the compensation of the business leaders for each of the Company’s operating segments. Revenue and operating income (loss) from continuing operations by operating segment are shown in the table below for the fiscal years ended: January 3, December 28, December 29, (In thousands) Human Health Product revenue $ 976,451 $ 996,767 $ 957,022 Service revenue 400,193 387,456 368,872 Total revenue 1,376,644 1,384,223 1,325,894 Operating income from continuing operations (1) 251,743 233,689 168,794 Environmental Health Product revenue 576,187 543,308 541,048 Service revenue 309,528 309,688 290,644 Total revenue 885,715 852,996 831,692 Operating income from continuing operations 89,544 95,605 84,710 Corporate Operating loss from continuing operations (2)(3) (55,153 ) (118,552 ) (25,710 ) Continuing Operations Product revenue $ 1,552,638 $ 1,540,075 $ 1,498,070 Service revenue 709,721 697,144 659,516 Total revenue 2,262,359 2,237,219 2,157,586 Operating income from continuing operations 286,134 210,742 227,794 Interest and other expense, net (see Note 5) 42,119 41,139 64,110 Income from continuing operations before income taxes $ 244,015 $ 169,603 $ 163,684 ____________________________ (1) Legal costs for a particular case in the Human Health segment were $0.8 million for fiscal year 2015 . The Company also recognized a $0.2 million pre-tax impairment charge in the Human Health segment in fiscal year 2013. Both of these items have been included in operating income from continuing operations in the Human Health segment. (2) Activity related to the mark-to-market adjustment on postretirement benefit plans has been included in the Corporate operating loss from continuing operations, and in the aggregate constituted a pre-tax loss of $12.4 million in fiscal year 2015 , a pre-tax loss of $75.9 million in fiscal year 2014 , and pre-tax income of $17.6 million in fiscal year 2013 . (3) Includes expenses related to litigation with Enzo Biochem, Inc. and Enzo Life Sciences, Inc. (collectively, “Enzo”). Enzo filed a complaint in 2002 that alleged that the Company separately and together with other defendants breached distributorship and settlement agreements with Enzo, infringed Enzo's patents, engaged in unfair competition and fraud, and committed torts against Enzo by, among other things, engaging in commercial development and exploitation of Enzo's patented products and technology. The Company entered into a settlement agreement with Enzo dated June 20, 2014 and during fiscal year 2014 paid $7.0 million into a designated escrow account to resolve this matter, of which $3.7 million had been accrued in previous years and $3.3 million was recorded during fiscal year 2014. In addition, $3.4 million of expenses were incurred and recorded in preparation for the trial during fiscal year 2014. Additional information relating to the Company’s reporting segments is as follows for the three fiscal years ended January 3, 2016 : Depreciation and Amortization Expense Capital Expenditures January 3, December 28, December 29, January 3, December 28, December 29, (In thousands) (In thousands) Human Health $ 81,335 $ 92,604 $ 100,941 $ 16,091 $ 16,922 $ 22,999 Environmental Health 29,213 22,101 23,556 10,352 10,428 14,433 Corporate 1,459 2,031 2,382 3,189 1,722 1,549 Continuing operations 112,007 116,736 126,879 29,632 29,072 38,981 Discontinued operations $ — $ 339 $ 1,590 $ — $ 213 $ 10 Total Assets January 3, December 28, December 29, (In thousands) Human Health $ 2,778,835 $ 2,737,824 $ 2,724,254 Environmental Health 1,358,963 1,361,270 1,182,356 Corporate 28,497 28,482 28,441 Net current and long-term assets of discontinued operations — — 5,831 Total assets $ 4,166,295 $ 4,127,576 $ 3,940,882 The following geographic area information for continuing operations includes revenue based on location of external customers for the three fiscal years ended January 3, 2016 and net long-lived assets based on physical location as of January 3, 2016 and December 28, 2014 : Revenue January 3, December 28, December 29, (In thousands) U.S. $ 916,314 $ 849,356 $ 826,991 International: China 312,915 276,230 254,838 United Kingdom 112,763 134,614 133,611 Germany 105,421 107,081 99,153 Italy 74,744 85,433 78,120 France 74,651 84,946 81,719 Japan 72,624 93,811 95,676 Other international 592,927 605,748 587,478 Total international 1,346,045 1,387,863 1,330,595 Total sales $ 2,262,359 $ 2,237,219 $ 2,157,586 Net Long-Lived Assets January 3, December 28, December 29, (In thousands) U.S. $ 192,681 $ 192,176 $ 208,891 International: China 34,494 36,797 30,682 United Kingdom 14,751 13,033 9,882 Finland 12,203 12,758 13,635 Singapore 7,679 7,041 6,812 Netherlands 3,835 3,614 4,037 Italy 2,958 4,107 2,735 Germany 2,171 2,493 2,591 Other international 10,598 12,664 11,045 Total international 88,689 92,507 81,419 Total net long-lived assets $ 281,370 $ 284,683 $ 290,310 |
Quarterly Financial Information
Quarterly Financial Information (Unaudited) | 12 Months Ended |
Jan. 03, 2016 | |
Quarterly Financial Information Disclosure [Abstract] | |
Quarterly Financial Information (Unaudited) | Quarterly Financial Information (Unaudited) Selected quarterly financial information is as follows for the fiscal years ended: First Quarter Second Quarter Third Quarter Fourth Quarter (1) Year (In thousands, except per share data) January 3, 2016 Revenue $ 526,901 $ 563,906 $ 563,436 $ 608,116 $ 2,262,359 Gross profit 235,374 252,512 254,603 282,011 1,024,500 Restructuring and contract termination charges, net — 4,956 (118 ) 8,752 13,590 Operating income from continuing operations 57,381 68,131 75,898 84,724 286,134 Income from continuing operations before income taxes 47,960 57,288 63,954 74,813 244,015 Income from continuing operations 40,311 48,996 54,897 68,484 212,688 Net income 40,334 48,974 54,863 68,254 212,425 Basic earnings per share: Income from continuing operations $ 0.36 $ 0.43 $ 0.49 $ 0.61 $ 1.89 Net income 0.36 0.43 0.49 0.61 1.89 Diluted earnings per share: Income from continuing operations $ 0.36 $ 0.43 $ 0.48 $ 0.61 $ 1.88 Net income 0.36 0.43 0.48 0.61 1.87 Cash dividends declared per common share 0.07 0.07 0.07 0.07 0.28 December 28, 2014 Revenue $ 530,610 $ 556,170 $ 542,049 $ 608,390 $ 2,237,219 Gross profit 235,713 247,984 243,309 277,602 1,004,608 Restructuring and contract termination charges, net 2,135 742 11,092 (579 ) 13,390 Operating income from continuing operations 51,762 69,637 58,776 30,567 210,742 Income from continuing operations before income taxes 40,473 60,673 47,810 20,647 169,603 Income from continuing operations 34,951 52,003 42,898 31,314 161,166 Net income 34,224 50,490 42,277 30,787 157,778 Basic earnings per share: Income from continuing operations $ 0.31 $ 0.46 $ 0.38 $ 0.28 $ 1.43 Net income 0.30 0.45 0.38 0.27 1.40 Diluted earnings per share: Income continuing operations $ 0.31 $ 0.46 $ 0.38 $ 0.28 $ 1.42 Net income 0.30 0.44 0.37 0.27 1.39 Cash dividends declared per common share 0.07 0.07 0.07 0.07 0.28 ____________________________ (1) The fourth quarter of fiscal year 2015 includes a pre-tax loss of $12.4 million as a result of the mark-to-market adjustment on postretirement benefit plans. The fourth quarter of fiscal year 2014 includes a pre-tax loss of $75.9 million as a result of the mark-to-market adjustment on postretirement benefit plans. See Note 1 for a discussion of this accounting policy. |
Nature of Operations and Acco32
Nature of Operations and Accounting Policies Nature of Operations and Accounting Policies (Policies) | 12 Months Ended |
Jan. 03, 2016 | |
Accounting Policies [Abstract] | |
Consolidation [Policy Text Block] | The consolidated financial statements include the accounts of PerkinElmer, Inc. and its subsidiaries (the “Company”). All intercompany balances and transactions have been eliminated in consolidation. |
Segment Reporting [Policy Text Block] | The Company has two operating segments; Human Health and Environmental Health. The Company’s Human Health segment concentrates on developing diagnostics, tools and applications to help detect diseases earlier and more accurately and to accelerate the discovery and development of critical new therapies. Within the Human Health segment, the Company serves both the diagnostics and research markets. The Company’s Environmental Health segment provides products, services and solutions to facilitate the creation of safer food and consumer products, more secure surroundings and efficient energy resources. The Environmental Health segment serves the environmental, industrial and laboratory services markets. The Company realigned its organization at the beginning of fiscal year 2015. OneSource, the Company's multivendor laboratory service business that serves the life sciences end market, was moved from the Environmental Health segment into the Human Health segment. The results reported for fiscal year 2015 reflect this new alignment of the Company's operating segments. Financial information in this report relating to fiscal years 2014 and 2013 has been retrospectively adjusted to reflect this change to the Company's operating segments. |
Fiscal Periods [Policy Text Block] | The Company's fiscal year ends on the Sunday nearest December 31. The Company reports fiscal years under a 52/53 week format and as a result, certain fiscal years will contain 53 weeks. The fiscal year ended January 3, 2016 included 53 weeks. The additional week in fiscal year 2015 has been reflected in the Company's third quarter. Each of the fiscal years ended December 28, 2014 and December 29, 2013 included 52 weeks. The fiscal year ending January 1, 2017 will include 52 weeks. |
Subsequent Events [Policy Text Block] | The Company has evaluated subsequent events from January 3, 2016 through the date of the issuance of these consolidated financial statements and has determined that other than the events the Company has disclosed within the notes to the consolidated financial statements, no material subsequent events have occurred that would affect the information presented in these consolidated financial statements. |
Accounting Policies and Estimates [Policy Text Block] | Accounting Policies and Estimates: The preparation of consolidated financial statements in accordance with United States (“U.S.”) Generally Accepted Accounting Principles (“GAAP”) requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. |
Revenue Recognition [Policy Text Block] | Revenue Recognition: The Company’s product revenue is recorded when persuasive evidence of an arrangement exists, delivery has occurred, the price to the buyer is fixed or determinable, and collectability is reasonably assured. For products that include installation, and if the installation meets the criteria to be considered a separate element, product revenue is recognized upon delivery, and installation revenue is recognized when the installation is complete. For revenue that includes customer-specified acceptance criteria, revenue is recognized after the acceptance criteria have been met. Certain of the Company’s products require specialized installation. Revenue for these products is deferred until installation is completed. Revenue from services is deferred and recognized over the contractual period, or as services are rendered. In limited circumstances, the Company has arrangements that include multiple elements that are delivered at different points of time, such as revenue from products and services with a remaining service or storage component, including cord blood processing and storage. For these arrangements, the revenue is allocated to each of the deliverables based upon their relative selling prices as determined by a selling-price hierarchy. A deliverable in an arrangement qualifies as a separate unit of accounting if the delivered item has value to the customer on a stand-alone basis. A delivered item that does not qualify as a separate unit of accounting is combined with the other undelivered items in the arrangement and revenue is recognized for those combined deliverables as a single unit of accounting. The selling price used for each deliverable is based upon vendor-specific objective evidence ("VSOE") if such evidence is available, third-party evidence ("TPE") if VSOE is not available, and management's best estimate of selling price ("BESP") if neither VSOE nor TPE are available. TPE is the price of the Company's or any competitor's largely interchangeable products or services in stand-alone sales to similarly-situated customers. BESP is the price at which the Company would sell the deliverable if it were sold regularly on a stand-alone basis, considering market conditions and entity-specific factors. Revenue from software licenses and services was 5% of the Company's total revenue for each of fiscal years 2015, 2014 and 2013 . The Company sells its software licenses with maintenance services and, in some cases, also with consulting services. For the undelivered elements, the Company determines VSOE of fair value to be the price charged when the undelivered element is sold separately. The Company determines VSOE for maintenance sold in connection with a software license based on the amount that will be separately charged for the maintenance renewal period. The Company determines VSOE for consulting services by reference to the amount charged for similar engagements when a software license sale is not involved. The Company recognizes revenue from software licenses sold together with maintenance and/or consulting services upon shipment using the residual method, provided that the above criteria have been met. If VSOE of fair value for the undelivered elements cannot be established, the Company defers all revenue from the arrangement until the earlier of the point at which such sufficient VSOE does exist or all elements of the arrangement have been delivered, or if the only undelivered element is maintenance, then the Company recognizes the entire fee ratably over the maintenance period. The Company recognizes revenue from the grant of certain intellectual property rights for patented technologies it owns. These rights typically include a combination of the following: the grant of a non-exclusive, retroactive and future license to patented technologies, a covenant-not-to-sue, the release of the licensee from certain claims, and the dismissal of any pending litigation. The intellectual property rights granted may be perpetual in nature, extending until the expiration of the related patents, or can be granted for a defined timeframe. For these arrangements, the revenue is allocated to each of the deliverables based upon their relative selling prices as determined by the selling-price hierarchy. In the case where the agreement includes the dismissal of any pending litigation, the Company allocates between revenue and litigation settlement using the residual method. The Company recognizes revenue when the earnings process is complete and upon the execution of the agreement, when collectability is reasonably assured, or upon receipt of the minimum upfront fee for term agreement renewals, and when all other revenue recognition criteria have been met. Service revenues represent the Company’s service offerings including service contracts, field service including related time and materials, diagnostic testing, cord blood processing and storage, and training. Service revenues are recognized as the service is performed. Revenues for service contracts and storage contracts are recognized over the contract period. The Company sells products and accessories predominantly through its direct sales force. As a result, the use of distributors is generally limited to geographic regions where the Company has no direct sales force. The Company does not offer product return or exchange rights (other than those relating to defective goods under warranty) or price protection allowances to its customers, including its distributors. Payment terms granted to distributors are the same as those granted to end-user customers and payments are not dependent upon the distributors’ receipt of payment from their end-user customers. Sales incentives related to distributor revenue are also the same as those for end-user customers. |
Warranty Costs [Policy Text Block] | Warranty Costs : The Company provides for estimated warranty costs for products at the time of their sale. Warranty liabilities are estimated using expected future repair costs based on historical labor and material costs incurred during the warranty period. |
Shipping and Handling Costs [Policy Text Block] | Shipping and Handling Costs: The Company reports shipping and handling revenue in revenue, to the extent they are billed to customers, and the associated costs in cost of product revenue. |
Inventories [Policy Text Block] | Inventories : Inventories, which include material, labor and manufacturing overhead, are valued at the lower of cost or market. Inventories are accounted for using the first-in, first-out method of determining inventory costs. Inventory quantities on-hand are regularly reviewed, and where necessary, provisions for excess and obsolete inventory are recorded based primarily on the Company’s estimated forecast of product demand and production requirements. |
Income Taxes [Policy Text Block] | Income Taxes: The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases. This method also requires the recognition of future tax benefits such as net operating loss carryforwards, to the extent that realization of such benefits is more likely than not. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the fiscal years in which those temporary differences are expected to be recovered or settled. A valuation allowance is established for any deferred tax asset for which realization is not more likely than not. With respect to earnings expected to be indefinitely reinvested offshore, the Company does not accrue tax for the repatriation of such foreign earnings. The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions and other issues. These reserves are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is more likely than not to be realized following resolution of any potential contingencies present related to the tax benefit. Potential interest and penalties associated with such uncertain tax positions is recorded as a component of income tax expense. See Note 6, below, for additional details. |
Property, Plant and Equipment [Policy Text Block] | Property, Plant and Equipment: The Company depreciates property, plant and equipment using the straight-line method over its estimated useful lives, which generally fall within the following ranges: buildings- 10 to 40 years; leasehold improvements-estimated useful life or remaining term of lease, whichever is shorter; and machinery and equipment- 3 to 7 years. Certain tooling costs are capitalized and amortized over a 3 -year life, while repairs and maintenance costs are expensed. |
Asset Retirement Obligations [Policy Text Block] | Asset Retirement Obligations : The Company records obligations associated with its lease obligations, the retirement of tangible long-lived assets and the associated asset retirement costs in accordance with authoritative guidance on asset retirement obligations. The Company reviews legal obligations associated with the retirement of long-lived assets that result from contractual obligations or the acquisition, construction, development and/or normal use of the assets. If it is determined that a legal obligation exists, regardless of whether the obligation is conditional on a future event, the fair value of the liability for an asset retirement obligation is recognized in the period in which it is incurred, if a reasonable estimate of fair value can be made. The fair value of the liability is added to the carrying amount of the associated asset, and this additional carrying amount is depreciated over the life of the asset. The difference between the gross expected future cash flow and its present value is accreted over the life of the related lease as interest expense. The amounts recorded in the consolidated financial statements are not material to any year presented. |
Change in Accounting for Pension and Other Postretirement Benefits [Policy Text Block] | Pension and Other Postretirement Benefits: The Company sponsors both funded and unfunded U.S. and non-U.S. defined benefit pension plans and other postretirement benefits. The Company immediately recognizes actuarial gains and losses in operating results in the year in which the gains and losses occur. Actuarial gains and losses are measured annually as of the calendar month-end that is closest to the Company's fiscal year end and accordingly will be recorded in the fourth quarter, unless the Company is required to perform an interim remeasurement. The remaining components of pension expense, primarily service and interest costs and assumed return on plan assets, are recorded on a quarterly basis. The Company’s funding policy provides that payments to the U.S. pension trusts shall at least be equal to the minimum funding requirements of the Employee Retirement Income Security Act of 1974. Non-U.S. plans are accrued for, but generally not fully funded, and benefits are paid from operating funds. |
Translation of Foreign Currencies [Policy Text Block] | Translation of Foreign Currencies: For foreign operations, asset and liability accounts are translated at current exchange rates; income and expenses are translated using weighted average exchange rates for the reporting period. Resulting translation adjustments, as well as translation gains and losses from certain intercompany transactions considered permanent in nature, are reported in accumulated other comprehensive (loss) income, a separate component of stockholders’ equity. Gains and losses arising from transactions and translation of period-end balances denominated in currencies other than the functional currency are included in other expense, net |
Business Combinations [Policy Text Block] | Business Combinations: Business combinations are accounted for at fair value. Acquisition costs are expensed as incurred and recorded in selling, general and administrative expenses; previously held equity interests are valued at fair value upon the acquisition of a controlling interest; in-process research and development (“IPR&D”) is recorded at fair value as an intangible asset at the acquisition date; restructuring costs associated with a business combination are expensed subsequent to the acquisition date; and changes in deferred tax asset valuation allowances and income tax uncertainties after the acquisition date affect income tax expense. Measurement period adjustments are made in the period in which the amounts are determined and the current period income effect of such adjustments will be calculated as if the adjustments had been completed as of the acquisition date. All changes that do not qualify as measurement period adjustments are also included in current period earnings. The accounting for business combinations requires estimates and judgment as to expectations for future cash flows of the acquired business, and the allocation of those cash flows to identifiable intangible assets, in determining the estimated fair value for assets acquired and liabilities assumed. The fair values assigned to tangible and intangible assets acquired and liabilities assumed, including contingent consideration, are based on management’s estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. If the actual results differ from the estimates and judgments used in these estimates, the amounts recorded in the financial statements could result in a possible impairment of the intangible assets and goodwill, require acceleration of the amortization expense of finite-lived intangible assets, or the recognition of additional consideration which would be expensed. |
Goodwill and Other Intangible Assets [Policy Text Block] | Goodwill and Other Intangible Assets: The Company’s intangible assets consist of (i) goodwill, which is not being amortized; (ii) indefinite lived intangibles, which consist of a trade name that is not subject to amortization; and (iii) amortizing intangibles, which consist of patents, trade names and trademarks, licenses, customer relationships, and purchased technologies, which are being amortized over their estimated useful lives. The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of a two-step process. The first step is the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. The second step measures the amount of an impairment loss, and is only performed if the carrying value exceeds the fair value of the reporting unit. This annual impairment assessment is performed by the Company on the later of January 1 or the first day of each fiscal year. This same impairment test will be performed at other times during the course of the year, should an event occur which suggests that the recoverability of goodwill should be reconsidered. Non-amortizing intangibles are also subject to an annual impairment test. The impairment test consists of a comparison of the fair value of the non-amortizing intangible asset with its carrying amount. If the carrying amount of a non-amortizing intangible asset exceeds its fair value, an impairment loss in an amount equal to that excess is recognized . In addition, the Company evaluates the remaining useful life of its non-amortizing intangible assets at least annually to determine whether events or circumstances continue to support an indefinite useful life. If events or circumstances indicate that the useful lives of non-amortizing intangible assets are no longer indefinite, the assets will be tested for impairment. These intangible assets will then be amortized prospectively over their estimated remaining useful life and accounted for in the same manner as other intangible assets that are subject to amortization. Recoverability of amortizing intangible assets is assessed only when events have occurred that may give rise to impairment. When a potential impairment has been identified, forecasted undiscounted net cash flows of the operations to which the asset relates are compared to the current carrying value of the long-lived assets present in that operation. If such cash flows are less than such carrying amounts, long-lived assets, including such intangibles, are written down to their respective fair values. See Note 12, below, for additional details. |
Stock-Based Compensation [Policy Text Block] | Stock-Based Compensation: The Company accounts for stock-based compensation expense based on estimated grant date fair value, generally using the Black-Scholes option-pricing model. The fair value is recognized, net of estimated forfeitures, as expense in the consolidated financial statements over the requisite service period. The determination of fair value and the timing of expense using option pricing models such as the Black-Scholes model require the input of highly subjective assumptions, including the expected term and the expected price volatility of the underlying stock. The Company estimates the expected term assumption based on historical experience. In determining the Company’s expected stock price volatility assumption, the Company reviews both the historical and implied volatility of the Company’s common stock, with implied volatility based on the implied volatility of publicly traded options on the Company’s common stock. The Company has one stock-based compensation plan from which it makes grants, which is described more fully in Note 18, below. |
Marketable Securities and Investments [Policy Text Block] | Marketable Securities and Investments: The cost of securities sold is based on the specific identification method. If securities are classified as available for sale, the Company records these investments at their fair values with unrealized gains and losses included in accumulated other comprehensive (loss) income. Under the cost method of accounting, equity investments in private companies are carried at cost and are adjusted for other-than-temporary declines in fair value, additional investments or distributions. |
Cash Flows [Policy Text Block] | Cash and Cash Equivalents: The Company considers all highly liquid unrestricted instruments with a purchased maturity of three months or less to be cash equivalents. The carrying amount of cash equivalents approximates fair value due to the short maturities of these instruments. |
Environmental Matters [Policy Text Block] | Environmental Matters: The Company accrues for costs associated with the remediation of environmental pollution when it is probable that a liability has been incurred and the Company’s proportionate share of the amount can be reasonably estimated. The recorded liabilities have not been discounted. |
Research and Development Expense, Policy [Policy Text Block] | Research and Development: Research and development costs are expensed as incurred. The fair value of acquired IPR&D costs are recorded at fair value as an intangible asset at the acquisition date and amortized once the product is ready for sale or expensed if abandoned. |
Restructuring Charges [Policy Text Block] | Restructuring Charges: In recent fiscal years, the Company has undertaken a series of restructuring actions related to the impact of acquisitions and divestitures, the alignment of its operations with its growth strategy, the integration of its business units and productivity initiatives. In connection with these initiatives, the Company has recorded restructuring charges, as more fully described in Note 4, below. Generally, costs associated with an exit or disposal activity are recognized when the liability is incurred. Prior to recording restructuring charges for employee separation agreements, the Company notifies all employees of termination. Costs related to employee separation arrangements requiring future service beyond a specified minimum retention period are recognized over the service period. Costs related to lease terminations are recorded at the fair value of the liability based on the remaining lease rental payments, reduced by estimated sublease rentals that could be reasonably obtained for the property, at the date the Company ceases use. |
New Accounting Pronouncement or Change in Accounting Principle, Description | Comprehensive Income: Comprehensive income is defined as net income or loss and other changes in stockholders’ equity from transactions and other events from sources other than stockholders. Comprehensive income is reflected in the consolidated statements of comprehensive income. |
Derivative Instruments and Hedging [Policy Text Block] | Derivative Instruments and Hedging: Derivatives are recorded on the consolidated balance sheets at fair value. Accounting for gains or losses resulting from changes in the values of those derivatives depends on the use of the derivative instrument and whether it qualifies for hedge accounting. For a cash flow hedge, the effective portion of the derivative’s gain or loss is initially reported as a component of other comprehensive income and subsequently amortized into net earnings when the hedged exposure affects net earnings. Cash flow hedges related to anticipated transactions are designated and documented at the inception of each hedge by matching the terms of the contract to the underlying transaction. The Company classifies the cash flows from hedging transactions in the same categories as the cash flows from the respective hedged items. Once established, cash flow hedges are generally recorded in other comprehensive income, unless an anticipated transaction is no longer likely to occur, and subsequently amortized into net earnings when the hedged exposure affects net earnings. Discontinued or dedesignated cash flow hedges are immediately settled with counterparties, and the related accumulated derivative gains or losses are recognized into net earnings on the consolidated financial statements. Settled cash flow hedges related to forecasted transactions that remain probable are recorded as a component of other comprehensive (loss) income and are subsequently amortized into net earnings when the hedged exposure affects net earnings. Forward contract effectiveness for cash flow hedges is calculated by comparing the fair value of the contract to the change in value of the anticipated transaction using forward rates on a monthly basis. The Company also has entered into other foreign currency forward contracts that are not designated as hedging instruments for accounting purposes. These contracts are recorded at fair value, with the changes in fair value recognized into interest and other expense, net on the consolidated financial statements. |
Description of New Accounting Pronouncements Not yet Adopted [Text Block] | Recently Issued Accounting Pronouncements: From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (the "FASB") and are adopted by the Company as of the specified effective dates. Unless otherwise discussed, such pronouncements did not have or will not have a significant impact on the Company’s consolidated financial position, results of operations and cash flows or do not apply to the Company’s operations. In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases . The provisions of this guidance are effective for annual periods beginning after December 15, 2018, and interim periods within those years, with early adoption permitted. The Company is evaluating the requirements of this guidance and has not yet determined the impact of the adoption on its consolidated financial position, results of operations and cash flows. In November 2015, the FASB issued Accounting Standards Update No. 2015-17, Balance Sheet Classification of Deferred Taxes ("ASU No. 2015-17"). Under this new guidance, companies are required to present deferred tax assets and deferred tax liabilities, and any related valuation allowances, as noncurrent on the company's consolidated balance sheet. The provisions of this guidance can be applied prospectively or retrospectively and are effective for interim and annual periods beginning after December 15, 2016, with early adoption permitted. During fiscal year 2015, the Company early adopted the new guidance on a prospective basis and has presented all deferred tax assets and deferred tax liabilities as noncurrent in the consolidated balance sheet at January 3, 2016. If the Company elected to adopt the standard on a retrospective basis, current deferred tax assets of $62.0 million would have been classified as noncurrent at December 28, 2014 . In September 2015, the FASB issued Accounting Standards Update No. 2015-16, Simplifying the Accounting for Measurement-Period Adjustments ("ASU No. 2015-16"). Under this new guidance, an acquirer should recognize adjustments to provisional amounts for items in a business combination that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. The acquirer should record, in the same period’s financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting had been completed at the acquisition date. The provisions of this guidance are to be applied prospectively and are effective for interim and annual periods beginning after December 15, 2015, with early adoption permitted. During the third quarter of fiscal year 2015, the Company early adopted the new guidance and adjusted the provisional amounts recorded for acquisitions in which the purchase accounting allocations were preliminary. During fiscal year 2015, there was an immaterial impact on the current period net income as a result of the change to the provisional amounts for items that would have been recognized in previous periods if the adjustments to provisional amounts had been recognized as of the acquisition date. See Note 2, below, for additional details. In July 2015, the FASB issued Accounting Standards Update No. 2015-11, Simplifying the Measurement of Inventory . Under this new guidance, companies that use inventory measurement methods other than last-in, first-out or the retail inventory method should measure inventory at the lower of cost and net realizable value. The provisions of this guidance are to be applied prospectively and are effective for interim and annual periods beginning after December 15, 2016, with early adoption permitted. The Company is evaluating the requirements of this guidance. The adoption is not expected to have a material impact on the Company’s consolidated financial position, results of operations and cash flows. In April 2015, the FASB issued Accounting Standards Update No. 2015-04, Practical Expedient for the Measurement Date of an Employer’s Defined Benefit Obligation and Plan Assets . Under this new guidance, an entity with a fiscal year-end that does not coincide with a calendar month-end (for example an entity that has a 52/53 week fiscal year) has the ability, as a practical expedient, to measure its defined benefit retirement obligations and related plan assets as of the month-end that is closest to its fiscal year end. The provisions of this guidance should be applied prospectively. During fiscal year 2015, the Company early adopted the new guidance. The adoption did not have a material impact on the Company's consolidated financial position, results of operations or cash flows. In April 2015, the FASB issued Accounting Standards Update No. 2015-03, Interest - Imputation of Interest - Simplifying the Presentation of Debt Issuance Costs . Under this new guidance, debt issuance costs related to a recognized debt liability should be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The provisions of this guidance are to be applied retrospectively and are effective for interim and annual periods beginning after December 15, 2015, with early adoption permitted. The Company early adopted this guidance in the fourth quarter of fiscal year 2015. The consolidated balance sheet as of December 28, 2014, included in these consolidated financial statements, reflects a restatement to reclassify unamortized debt issuance costs of $6.5 million from other long-term assets to long-term debt. For debt issuance costs paid to secure revolving credit facilities, the Company made a policy election to present such costs as a direct deduction from the debt liability on the consolidated balance sheet. In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers . Under this new guidance, an entity should use a five-step process to recognize revenue, depicting the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard also requires new disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. Subsequent to the issuance of the standard, the FASB decided to defer the effective date for one year to annual periods beginning after December 15, 2017, with early adoption permitted for annual periods beginning after December 15, 2016. The standard may be adopted either using a full retrospective approach or a modified retrospective approach. The Company is evaluating the requirements of this guidance and has not yet determined the transition method to use or the impact of its adoption on the Company’s consolidated financial position, results of operations and cash flows. The Company does not intend to early adopt this standard. |
Business Combinations and Ass33
Business Combinations and Asset Purchases (Tables) | 12 Months Ended |
Jan. 03, 2016 | |
Business Acquisition [Line Items] | |
Fair Values of the Business Combinations and Allocations for the Acquisitions Completed | The total purchase price for the acquisitions in fiscal year 2015 has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: 2015 Acquisitions (Preliminary) (In thousands) Fair value of business combination: Cash payments $ 75,285 Contingent consideration 56,878 Working capital and other adjustments 1,832 Less: cash acquired (3,864 ) Total $ 130,131 Identifiable assets acquired and liabilities assumed: Current assets $ 2,551 Property, plant and equipment 998 Identifiable intangible assets: Core technology 15,759 Trade names 200 Licenses 116 Customer relationships 3,073 IPR&D 75,700 Goodwill 51,356 Deferred taxes (16,772 ) Liabilities assumed (2,850 ) Total $ 130,131 The total purchase price for the acquisitions in fiscal year 2014 has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: Perten 2014 Other Acquisitions (In thousands) Fair value of business combination: Cash payments $ 269,937 $ 17,898 Working capital and other adjustments — (294 ) Less: cash acquired (16,732 ) (124 ) Total $ 253,205 $ 17,480 Identifiable assets acquired and liabilities assumed: Current assets $ 32,578 $ 1,935 Property, plant and equipment 1,485 125 Other assets — 364 Identifiable intangible assets: Core technology 17,000 1,705 Trade names 8,000 — Customer relationships 87,000 6,800 IPR&D — 1,266 Goodwill 160,776 15,518 Deferred taxes (28,612 ) (3,072 ) Deferred revenue — (589 ) Liabilities assumed (17,422 ) (2,285 ) Debt assumed (7,600 ) (4,287 ) Total $ 253,205 $ 17,480 |
Discontinued Operations (Tables
Discontinued Operations (Tables) | 12 Months Ended |
Jan. 03, 2016 | |
Discontinued Operations and Disposal Groups [Abstract] | |
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block] | Summary pre-tax operating results of the discontinued operations, which include the periods prior to disposition and a $1.0 million pre-tax restructuring charge related to workforce reductions in the microarray-based diagnostic testing laboratory in the United States during fiscal year 2014, were as follows during the three fiscal years ended: January 3, December 28, December 29, (In thousands) Revenue $ 98 $ 348 $ 8,646 Costs and expenses 101 5,307 18,998 Loss from discontinued operations before income taxes $ (3 ) $ (4,959 ) $ (10,352 ) |
Restructuring and Contract Te35
Restructuring and Contract Terminaiton Charges, Net (Tables) | 12 Months Ended |
Jan. 03, 2016 | |
Restructuring and Related Activities [Abstract] | |
Restructuring and Related Costs [Table Text Block] | The following table summarizes the number of employees reduced, the initial restructuring or contract termination charges by operating segment, and the dates by which payments were substantially completed, or the expected dates by which payments will be substantially completed, for restructuring actions implemented during fiscal years 2015, 2014 and 2013 : Workforce Reductions Closure of Excess Facility Total (Expected) Date Payments Substantially Completed by Headcount Reduction Human Health Environmental Health Human Health Environmental Health Severance Excess Facility (In thousands, except headcount data) Q4 2015 Plan 174 $ 2,230 $ 9,065 $ 285 $ — $ 11,580 Q1 FY2017 Q4 FY2017 Q2 2015 Plan 97 1,850 4,160 — — 6,010 Q2 FY2016 — Q3 2014 Plan 152 7,126 5,925 — — 13,051 Q4 FY2015 — Q2 2014 Plan 22 545 190 — — 735 Q2 FY2015 — Q1 2014 Plan 17 370 197 — — 567 Q4 FY2014 — Q4 2013 Plan 73 955 2,953 7,271 — 11,179 Q4 FY2014 Q1 FY2019 Q3 2013 Plan 29 394 — 138 — 532 Q1 FY2014 Q4 FY2013 Q2 2013 Plan (1) 264 9,523 8,609 522 50 18,704 Q4 FY2014 Q3 FY2014 Q1 2013 Plan 62 2,340 245 — — 2,585 Q3 FY2013 — ____________________________ (1) Subsequent to the initial charge, during fiscal year 2013, the Company recorded an additional $0.6 million pre-tax restructuring charge in the Human Health segment for the Q2 2013 Plan for services that were provided for one-time termination benefits in which the employee was required to render service beyond the legal notification period. |
Schedule of Restructuring Reserve by Type of Cost [Table Text Block] | The following table summarizes the Company's restructuring accrual balances and related activity by restructuring plan, as well as contract termination accrual balances and related activity, during fiscal years 2015, 2014 and 2013 : Balance at December 30, 2012 2013 Charges and Changes in Estimates, Net 2013 Amounts Paid Balance at December 29, 2013 2014 Charges and Changes in Estimates, Net 2014 Amounts Paid Balance at December 28, 2014 2015 Charges and Changes in Estimates, Net 2015 Amounts Paid Balance at January 3, 2016 (In thousands) Severance: Q4 2015 Plan $ — $ — $ — $ — $ — $ — $ — $ 11,295 $ (925 ) $ 10,370 Q2 2015 Plan (1) — — — — — — — 5,471 (4,322 ) 1,149 Q3 2014 Plan (2) — — — — 13,051 (2,992 ) 10,059 (3,064 ) (5,460 ) 1,535 Q2 2014 Plan (3) — — — — 735 (484 ) 251 (179 ) (13 ) 59 Q1 2014 Plan (4) — — — — 567 (475 ) 92 (92 ) — — Facility: Q4 2015 Plan — — — — — — — 285 (26 ) 259 Previous Plans including 2013 plans (5) 27,151 33,196 (25,112 ) 35,235 (2,508 ) (19,603 ) 13,124 (209 ) (4,222 ) 8,693 Restructuring 27,151 33,196 (25,112 ) 35,235 11,845 (23,554 ) 23,526 13,507 (14,968 ) 22,065 Contract Termination 596 696 (992 ) 300 1,545 (1,541 ) 304 83 (255 ) 132 Total Restructuring and Contract Termination $ 27,747 $ 33,892 $ (26,104 ) $ 35,535 $ 13,390 $ (25,095 ) $ 23,830 $ 13,590 $ (15,223 ) $ 22,197 ____________________________ (1) During fiscal year 2015 , the Company recognized pre-tax restructuring reversals of $0.2 million in the Human Health segment and $0.3 million in the Environmental Health segment related to lower than expected costs associated with workforce reductions for the Q2 2015 Plan. (2) During fiscal year 2015 , the Company recognized pre-tax restructuring reversals of $1.2 million in the Human Health segment and $1.9 million in the Environmental Health segment related to lower than expected costs associated with workforce reductions for the Q3 2014 Plan. (3) During fiscal year 2015 , the Company recognized pre-tax restructuring reversals of $0.1 million in each of the Human Health and Environmental Health segments related to lower than expected costs associated with workforce reductions for the Q2 2014 Plan. (4) During fiscal year 2015 , the Company recognized a pre-tax restructuring reversal of $0.1 million in the Human Health segment related to lower than expected costs associated with workforce reductions for the Q1 2014 Plan. (5) During fiscal year 2015 , the Company recognized a pre-tax restructuring charge of $1.4 million in the Human Health segment primarily related to higher than expected costs associated with the closure of the excess facility space, which was offset by a pre-tax restructuring reversal of $1.6 million in the Environmental Health segment primarily related to lower than expected costs associated with workforce reductions for the previous restructuring plans. During fiscal year 2014 , the Company recognized pre-tax restructuring reversals of $0.8 million in the Human Health segment and $1.7 million in the Environmental Health segment primarily related to lower than expected costs associated with workforce reductions, which was partially offset by higher than expected costs associated with the closure of the excess facility space for the previous restructuring plans. |
Interest and Other Expense (I36
Interest and Other Expense (Income), Net (Tables) | 12 Months Ended |
Jan. 03, 2016 | |
Other Income and Expenses [Abstract] | |
Interest and Other Expense (Income), Net | Interest and other expense, net, consisted of the following for the fiscal years ended: January 3, December 28, December 29, (In thousands) Interest income $ (673 ) $ (667 ) $ (650 ) Interest expense 37,997 36,270 49,924 Other expense, net 4,795 5,536 14,836 Total interest and other expense, net $ 42,119 $ 41,139 $ 64,110 |
Income Taxes (Tables)
Income Taxes (Tables) | 12 Months Ended |
Jan. 03, 2016 | |
Income Tax Disclosure [Abstract] | |
Summary of Income Tax Contingencies [Table Text Block] | The tabular reconciliation of the total amounts of unrecognized tax benefits is as follows for the fiscal years ended: January 3, December 28, December 29, (In thousands) Unrecognized tax benefits, beginning of year $ 32,342 $ 39,410 $ 58,110 Gross increases—tax positions in prior periods 325 — 325 Gross decreases—tax positions in prior periods (2,305 ) (1,809 ) (10,539 ) Gross increases—current-period tax positions — 239 2,222 Settlements (441 ) (1,400 ) (3,643 ) Lapse of statute of limitations (1,077 ) (4,129 ) (6,495 ) Foreign currency translation adjustments (701 ) 31 (570 ) Unrecognized tax benefits, end of year $ 28,143 $ 32,342 $ 39,410 |
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] | The components of income (loss) from continuing operations before income taxes were as follows for the fiscal years ended: January 3, December 28, December 29, (In thousands) U.S. $ 3,160 $ (37,758 ) $ (71,901 ) Non-U.S. 240,855 207,361 235,585 Total $ 244,015 $ 169,603 $ 163,684 |
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] | The components of the provision for (benefit from) income taxes for continuing operations were as follows: Current Expense (Benefit) Deferred Expense (Benefit) Total (In thousands) Fiscal year ended January 3, 2016 Federal $ (5,532 ) $ (1,799 ) $ (7,331 ) State 3,112 (2,492 ) 620 Non-U.S. 40,318 (2,280 ) 38,038 Total $ 37,898 $ (6,571 ) $ 31,327 Fiscal year ended December 28, 2014 Federal $ (262 ) $ (19,169 ) $ (19,431 ) State 2,416 (3,842 ) (1,426 ) Non-U.S. 39,634 (10,340 ) 29,294 Total $ 41,788 $ (33,351 ) $ 8,437 Fiscal year ended December 29, 2013 Federal $ 2,331 $ (29,961 ) $ (27,630 ) State 1,968 (2,147 ) (179 ) Non-U.S. 15,025 2,201 17,226 Total $ 19,324 $ (29,907 ) $ (10,583 ) |
Schedule of Income Tax Expense (Benefit), Continuing Operations and Discontinued Operations [Table Text Block] | The total provision for (benefit from) income taxes included in the consolidated financial statements is as follows for the fiscal years ended: January 3, December 28, December 29, (In thousands) Continuing operations $ 31,327 $ 8,437 $ (10,583 ) Discontinued operations 232 (1,831 ) (5,107 ) Total $ 31,559 $ 6,606 $ (15,690 ) |
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | A reconciliation of income tax expense at the U.S. federal statutory income tax rate to the recorded tax provision is as follows for the fiscal years ended: January 3, December 28, December 29, (In thousands) Tax at statutory rate $ 85,405 $ 59,361 $ 57,289 Non-U.S. rate differential, net (51,814 ) (36,616 ) (36,377 ) U.S. taxation of multinational operations 1,732 2,367 3,658 State income taxes, net 649 1,970 (1,762 ) Prior year tax matters (7,202 ) (7,009 ) (23,534 ) Federal tax credits (2,295 ) (3,399 ) (5,452 ) Change in valuation allowance 2,593 (7,679 ) (4,675 ) Other, net 2,259 (558 ) 270 Total $ 31,327 $ 8,437 $ (10,583 ) |
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | The tax effects of temporary differences and attributes that gave rise to deferred income tax assets and liabilities as of January 3, 2016 and December 28, 2014 were as follows: January 3, December 28, (In thousands) Deferred tax assets: Inventory $ 9,887 $ 9,041 Reserves and accruals 29,137 30,641 Accrued compensation 23,620 22,915 Net operating loss and credit carryforwards 100,336 106,020 Accrued pension 34,736 44,342 Restructuring reserve 6,362 7,522 Deferred revenue 40,065 46,413 All other, net — 824 Total deferred tax assets 244,143 267,718 Deferred tax liabilities: Postretirement health benefits (4,202 ) (4,472 ) Depreciation and amortization (140,091 ) (176,043 ) Total deferred tax liabilities (144,293 ) (180,515 ) Valuation allowance (67,400 ) (55,460 ) Net deferred tax assets $ 32,450 $ 31,743 |
Schedule of Deferred Income Taxes, Domestic and Foreign [Table Text Block] | The components of net deferred tax assets (liabilities) as of January 3, 2016 and December 28, 2014 were as follows: January 3, December 28, (In thousands) U.S. $ 54,411 $ 44,073 Non-U.S. (21,961 ) (12,330 ) Total $ 32,450 $ 31,743 |
Earnings Per Share (Tables)
Earnings Per Share (Tables) | 12 Months Ended |
Jan. 03, 2016 | |
Earnings Per Share [Abstract] | |
Schedule of Reconciliation of Number of Shares Utilized in Earnings Per Share Calculations | The following table reconciles the number of shares utilized in the earnings per share calculations for the fiscal years ended: January 3, December 28, December 29, (In thousands) Number of common shares—basic 112,507 112,593 112,254 Effect of dilutive securities: Stock options 621 922 982 Restricted stock awards 187 224 267 Number of common shares—diluted 113,315 113,739 113,503 Number of potentially dilutive securities excluded from calculation due to antidilutive impact 607 475 485 |
Inventories, Net (Tables)
Inventories, Net (Tables) | 12 Months Ended |
Jan. 03, 2016 | |
Inventory Disclosure [Abstract] | |
Schedule of Net Inventories | Inventories as of January 3, 2016 and December 28, 2014 consisted of the following: January 3, December 28, (In thousands) Raw materials $ 98,984 $ 96,169 Work in progress 17,858 18,783 Finished goods 171,186 170,505 Total inventories $ 288,028 $ 285,457 |
Property, Plant and Equipment40
Property, Plant and Equipment, Net (Tables) | 12 Months Ended |
Jan. 03, 2016 | |
Property, Plant and Equipment, Net [Abstract] | |
Property, Plant and Equipment [Table Text Block] | Property, plant and equipment, at cost, as of January 3, 2016 and December 28, 2014 , consisted of the following: January 3, December 28, (In thousands) Land $ 802 $ 906 Building and leasehold improvements 177,587 175,040 Machinery and equipment 316,567 316,868 Total property, plant and equipment 494,956 492,814 Accumulated depreciation (327,927 ) (316,620 ) Total property, plant and equipment, net $ 167,029 $ 176,194 |
Marketable Securities and Inv41
Marketable Securities and Investments (Tables) | 12 Months Ended |
Jan. 03, 2016 | |
Marketable Securities [Abstract] | |
Schedule of Investments, Noncurrent [Table Text Block] | Investments as of January 3, 2016 and December 28, 2014 consisted of the following: January 3, December 28, (In thousands) Marketable securities $ 1,586 $ 1,568 |
Available-for-sale Securities [Table Text Block] | Marketable securities classified as available for sale as of January 3, 2016 and December 28, 2014 consisted of the following: Market Gross Unrealized Holding Value Cost Gains (Losses) (In thousands) January 3, 2016 Equity securities $ 908 $ 1,299 $ — $ (391 ) Fixed-income securities 57 57 — — Other 621 822 — (201 ) $ 1,586 $ 2,178 $ — $ (592 ) December 28, 2014 Equity securities $ 1,002 $ 1,110 $ 7 $ (115 ) Fixed-income securities 88 88 — — Other 478 541 — (63 ) $ 1,568 $ 1,739 $ 7 $ (178 ) |
Goodwill and Intangible Asset42
Goodwill and Intangible Assets, Net (Tables) | 12 Months Ended |
Jan. 03, 2016 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Changes in the Carrying Amount of Goodwill | The changes in the carrying amount of goodwill for fiscal years 2015 and 2014 are as follows: Human Health Environmental Health Consolidated (In thousands) Balance at December 29, 2013 $ 1,689,492 $ 453,628 $ 2,143,120 Foreign currency translation (29,145 ) (8,741 ) (37,886 ) Acquisitions, earnouts and other 2,408 176,435 178,843 Balance at December 28, 2014 1,662,755 621,322 2,284,077 Foreign currency translation (28,368 ) (27,066 ) (55,434 ) Acquisitions, earnouts and other 38,104 9,402 47,506 Balance at January 3, 2016 $ 1,672,491 $ 603,658 $ 2,276,149 |
Identifiable Intangible Asset Balances | Identifiable intangible asset balances at January 3, 2016 by category and by business segment were as follows: Human Health Environmental Health Consolidated (In thousands) Patents $ 37,111 $ 2,800 $ 39,911 Less: Accumulated amortization (27,466 ) (2,322 ) (29,788 ) Net patents 9,645 478 10,123 Trade names and trademarks 32,887 7,362 40,249 Less: Accumulated amortization (19,810 ) (876 ) (20,686 ) Net trade names and trademarks 13,077 6,486 19,563 Licenses 58,969 — 58,969 Less: Accumulated amortization (45,286 ) — (45,286 ) Net licenses 13,683 — 13,683 Core technology 181,807 125,435 307,242 Less: Accumulated amortization (121,262 ) (90,567 ) (211,829 ) Net core technology 60,545 34,868 95,413 Customer relationships 298,978 92,588 391,566 Less: Accumulated amortization (177,730 ) (13,925 ) (191,655 ) Net customer relationships 121,248 78,663 199,911 IPR&D 80,748 4,931 85,679 Less: Accumulated amortization (1,378 ) (2,767 ) (4,145 ) Net IPR&D 79,370 2,164 81,534 Net amortizable intangible assets 297,568 122,659 420,227 Non-amortizable intangible assets: Trade name — 70,584 70,584 Total $ 297,568 $ 193,243 $ 490,811 Identifiable intangible asset balances at December 28, 2014 by category and business segment were as follows: Human Health Environmental Health Consolidated (In thousands) Patents $ 37,153 $ 2,800 $ 39,953 Less: Accumulated amortization (25,018 ) (2,182 ) (27,200 ) Net patents 12,135 618 12,753 Trade names and trademarks 33,069 7,000 40,069 Less: Accumulated amortization (16,878 ) (58 ) (16,936 ) Net trade names and trademarks 16,191 6,942 23,133 Licenses 59,631 — 59,631 Less: Accumulated amortization (41,792 ) — (41,792 ) Net licenses 17,839 — 17,839 Core technology 171,163 127,328 298,491 Less: Accumulated amortization (100,050 ) (84,647 ) (184,697 ) Net core technology 71,113 42,681 113,794 Customer relationships 301,371 100,814 402,185 Less: Accumulated amortization (149,917 ) (7,077 ) (156,994 ) Net customer relationships 151,454 93,737 245,191 IPR&D 5,079 5,024 10,103 Less: Accumulated amortization (998 ) (2,134 ) (3,132 ) Net IPR&D 4,081 2,890 6,971 Net amortizable intangible assets 272,813 146,868 419,681 Non-amortizable intangible assets: Trade name — 70,584 70,584 Total $ 272,813 $ 217,452 $ 490,265 |
Debt (Tables)
Debt (Tables) | 12 Months Ended |
Jan. 03, 2016 | |
Debt Disclosure [Abstract] | |
Schedule of Maturities of Long-term Debt [Table Text Block] | The following table summarizes the maturities of the Company’s indebtedness as of January 3, 2016 : Sr. Unsecured Revolving Credit Facility Maturing 2019 5.0% Sr. Notes Maturing 2021 Financing Lease Obligations Total (In thousands) 2016 $ — $ — $ 1,123 $ 1,123 2017 — — 1,169 1,169 2018 — — 1,367 1,367 2019 482,000 — 1,532 483,532 2020 — — 1,597 1,597 2021 and thereafter — 500,000 31,409 531,409 Total before unamortized discount 482,000 500,000 38,197 1,020,197 Unamortized discount and debt issuance costs (2,384 ) (4,928 ) — (7,312 ) Total $ 479,616 $ 495,072 $ 38,197 $ 1,012,885 |
Accrued Expenses and Other Cu44
Accrued Expenses and Other Current Liabilities (Tables) | 12 Months Ended |
Jan. 03, 2016 | |
Accounts Payable and Accrued Liabilities, Current [Abstract] | |
Schedule of Accrued Liabilities [Table Text Block] | Accrued expenses and other current liabilities as of January 3, 2016 and December 28, 2014 consisted of the following: January 3, December 28, (In thousands) Payroll and incentives $ 62,813 $ 61,018 Employee benefits 33,446 40,318 Deferred revenue 163,167 168,928 Federal, non-U.S. and state income taxes 2,882 9,801 Other accrued operating expenses 126,138 122,956 Total accrued expenses and other current liabilities $ 388,446 $ 403,021 |
Employee Benefit Plans (Tables)
Employee Benefit Plans (Tables) | 12 Months Ended |
Jan. 03, 2016 | |
Pension Plans, Defined Benefit | |
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | |
Components of Net Periodic Benefit Cost (Credit) | Net periodic pension cost (credit) for U.S. and non-U.S. plans included the following components for fiscal years ended: January 3, December 28, December 29, (In thousands) Service cost $ 4,332 $ 4,070 $ 3,664 Interest cost 20,696 23,475 21,334 Expected return on plan assets (26,021 ) (25,007 ) (25,106 ) Curtailment gain (907 ) — — Actuarial loss (gain) 12,953 71,700 (16,464 ) Amortization of prior service cost (238 ) (281 ) (267 ) Net periodic pension cost (credit) $ 10,815 $ 73,957 $ (16,839 ) |
Schedule of Net Funded Status | The following table sets forth the changes in the funded status of the principal U.S. pension plan and the principal non-U.S. pension plans and the amounts recognized in the Company’s consolidated balance sheets as of January 3, 2016 and December 28, 2014 . January 3, 2016 December 28, 2014 Non-U.S. U.S. Non-U.S. U.S. (In thousands) Actuarial present value of benefit obligations: Accumulated benefit obligations $ 267,862 $ 301,416 $ 291,640 $ 327,632 Change in benefit obligations: Projected benefit obligations at beginning of year $ 303,809 $ 327,632 $ 288,216 $ 279,299 Service cost 2,532 1,800 2,670 1,400 Interest cost 7,695 13,001 10,575 12,900 Benefits paid and plan expenses (11,100 ) (24,127 ) (12,280 ) (19,282 ) Participants’ contributions 343 — 394 — Plan curtailments (759 ) — — — Plan settlements (1,401 ) — — — Actuarial loss (gain) 131 (16,890 ) 42,095 53,315 Effect of exchange rate changes (24,290 ) — (27,861 ) — Projected benefit obligations at end of year $ 276,960 $ 301,416 $ 303,809 $ 327,632 Change in plan assets: Fair value of plan assets at beginning of year $ 156,767 $ 256,254 $ 143,704 $ 249,756 Actual return on plan assets 3,745 (7,434 ) 22,939 25,780 Benefits paid and plan expenses (11,100 ) (24,127 ) (12,280 ) (19,282 ) Employer’s contributions 10,908 20,000 11,195 — Participants’ contributions 343 — 394 — Plan settlements (1,401 ) — — — Effect of exchange rate changes (8,368 ) — (9,185 ) — Fair value of plan assets at end of year 150,894 244,693 156,767 256,254 Net liabilities recognized in the consolidated balance sheets $ (126,066 ) $ (56,723 ) $ (147,042 ) $ (71,378 ) Net amounts recognized in the consolidated balance sheets consist of: Noncurrent assets $ 12,135 $ — $ 9,825 $ — Current liabilities (6,261 ) — (6,786 ) — Noncurrent liabilities (131,940 ) (56,723 ) (150,081 ) (71,378 ) Net liabilities recognized in the consolidated balance sheets $ (126,066 ) $ (56,723 ) $ (147,042 ) $ (71,378 ) Net amounts recognized in accumulated other comprehensive income consist of: Prior service cost $ (932 ) $ — $ (1,371 ) $ — Net amounts recognized in accumulated other comprehensive income $ (932 ) $ — $ (1,371 ) $ — Actuarial assumptions as of the year-end measurement date: Discount rate 2.88 % 4.25 % 2.75 % 4.08 % Rate of compensation increase 3.26 % None 3.07 % None Actuarial assumptions used to determine net periodic pension cost during the year were as follows: January 3, 2016 December 28, 2014 December 29, 2013 Non-U.S. U.S. Non-U.S. U.S. Non-U.S. U.S. Discount rate 2.75 % 4.08 % 3.77 % 4.77 % 3.62 % 3.92 % Rate of compensation increase 3.28 % None 3.23 % None 2.88 % None Expected rate of return on assets 4.60 % 7.25 % 5.30 % 7.25 % 5.50 % 7.50 % |
Schedule of Benefit Obligations in Excess of Fair Value of Plan Assets [Table Text Block] | The following table provides a breakdown of the non-U.S. benefit obligations and fair value of assets for pension plans that have benefit obligations in excess of plan assets: January 3, December 28, (In thousands) Pension Plans with Projected Benefit Obligations in Excess of Plan Assets Projected benefit obligations $ 138,201 $ 156,867 Fair value of plan assets — — Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets Accumulated benefit obligations $ 134,858 $ 153,239 Fair value of plan assets — — |
Schedule of Allocation of Plan Assets | Assets of the defined benefit pension plans are primarily equity and debt securities. Asset allocations as of January 3, 2016 and December 28, 2014 , and target asset allocations for fiscal year 2016 are as follows: Target Allocation Percentage of Plan Assets at January 1, 2017 January 3, 2016 December 28, 2014 Asset Category Non-U.S. U.S. Non-U.S. U.S. Non-U.S. U.S. Equity securities 45-55% 40-50% 49 % 42 % 49 % 39 % Debt securities 45-55% 50-60% 50 % 58 % 50 % 61 % Other 0-5% 0-5% 1 % — % 1 % — % Total 100 % 100 % 100 % 100 % 100 % 100 % |
Schedule of Changes in Fair Value of Plan Assets | The fair values of the Company’s pension plan assets as of January 3, 2016 and December 28, 2014 by asset category, classified in the three levels of inputs described in Note 21 to the consolidated financial statements are as follows: Fair Value Measurements at January 3, 2016 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Cash $ 2,890 $ 2,890 $ — $ — Equity Securities: U.S. large-cap 30,357 30,357 — — International large-cap value 26,686 26,686 — — Emerging markets growth 10,600 10,600 — — Equity index funds 74,974 — 74,974 — Domestic real estate funds 2,735 2,735 — — Commodity funds 8,128 8,128 — — Fixed income securities: Non-U.S. Treasury Securities 21,531 — 21,531 — Corporate and U.S. debt instruments 137,117 28,746 108,371 — Corporate bonds 23,871 — 23,871 — High yield bond funds 3,324 3,324 — — Other types of investments: Multi-strategy hedge funds 23,415 — — 23,415 Venture capital funds 1 — — 1 Non-U.S. government index linked bonds 29,958 — 29,958 — Total assets measured at fair value $ 395,587 $ 113,466 $ 258,705 $ 23,416 Fair Value Measurements at December 28, 2014 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Cash $ 4,971 $ 4,971 $ — $ — Equity Securities: U.S. large-cap 28,602 28,602 — — International large-cap value 25,202 25,202 — — Emerging markets growth 13,010 13,010 — — Equity index funds 77,432 — 77,432 — Domestic real estate funds 2,860 2,860 — — Commodity funds 7,423 7,423 — — Fixed income securities: Non-U.S. Treasury Securities 22,025 — 22,025 — Corporate and U.S. debt instruments 147,834 53,813 94,021 — Corporate bonds 25,164 — 25,164 — High yield bond funds 3,614 3,614 — — Other types of investments: Multi-strategy hedge funds 23,332 — — 23,332 Venture capital funds 1 — — 1 Non-U.S. government index linked bonds 31,551 — 31,551 — Total assets measured at fair value $ 413,021 $ 139,495 $ 250,193 $ 23,333 |
Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets | A reconciliation of the beginning and ending Level 3 assets for fiscal years 2015, 2014 and 2013 is as follows: Fair Value Measurements Using Significant Unobservable Inputs (Level 3): Common Collective Trusts/Private Funds Venture Capital Funds Multi-strategy Hedge Funds Total (In thousands) Balance at December 30, 2012 $ 162 $ 7 $ 20,262 $ 20,431 Realized losses 7 — — 7 Unrealized (losses) gains (19 ) 1 2,427 2,409 Issuances, sales and settlements (150 ) — — (150 ) Balance at December 29, 2013 — 8 22,689 22,697 Unrealized (losses) gains — (7 ) 643 636 Balance at December 28, 2014 — 1 23,332 23,333 Unrealized gains — — 83 83 Balance at January 3, 2016 $ — $ 1 $ 23,415 $ 23,416 |
Schedule of Expected Benefit Payments | The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows: Non-U.S. U.S. (In thousands) 2016 $ 10,490 $ 17,950 2017 11,051 18,018 2018 11,466 18,289 2019 11,855 18,469 2020 12,473 18,683 2021-2025 67,253 95,733 |
Other Postretirement Benefit Plans, Defined Benefit [Member] | |
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | |
Components of Net Periodic Benefit Cost (Credit) | Net periodic postretirement medical benefit cost (credit) included the following components for the fiscal years ended: January 3, December 28, December 29, (In thousands) Service cost $ 108 $ 95 $ 106 Interest cost 143 155 135 Expected return on plan assets (1,062 ) (964 ) (965 ) Actuarial loss (gain) 971 (384 ) (182 ) Net periodic postretirement medical benefit cost (credit) $ 160 $ (1,098 ) $ (906 ) |
Schedule of Net Funded Status | The following table sets forth the changes in the postretirement medical plan’s funded status and the amounts recognized in the Company’s consolidated balance sheets as of January 3, 2016 and December 28, 2014 . January 3, December 28, (In thousands) Actuarial present value of benefit obligations: Retirees $ 1,033 $ 1,159 Active employees eligible to retire 424 388 Other active employees 2,119 1,795 Accumulated benefit obligations at beginning of year 3,576 3,342 Service cost 108 95 Interest cost 143 155 Benefits paid (158 ) (157 ) Actuarial (gain) loss (308 ) 141 Change in accumulated benefit obligations during the year (215 ) 234 Retirees 907 1,033 Active employees eligible to retire 423 424 Other active employees 2,031 2,119 Accumulated benefit obligations at end of year 3,361 3,576 Change in plan assets: Fair value of plan assets at beginning of year 14,728 13,396 Actual return on plan assets (375 ) 1,332 Fair value of plan assets at end of year 14,353 14,728 Net assets recognized in the consolidated balance sheets $ 10,992 $ 11,152 Net amounts recognized in the consolidated balance sheets consist of: Noncurrent assets $ 10,992 $ 11,152 Net assets recognized in the consolidated balance sheets $ 10,992 $ 11,152 Net amounts recognized in accumulated other comprehensive income consist of: Prior service cost $ — $ — Net amounts recognized in accumulated other comprehensive income $ — $ — Actuarial assumptions as of the year-end measurement date: Discount rate 4.34 % 4.10 % Actuarial assumptions used to determine net cost during the year are as follows: January 3, December 28, December 29, Discount rate 4.10 % 4.77 % 3.86 % Expected rate of return on assets 7.25 % 7.25 % 7.50 % |
Schedule of Changes in Fair Value of Plan Assets | The fair values of the Company’s plan assets at January 3, 2016 and December 28, 2014 by asset category, classified in the three levels of inputs described in Note 21, are as follows: Fair Value Measurements at January 3, 2016 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Cash $ 133 $ 133 $ — $ — Equity Securities: U.S. large-cap 1,781 1,781 — — International large-cap value 1,566 1,566 — — Emerging markets growth 622 622 — — Domestic real estate funds 160 160 — — Commodity funds 477 477 — — Fixed income securities: Corporate debt instruments 8,045 1,687 6,358 — High yield bond funds 195 195 — — Other types of investments: Multi-strategy hedge funds 1,374 — — 1,374 Total assets measured at fair value $ 14,353 $ 6,621 $ 6,358 $ 1,374 Fair Value Measurements at December 28, 2014 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Cash $ 248 $ 248 $ — $ — Equity Securities: U.S. large-cap 1,644 1,644 — — International large-cap value 1,449 1,449 — — Emerging markets growth 748 748 — — Domestic real estate funds 164 164 — — Commodity funds 427 427 — — Fixed income securities: Corporate debt instruments 8,499 3,094 5,405 — High yield bond funds 208 208 — — Other types of investments: Multi-strategy hedge funds 1,341 — — 1,341 Total assets measured at fair value $ 14,728 $ 7,982 $ 5,405 $ 1,341 |
Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets | A reconciliation of the beginning and ending Level 3 assets for fiscal years 2015, 2014 and 2013 is as follows: Fair Value Measurements Using Significant Unobservable Inputs (Level 3): Common Collective Trusts/Private Funds Venture Capital Funds Multi-strategy Hedge Funds Total (In thousands) Balance at December 30, 2012 $ 9 $ 1 $ 1,184 $ 1,194 Unrealized (losses) gains (1 ) (1 ) 33 31 Issuances, sales and settlements (8 ) — — (8 ) Balance at December 29, 2013 — — 1,217 1,217 Unrealized gains — — 124 124 Balance at December 28, 2014 — — 1,341 1,341 Unrealized gains — — 33 33 Balance at January 3, 2016 $ — $ — $ 1,374 $ 1,374 |
Schedule of Expected Benefit Payments | The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows: Postretirement Medical Plan (In thousands) 2016 $ 162 2017 171 2018 179 2019 189 2020 197 2021-2025 1,154 |
Warranty Reserves (Tables)
Warranty Reserves (Tables) | 12 Months Ended |
Jan. 03, 2016 | |
Product Warranties Disclosures [Abstract] | |
Warranty Reserve Activity | A summary of warranty reserve activity for the fiscal years ended January 3, 2016 , December 28, 2014 and December 29, 2013 is as follows: (In thousands) Balance at December 30, 2012 $ 11,003 Provision charged to income 17,291 Payments (17,116 ) Adjustments to previously provided warranties, net (693 ) Foreign currency translation and acquisitions 49 Balance at December 29, 2013 10,534 Provision charged to income 17,447 Payments (16,750 ) Adjustments to previously provided warranties, net 73 Foreign currency translation and acquisitions (521 ) Balance at December 28, 2014 10,783 Provision charged to income 16,904 Payments (16,204 ) Adjustments to previously provided warranties, net (60 ) Foreign currency translation and acquisitions (501 ) Balance at January 3, 2016 $ 10,922 |
Stock Plans (Tables)
Stock Plans (Tables) | 12 Months Ended |
Jan. 03, 2016 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |
Summary of Total Compensation Recognized Related to Outstanding Equity Awards | The following table summarizes total pre-tax compensation expense recognized related to the Company’s stock options, restricted stock, restricted stock units, performance units and stock grants, net of estimated forfeitures, included in the Company’s consolidated statements of operations for fiscal years 2015, 2014 and 2013 : January 3, December 28, December 29, (In thousands) Cost of product and service revenue $ 1,339 $ 1,456 $ 1,304 Research and development expenses 600 546 853 Selling, general and administrative expenses 15,780 12,462 11,896 Total stock-based compensation expense $ 17,719 $ 14,464 $ 14,053 |
Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model | The Company’s weighted-average assumptions used in the Black-Scholes option pricing model were as follows for the fiscal years ended: January 3, December 28, December 29, Risk-free interest rate 1.3 % 1.5 % 0.9 % Expected dividend yield 0.6 % 0.7 % 0.8 % Expected lives 5 years 5 years 5 years Expected stock volatility 26.5 % 30.9 % 38.5 % |
Summary of Stock Option Activity | The following table summarizes stock option activity for the three fiscal years ended January 3, 2016 : January 3, 2016 December 28, 2014 December 29, 2013 Number of Shares Weighted- Average Exercise Price Number of Shares Weighted- Average Exercise Price Number of Shares Weighted- Average Exercise Price (Shares in thousands) Outstanding at beginning of year 2,828 $ 26.11 3,494 $ 23.34 4,266 $ 21.64 Granted 502 46.36 520 43.12 518 33.62 Exercised (849 ) 17.56 (1,024 ) 23.89 (947 ) 21.45 Canceled (4 ) 20.20 (4 ) 20.97 (8 ) 22.88 Forfeited (105 ) 33.90 (158 ) 35.33 (335 ) 23.04 Outstanding at end of year 2,372 $ 33.12 2,828 $ 26.11 3,494 $ 23.34 Exercisable at end of year 1,500 $ 27.01 1,900 $ 21.13 2,392 $ 20.66 |
Summary of Restricted Stock Award Activity | The following table summarizes restricted stock award activity for the three fiscal years ended January 3, 2016 : January 3, 2016 December 28, 2014 December 29, 2013 Number of Shares Weighted- Average Grant- Date Fair Value Number of Shares Weighted- Average Grant- Date Fair Value Number of Shares Weighted- Average Grant- Date Fair Value (Shares in thousands) Nonvested at beginning of year 558 $ 35.51 649 $ 29.24 781 $ 24.71 Granted 245 46.86 261 42.61 289 33.87 Vested (249 ) 31.11 (258 ) 27.64 (346 ) 22.98 Forfeited (52 ) 40.71 (94 ) 33.58 (75 ) 28.76 Nonvested at end of year 502 $ 42.61 558 $ 35.51 649 $ 29.24 |
Stockholders' Equity (Tables)
Stockholders' Equity (Tables) | 12 Months Ended |
Jan. 03, 2016 | |
Stockholders' Equity Note [Abstract] | |
Components of Accumulated Other Comprehensive Loss | The components of accumulated other comprehensive (loss) income consisted of the following: Foreign Currency Translation Adjustment, net of tax Unrecognized Prior Service Costs, net of tax Unrealized (Losses) Gains on Securities, net of tax Unrealized and Realized (Losses) Gains on Derivatives, net of tax Accumulated Other Comprehensive Income (Loss) (In thousands) Balance, December 30, 2012 $ 67,527 $ 2,087 $ (129 ) $ (2,892 ) $ 66,593 Current year change 8,756 (658 ) 8 2,892 10,998 Balance, December 29, 2013 76,283 1,429 (121 ) — 77,591 Current year change (52,951 ) 146 14 — (52,791 ) Balance, December 28, 2014 23,332 1,575 (107 ) — 24,800 Current year change (70,178 ) (316 ) (262 ) — (70,756 ) Balance, January 3, 2016 $ (46,846 ) $ 1,259 $ (369 ) $ — $ (45,956 ) |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 12 Months Ended |
Jan. 03, 2016 | |
Fair Value Disclosures [Abstract] | |
Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis | The following tables show the assets and liabilities carried at fair value measured on a recurring basis as of January 3, 2016 and December 28, 2014 classified in one of the three classifications described above: Fair Value Measurements at January 3, 2016 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Marketable securities $ 1,586 $ 1,586 $ — $ — Foreign exchange derivative assets 2,659 — 2,659 — Foreign exchange derivative liabilities (442 ) — (442 ) — Contingent consideration (57,350 ) — — (57,350 ) Fair Value Measurements at December 28, 2014 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Marketable securities $ 1,568 $ 1,568 $ — $ — Foreign exchange derivative assets 3,205 — 3,205 — Foreign exchange derivative liabilities, net (302 ) — (302 ) — Contingent consideration (91 ) — — (91 ) |
Reconciliation of Beginning and Ending Level 3 Net Liabilities | A reconciliation of the beginning and ending Level 3 net liabilities for contingent consideration is as follows: (In thousands) Balance at December 30, 2012 $ (3,017 ) Additions (1,100 ) Amounts paid and foreign currency translation 135 Change in fair value (included within selling, general and administrative expenses) (944 ) Balance at December 29, 2013 (4,926 ) Additions — Amounts paid and foreign currency translation 2,074 Change in fair value (included within selling, general and administrative expenses) 2,761 Balance at December 28, 2014 (91 ) Additions (57,353 ) Amounts paid and foreign currency translation 113 Change in fair value (included within selling, general and administrative expenses) (19 ) Balance at January 3, 2016 $ (57,350 ) |
Industry Segment and Geograph50
Industry Segment and Geographic Area Information (Tables) | 12 Months Ended |
Jan. 03, 2016 | |
Segment Reporting [Abstract] | |
Schedule of Sales and Operating Income by Operating Segment, Excluding Discontinued Operations | Revenue and operating income (loss) from continuing operations by operating segment are shown in the table below for the fiscal years ended: January 3, December 28, December 29, (In thousands) Human Health Product revenue $ 976,451 $ 996,767 $ 957,022 Service revenue 400,193 387,456 368,872 Total revenue 1,376,644 1,384,223 1,325,894 Operating income from continuing operations (1) 251,743 233,689 168,794 Environmental Health Product revenue 576,187 543,308 541,048 Service revenue 309,528 309,688 290,644 Total revenue 885,715 852,996 831,692 Operating income from continuing operations 89,544 95,605 84,710 Corporate Operating loss from continuing operations (2)(3) (55,153 ) (118,552 ) (25,710 ) Continuing Operations Product revenue $ 1,552,638 $ 1,540,075 $ 1,498,070 Service revenue 709,721 697,144 659,516 Total revenue 2,262,359 2,237,219 2,157,586 Operating income from continuing operations 286,134 210,742 227,794 Interest and other expense, net (see Note 5) 42,119 41,139 64,110 Income from continuing operations before income taxes $ 244,015 $ 169,603 $ 163,684 ____________________________ (1) Legal costs for a particular case in the Human Health segment were $0.8 million for fiscal year 2015 . The Company also recognized a $0.2 million pre-tax impairment charge in the Human Health segment in fiscal year 2013. Both of these items have been included in operating income from continuing operations in the Human Health segment. (2) Activity related to the mark-to-market adjustment on postretirement benefit plans has been included in the Corporate operating loss from continuing operations, and in the aggregate constituted a pre-tax loss of $12.4 million in fiscal year 2015 , a pre-tax loss of $75.9 million in fiscal year 2014 , and pre-tax income of $17.6 million in fiscal year 2013 . (3) Includes expenses related to litigation with Enzo Biochem, Inc. and Enzo Life Sciences, Inc. (collectively, “Enzo”). Enzo filed a complaint in 2002 that alleged that the Company separately and together with other defendants breached distributorship and settlement agreements with Enzo, infringed Enzo's patents, engaged in unfair competition and fraud, and committed torts against Enzo by, among other things, engaging in commercial development and exploitation of Enzo's patented products and technology. The Company entered into a settlement agreement with Enzo dated June 20, 2014 and during fiscal year 2014 paid $7.0 million into a designated escrow account to resolve this matter, of which $3.7 million had been accrued in previous years and $3.3 million was recorded during fiscal year 2014. In addition, $3.4 million of expenses were incurred and recorded in preparation for the trial during fiscal year 2014. |
Schedule of Depreciation, Amortization and Capital Expenditures | Additional information relating to the Company’s reporting segments is as follows for the three fiscal years ended January 3, 2016 : Depreciation and Amortization Expense Capital Expenditures January 3, December 28, December 29, January 3, December 28, December 29, (In thousands) (In thousands) Human Health $ 81,335 $ 92,604 $ 100,941 $ 16,091 $ 16,922 $ 22,999 Environmental Health 29,213 22,101 23,556 10,352 10,428 14,433 Corporate 1,459 2,031 2,382 3,189 1,722 1,549 Continuing operations 112,007 116,736 126,879 29,632 29,072 38,981 Discontinued operations $ — $ 339 $ 1,590 $ — $ 213 $ 10 |
Schedule of Total Assets by Segment | Total Assets January 3, December 28, December 29, (In thousands) Human Health $ 2,778,835 $ 2,737,824 $ 2,724,254 Environmental Health 1,358,963 1,361,270 1,182,356 Corporate 28,497 28,482 28,441 Net current and long-term assets of discontinued operations — — 5,831 Total assets $ 4,166,295 $ 4,127,576 $ 3,940,882 |
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas | The following geographic area information for continuing operations includes revenue based on location of external customers for the three fiscal years ended January 3, 2016 and net long-lived assets based on physical location as of January 3, 2016 and December 28, 2014 : Revenue January 3, December 28, December 29, (In thousands) U.S. $ 916,314 $ 849,356 $ 826,991 International: China 312,915 276,230 254,838 United Kingdom 112,763 134,614 133,611 Germany 105,421 107,081 99,153 Italy 74,744 85,433 78,120 France 74,651 84,946 81,719 Japan 72,624 93,811 95,676 Other international 592,927 605,748 587,478 Total international 1,346,045 1,387,863 1,330,595 Total sales $ 2,262,359 $ 2,237,219 $ 2,157,586 Net Long-Lived Assets January 3, December 28, December 29, (In thousands) U.S. $ 192,681 $ 192,176 $ 208,891 International: China 34,494 36,797 30,682 United Kingdom 14,751 13,033 9,882 Finland 12,203 12,758 13,635 Singapore 7,679 7,041 6,812 Netherlands 3,835 3,614 4,037 Italy 2,958 4,107 2,735 Germany 2,171 2,493 2,591 Other international 10,598 12,664 11,045 Total international 88,689 92,507 81,419 Total net long-lived assets $ 281,370 $ 284,683 $ 290,310 |
Quarterly Financial Informati51
Quarterly Financial Information (Unaudited) Quarterly Financial Information (Unaudited) (Tables) | 12 Months Ended |
Jan. 03, 2016 | |
Quarterly Financial Information Disclosure [Abstract] | |
Schedule of Quarterly Financial Information | Selected quarterly financial information is as follows for the fiscal years ended: First Quarter Second Quarter Third Quarter Fourth Quarter (1) Year (In thousands, except per share data) January 3, 2016 Revenue $ 526,901 $ 563,906 $ 563,436 $ 608,116 $ 2,262,359 Gross profit 235,374 252,512 254,603 282,011 1,024,500 Restructuring and contract termination charges, net — 4,956 (118 ) 8,752 13,590 Operating income from continuing operations 57,381 68,131 75,898 84,724 286,134 Income from continuing operations before income taxes 47,960 57,288 63,954 74,813 244,015 Income from continuing operations 40,311 48,996 54,897 68,484 212,688 Net income 40,334 48,974 54,863 68,254 212,425 Basic earnings per share: Income from continuing operations $ 0.36 $ 0.43 $ 0.49 $ 0.61 $ 1.89 Net income 0.36 0.43 0.49 0.61 1.89 Diluted earnings per share: Income from continuing operations $ 0.36 $ 0.43 $ 0.48 $ 0.61 $ 1.88 Net income 0.36 0.43 0.48 0.61 1.87 Cash dividends declared per common share 0.07 0.07 0.07 0.07 0.28 December 28, 2014 Revenue $ 530,610 $ 556,170 $ 542,049 $ 608,390 $ 2,237,219 Gross profit 235,713 247,984 243,309 277,602 1,004,608 Restructuring and contract termination charges, net 2,135 742 11,092 (579 ) 13,390 Operating income from continuing operations 51,762 69,637 58,776 30,567 210,742 Income from continuing operations before income taxes 40,473 60,673 47,810 20,647 169,603 Income from continuing operations 34,951 52,003 42,898 31,314 161,166 Net income 34,224 50,490 42,277 30,787 157,778 Basic earnings per share: Income from continuing operations $ 0.31 $ 0.46 $ 0.38 $ 0.28 $ 1.43 Net income 0.30 0.45 0.38 0.27 1.40 Diluted earnings per share: Income continuing operations $ 0.31 $ 0.46 $ 0.38 $ 0.28 $ 1.42 Net income 0.30 0.44 0.37 0.27 1.39 Cash dividends declared per common share 0.07 0.07 0.07 0.07 0.28 ____________________________ (1) The fourth quarter of fiscal year 2015 includes a pre-tax loss of $12.4 million as a result of the mark-to-market adjustment on postretirement benefit plans. The fourth quarter of fiscal year 2014 includes a pre-tax loss of $75.9 million as a result of the mark-to-market adjustment on postretirement benefit plans. See Note 1 for a discussion of this accounting policy. |
Nature of Operations and Acco52
Nature of Operations and Accounting Policies Nature of Operations and Accounting Policies (Narrative) (Details) (Details) $ in Millions | 12 Months Ended | |||
Jan. 01, 2017 | Jan. 03, 2016plansegments | Dec. 28, 2014USD ($) | Dec. 29, 2013 | |
Current deferred tax assets | $ 62 | |||
Number of Stock-based Compensation Plans | plan | 1 | |||
Number of Operating Segments | segments | 2 | |||
Operating Cycle | 53 | 52 | 52 | |
License and services revenue as a percentage of total revenue | 5.00% | 5.00% | 5.00% | |
Unamortized Debt Issuance Expense | $ 6.5 | |||
Minimum [Member] | Building [Member] | ||||
Property, Plant and Equipment, Useful Life, Maximum | 10 years | |||
Maximum [Member] | Building [Member] | ||||
Property, Plant and Equipment, Useful Life, Maximum | 40 years | |||
Maximum [Member] | Tools, Dies and Molds [Member] | ||||
Property, Plant and Equipment, Useful Life, Maximum | 3 years | |||
Maximum [Member] | Machinery and Equipment [Member] | ||||
Property, Plant and Equipment, Useful Life, Maximum | 7 years | |||
Scenario, Forecast [Member] | ||||
Operating Cycle | 52 |
Business Combinations and Ass53
Business Combinations and Asset Purchases (Narrative) (Details) - USD ($) $ in Thousands | 1 Months Ended | 3 Months Ended | 12 Months Ended | ||||||||||||
Dec. 28, 2014 | Jan. 03, 2016 | Oct. 04, 2015 | Jun. 28, 2015 | Mar. 29, 2015 | Dec. 28, 2014 | Sep. 28, 2014 | Jun. 29, 2014 | Mar. 30, 2014 | Jan. 03, 2016 | Dec. 28, 2014 | Dec. 29, 2013 | Dec. 05, 2014 | Oct. 21, 2014 | Dec. 30, 2012 | |
Business Acquisition [Line Items] | |||||||||||||||
Revenue | $ 608,116 | $ 563,436 | $ 563,906 | $ 526,901 | $ 608,390 | $ 542,049 | $ 556,170 | $ 530,610 | $ 2,262,359 | $ 2,237,219 | |||||
Business Acquisition, Goodwill, Expected Tax Deductible Amount | 9,200 | 9,200 | |||||||||||||
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value | $ 91 | 57,350 | 91 | 57,350 | 91 | $ 4,926 | $ 3,017 | ||||||||
Business Combination, Contingent Consideration, Liability, Current | (100) | (9,400) | $ (100) | (9,400) | (100) | ||||||||||
Business Combination, Contingent Consideration, Liability, Noncurrent | 48,000 | $ 48,000 | |||||||||||||
Business Combination, Contingent Consideration Arrangements, Maximum Period | 6 years | ||||||||||||||
Business Combination, Contingent Consideration Arrangements, Description | Contingent consideration is measured at fair value at the acquisition date, based on the probability that revenue thresholds or product development milestones will be achieved during the earnout period. The earnout periods for each of these acquisitions does not exceed 6 years from the acquisition date, and the remaining weighted average earnout period at January 3, 2016 was 2 years. | ||||||||||||||
Number of Years in Measurement Period from Acquisition Date to Change Underlying Assumptions | 1 year | ||||||||||||||
Business Combination, Contingent Consideration Arrangements, Weighted Average Period | 2 years | ||||||||||||||
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High | 95,400 | $ 95,400 | |||||||||||||
Business Acquisition, Transaction Costs | 700 | 3,100 | 100 | ||||||||||||
Fiscal Year 2015 Acquisitions [Member] | |||||||||||||||
Business Acquisition [Line Items] | |||||||||||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid | 75,285 | ||||||||||||||
Contingent consideration | 56,878 | ||||||||||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments | 77,117 | ||||||||||||||
Working capital and other adjustments | (1,832) | ||||||||||||||
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Taxes | (500) | ||||||||||||||
Cash Acquired | (3,864) | ||||||||||||||
Vanadis Diagnostics AB [Member] | |||||||||||||||
Business Acquisition [Line Items] | |||||||||||||||
Contingent consideration | 56,878 | ||||||||||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments | 35,141 | ||||||||||||||
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High | $ 93,000 | 93,000 | |||||||||||||
2015 Acquisitions (excluding Vanadis) [Domain] | |||||||||||||||
Business Acquisition [Line Items] | |||||||||||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments | 42,000 | ||||||||||||||
Perten Instruments Group AB [Member] | |||||||||||||||
Business Acquisition [Line Items] | |||||||||||||||
Revenue | 65,730 | ||||||||||||||
Business Acquisition, Goodwill, Expected Tax Deductible Amount | $ 0 | ||||||||||||||
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Taxes | (2,800) | ||||||||||||||
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles | 2,000 | ||||||||||||||
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Financial Liabilities | 1,200 | ||||||||||||||
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Current Assets | (200) | ||||||||||||||
Goodwill, Purchase Accounting Adjustments | (3,400) | ||||||||||||||
Goodwill, Other Changes | 21,400 | 8,200 | |||||||||||||
Fiscal Year 2014 Acquisitions (excluding Perten) [Member] | |||||||||||||||
Business Acquisition [Line Items] | |||||||||||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid | 17,898 | ||||||||||||||
Business Acquisition, Goodwill, Expected Tax Deductible Amount | $ 0 | ||||||||||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments | 17,600 | ||||||||||||||
Working capital and other adjustments | 294 | ||||||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt | $ 4,287 | ||||||||||||||
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred | $ (500) | ||||||||||||||
Cash Acquired | (124) | ||||||||||||||
Fiscal Year 2013 Acquisitions [Member] | |||||||||||||||
Business Acquisition [Line Items] | |||||||||||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid | $ 400 | 11,400 | |||||||||||||
Contingent consideration | 1,100 | ||||||||||||||
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High | $ 2,200 | ||||||||||||||
Core Technology [Member] | Fiscal Year 2015 Acquisitions [Member] | |||||||||||||||
Business Acquisition [Line Items] | |||||||||||||||
Weighted average amortization period (in years) | 9 years | ||||||||||||||
Environmental Health [Member] | Perten Instruments Group AB [Member] | |||||||||||||||
Business Acquisition [Line Items] | |||||||||||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid | 269,937 | ||||||||||||||
Working capital and other adjustments | 0 | ||||||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt | $ 7,600 | ||||||||||||||
Cash Acquired | $ (16,732) | ||||||||||||||
Environmental Health [Member] | Minimum [Member] | Perten Instruments Group AB [Member] | |||||||||||||||
Business Acquisition [Line Items] | |||||||||||||||
Weighted average amortization period (in years) | 5 years | ||||||||||||||
Environmental Health [Member] | Maximum [Member] | Perten Instruments Group AB [Member] | |||||||||||||||
Business Acquisition [Line Items] | |||||||||||||||
Weighted average amortization period (in years) | 10 years |
Business Combinations and Ass54
Business Combinations and Asset Purchases (Fair Values of the Business Combinations and Allocations for the Acquisitions Completed) (Details) - USD ($) $ in Thousands | 1 Months Ended | 12 Months Ended | ||||
Dec. 28, 2014 | Jan. 03, 2016 | Dec. 28, 2014 | Dec. 05, 2014 | Oct. 21, 2014 | Dec. 29, 2013 | |
Business Acquisition [Line Items] | ||||||
Goodwill | $ 2,284,077 | $ 2,276,149 | $ 2,284,077 | $ 2,143,120 | ||
Fiscal Year 2015 Acquisitions [Member] | ||||||
Business Acquisition [Line Items] | ||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid | 75,285 | |||||
Contingent consideration | 56,878 | |||||
Working capital and other adjustments | 1,832 | |||||
Less: cash acquired | 3,864 | |||||
Total | 130,131 | |||||
Current assets | 2,551 | |||||
Property, plant and equipment | 998 | |||||
Goodwill | 51,356 | |||||
Deferred taxes | (16,772) | |||||
Liabilities assumed | (2,850) | |||||
Total | 130,131 | |||||
Fiscal Year 2014 Acquisitions (excluding Perten) [Member] | ||||||
Business Acquisition [Line Items] | ||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid | 17,898 | |||||
Working capital and other adjustments | (294) | |||||
Less: cash acquired | 124 | |||||
Total | 17,480 | |||||
Current assets | $ 1,935 | |||||
Property, plant and equipment | 125 | |||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets | 364 | |||||
Goodwill | 15,518 | |||||
Deferred taxes | (3,072) | |||||
Business Acquisition, Purchase Price Allocation, Current and Non-current Liabilities, Deferred Revenue | (589) | |||||
Liabilities assumed | (2,285) | |||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt | (4,287) | |||||
Total | 17,480 | |||||
Core Technology [Member] | Fiscal Year 2015 Acquisitions [Member] | ||||||
Business Acquisition [Line Items] | ||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 15,759 | |||||
Core Technology [Member] | Fiscal Year 2014 Acquisitions (excluding Perten) [Member] | ||||||
Business Acquisition [Line Items] | ||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 1,705 | |||||
Trade Names [Member] | Fiscal Year 2015 Acquisitions [Member] | ||||||
Business Acquisition [Line Items] | ||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 200 | |||||
Trade Names [Member] | Fiscal Year 2014 Acquisitions (excluding Perten) [Member] | ||||||
Business Acquisition [Line Items] | ||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 0 | |||||
Customer Relationships [Member] | Fiscal Year 2015 Acquisitions [Member] | ||||||
Business Acquisition [Line Items] | ||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 3,073 | |||||
Customer Relationships [Member] | Fiscal Year 2014 Acquisitions (excluding Perten) [Member] | ||||||
Business Acquisition [Line Items] | ||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 6,800 | |||||
Licenses [Member] | Fiscal Year 2015 Acquisitions [Member] | ||||||
Business Acquisition [Line Items] | ||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 116 | |||||
In Process Research and Development [Member] | Fiscal Year 2015 Acquisitions [Member] | ||||||
Business Acquisition [Line Items] | ||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 75,700 | |||||
In Process Research and Development [Member] | Fiscal Year 2014 Acquisitions (excluding Perten) [Member] | ||||||
Business Acquisition [Line Items] | ||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | $ 1,266 | |||||
Human Health [Member] | ||||||
Business Acquisition [Line Items] | ||||||
Goodwill | 1,662,755 | 1,672,491 | 1,662,755 | 1,689,492 | ||
Environmental Health [Member] | ||||||
Business Acquisition [Line Items] | ||||||
Goodwill | 621,322 | $ 603,658 | $ 621,322 | $ 453,628 | ||
Environmental Health [Member] | Perten Instruments Group AB [Member] | ||||||
Business Acquisition [Line Items] | ||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid | 269,937 | |||||
Working capital and other adjustments | 0 | |||||
Less: cash acquired | 16,732 | |||||
Total | $ 253,205 | |||||
Current assets | $ 32,578 | |||||
Property, plant and equipment | 1,485 | |||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets | 0 | |||||
Goodwill | 160,776 | |||||
Deferred taxes | (28,612) | |||||
Business Acquisition, Purchase Price Allocation, Current and Non-current Liabilities, Deferred Revenue | 0 | |||||
Liabilities assumed | (17,422) | |||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt | (7,600) | |||||
Total | 253,205 | |||||
Environmental Health [Member] | Core Technology [Member] | Perten Instruments Group AB [Member] | ||||||
Business Acquisition [Line Items] | ||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 17,000 | |||||
Environmental Health [Member] | Trade Names [Member] | Perten Instruments Group AB [Member] | ||||||
Business Acquisition [Line Items] | ||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 8,000 | |||||
Environmental Health [Member] | Customer Relationships [Member] | Perten Instruments Group AB [Member] | ||||||
Business Acquisition [Line Items] | ||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 87,000 | |||||
Environmental Health [Member] | In Process Research and Development [Member] | Perten Instruments Group AB [Member] | ||||||
Business Acquisition [Line Items] | ||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | $ 0 |
Discontinued Operations Narrati
Discontinued Operations Narrative (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Jan. 03, 2016 | Dec. 28, 2014 | Dec. 29, 2013 | |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||
Loss on disposition of discontinued operations before income taxes | $ (28) | $ (260) | $ (1,810) |
(Benefit from) provision for income taxes on discontinued operations and dispositions | 232 | (1,831) | (5,107) |
Microarray-based diagnostic testing laboratory in the United States [Member] | |||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||
Disposal Group, Including Discontinued Operations, Severance Costs | 1,000 | ||
Loss on disposition of discontinued operations before income taxes | (90) | ||
Technical Services Business [Member] | |||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||
Loss on disposition of discontinued operations before income taxes | $ (30) | $ (156) | (2,100) |
Other Discontinued Operations [Member] | |||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||
Loss on disposition of discontinued operations before income taxes | $ 290 |
Summary Operating Results of Di
Summary Operating Results of Discontinued Operations for the Periods Prior to Disposition (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Jan. 03, 2016 | Dec. 28, 2014 | Dec. 29, 2013 | |
Operating Results of Discontinued Operations Prior to Disposition [Abstract] | |||
Disposal Group, Including Discontinued Operation, Revenue | $ 98 | $ 348 | $ 8,646 |
Disposal Group, Including Discontinued Operations, Costs and Expenses | 101 | 5,307 | 18,998 |
Loss from discontinued operations before income taxes | $ (3) | $ (4,959) | $ (10,352) |
Restructuring and Contract Te57
Restructuring and Contract Termination Charges, Net (Narrative) (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | ||||||||||
Jan. 03, 2016 | Oct. 04, 2015 | Jun. 28, 2015 | Mar. 29, 2015 | Dec. 28, 2014 | Sep. 28, 2014 | Jun. 29, 2014 | Mar. 30, 2014 | Jan. 03, 2016 | Dec. 28, 2014 | Dec. 29, 2013 | Dec. 30, 2012 | |
Restructuring Cost and Reserve [Line Items] | ||||||||||||
Restructuring and contract termination charges, net | $ 8,752 | $ (118) | $ 4,956 | $ 0 | $ (579) | $ 11,092 | $ 742 | $ 2,135 | $ 13,590 | $ 13,390 | $ 33,892 | |
Accrued restructuring and contract termination costs | 22,197 | 23,830 | 22,197 | 23,830 | 35,535 | $ 27,747 | ||||||
Accrued restructuring and contract termination costs | 17,090 | 17,124 | 17,090 | 17,124 | ||||||||
Restructuring Reserve, Noncurrent | 5,100 | 6,700 | 5,100 | 6,700 | ||||||||
Contract Termination [Member] | ||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||
Accrued restructuring and contract termination costs | $ 132 | $ 304 | 132 | 304 | 300 | $ 596 | ||||||
Environmental Health [Member] | Contract Termination [Member] | 2015 Contract Termination Charges [Member] | ||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||
Restructuring and contract termination charges, net | $ 83 | |||||||||||
Environmental Health [Member] | Contract Termination [Member] | 2014 Contract Termination Charges [Member] | ||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||
Restructuring and contract termination charges, net | $ 1,545 | |||||||||||
Environmental Health [Member] | Contract Termination [Member] | 2013 Contract Termination Charges [Member] | ||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||
Restructuring and contract termination charges, net | $ 696 |
Restructuring and Contract Te58
Restructuring and Contract Termination Charges, Net Restructuring and Contract Termination Charges, Net (Schedule of Initial Charges) (Details) $ in Thousands | 3 Months Ended | 12 Months Ended | ||||||||||||||
Jan. 03, 2016USD ($)employees | Oct. 04, 2015USD ($) | Jun. 28, 2015USD ($)employees | Mar. 29, 2015USD ($) | Dec. 28, 2014USD ($) | Sep. 28, 2014USD ($)employees | Jun. 29, 2014USD ($)employees | Mar. 30, 2014USD ($)employees | Dec. 29, 2013USD ($)employees | Sep. 29, 2013USD ($)employees | Jun. 30, 2013USD ($)employees | Mar. 31, 2013USD ($)employees | Jan. 03, 2016USD ($) | Dec. 28, 2014USD ($) | Dec. 29, 2013USD ($) | ||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and contract termination charges, net | $ 8,752 | $ (118) | $ 4,956 | $ 0 | $ (579) | $ 11,092 | $ 742 | $ 2,135 | $ 13,590 | $ 13,390 | $ 33,892 | |||||
Q4 2015 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and Related Cost, Number of Positions Eliminated | employees | 174 | |||||||||||||||
Restructuring and contract termination charges, net | $ 11,580 | |||||||||||||||
Q2 2015 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and Related Cost, Number of Positions Eliminated | employees | 97 | |||||||||||||||
Restructuring and contract termination charges, net | $ 6,010 | |||||||||||||||
Q3 2014 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and Related Cost, Number of Positions Eliminated | employees | 152 | |||||||||||||||
Restructuring and contract termination charges, net | $ 13,051 | |||||||||||||||
Q2 2014 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and Related Cost, Number of Positions Eliminated | employees | 22 | |||||||||||||||
Restructuring and contract termination charges, net | $ 735 | |||||||||||||||
Q1 2014 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and Related Cost, Number of Positions Eliminated | employees | 17 | |||||||||||||||
Restructuring and contract termination charges, net | $ 567 | |||||||||||||||
Q4 2013 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and Related Cost, Number of Positions Eliminated | employees | 73 | |||||||||||||||
Restructuring and contract termination charges, net | $ 11,179 | |||||||||||||||
Q3 2013 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and Related Cost, Number of Positions Eliminated | employees | 29 | |||||||||||||||
Restructuring and contract termination charges, net | $ 532 | |||||||||||||||
Q2 2013 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and Related Cost, Number of Positions Eliminated | employees | 264 | |||||||||||||||
Restructuring and contract termination charges, net | $ 18,704 | |||||||||||||||
Q1 2013 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and Related Cost, Number of Positions Eliminated | employees | 62 | |||||||||||||||
Restructuring and contract termination charges, net | $ 2,585 | |||||||||||||||
Human Health [Member] | Severance [Member] | Q4 2015 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and contract termination charges, net | 2,230 | |||||||||||||||
Human Health [Member] | Severance [Member] | Q2 2015 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and contract termination charges, net | 1,850 | |||||||||||||||
Human Health [Member] | Severance [Member] | Q3 2014 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and contract termination charges, net | 7,126 | |||||||||||||||
Human Health [Member] | Severance [Member] | Q2 2014 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and contract termination charges, net | 545 | |||||||||||||||
Human Health [Member] | Severance [Member] | Q1 2014 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and contract termination charges, net | 370 | |||||||||||||||
Human Health [Member] | Severance [Member] | Q4 2013 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and contract termination charges, net | 955 | |||||||||||||||
Human Health [Member] | Severance [Member] | Q3 2013 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and contract termination charges, net | 394 | |||||||||||||||
Human Health [Member] | Severance [Member] | Q2 2013 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and contract termination charges, net | 600 | 9,523 | [1] | |||||||||||||
Human Health [Member] | Severance [Member] | Q1 2013 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and contract termination charges, net | 2,340 | |||||||||||||||
Human Health [Member] | Facility Closing [Member] | Q4 2015 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and contract termination charges, net | 285 | |||||||||||||||
Human Health [Member] | Facility Closing [Member] | Q2 2015 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and contract termination charges, net | 0 | |||||||||||||||
Human Health [Member] | Facility Closing [Member] | Q3 2014 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and contract termination charges, net | 0 | |||||||||||||||
Human Health [Member] | Facility Closing [Member] | Q2 2014 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and contract termination charges, net | 0 | |||||||||||||||
Human Health [Member] | Facility Closing [Member] | Q1 2014 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and contract termination charges, net | 0 | |||||||||||||||
Human Health [Member] | Facility Closing [Member] | Q4 2013 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and contract termination charges, net | 7,271 | |||||||||||||||
Human Health [Member] | Facility Closing [Member] | Q3 2013 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and contract termination charges, net | 138 | |||||||||||||||
Human Health [Member] | Facility Closing [Member] | Q2 2013 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and contract termination charges, net | 522 | |||||||||||||||
Human Health [Member] | Facility Closing [Member] | Q1 2013 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and contract termination charges, net | 0 | |||||||||||||||
Environmental Health [Member] | Severance [Member] | Q4 2015 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and contract termination charges, net | 9,065 | |||||||||||||||
Environmental Health [Member] | Severance [Member] | Q2 2015 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and contract termination charges, net | 4,160 | |||||||||||||||
Environmental Health [Member] | Severance [Member] | Q3 2014 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and contract termination charges, net | 5,925 | |||||||||||||||
Environmental Health [Member] | Severance [Member] | Q2 2014 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and contract termination charges, net | 190 | |||||||||||||||
Environmental Health [Member] | Severance [Member] | Q1 2014 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and contract termination charges, net | 197 | |||||||||||||||
Environmental Health [Member] | Severance [Member] | Q4 2013 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and contract termination charges, net | 2,953 | |||||||||||||||
Environmental Health [Member] | Severance [Member] | Q3 2013 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and contract termination charges, net | 0 | |||||||||||||||
Environmental Health [Member] | Severance [Member] | Q2 2013 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and contract termination charges, net | 8,609 | |||||||||||||||
Environmental Health [Member] | Severance [Member] | Q1 2013 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and contract termination charges, net | 245 | |||||||||||||||
Environmental Health [Member] | Facility Closing [Member] | Q4 2015 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and contract termination charges, net | $ 0 | |||||||||||||||
Environmental Health [Member] | Facility Closing [Member] | Q2 2015 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and contract termination charges, net | $ 0 | |||||||||||||||
Environmental Health [Member] | Facility Closing [Member] | Q3 2014 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and contract termination charges, net | $ 0 | |||||||||||||||
Environmental Health [Member] | Facility Closing [Member] | Q2 2014 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and contract termination charges, net | $ 0 | |||||||||||||||
Environmental Health [Member] | Facility Closing [Member] | Q1 2014 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and contract termination charges, net | $ 0 | |||||||||||||||
Environmental Health [Member] | Facility Closing [Member] | Q4 2013 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and contract termination charges, net | $ 0 | |||||||||||||||
Environmental Health [Member] | Facility Closing [Member] | Q3 2013 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and contract termination charges, net | $ 0 | |||||||||||||||
Environmental Health [Member] | Facility Closing [Member] | Q2 2013 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and contract termination charges, net | $ 50 | |||||||||||||||
Environmental Health [Member] | Facility Closing [Member] | Q1 2013 Restructuring Plan [Member] | ||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ||||||||||||||||
Restructuring and contract termination charges, net | $ 0 | |||||||||||||||
[1] | Subsequent to the initial charge, during fiscal year 2013, the Company recorded an additional $0.6 million pre-tax restructuring charge in the Human Health segment for the Q2 2013 Plan for services that were provided for one-time termination benefits in which the employee was required to render service beyond the legal notification period. |
Restructuring and Contract Te59
Restructuring and Contract Termination Charges, Net (Schedule of Restructuring Plan Activity) (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |||||||||||
Jan. 03, 2016 | Oct. 04, 2015 | Jun. 28, 2015 | Mar. 29, 2015 | Dec. 28, 2014 | Sep. 28, 2014 | Jun. 29, 2014 | Mar. 30, 2014 | Jan. 03, 2016 | Dec. 28, 2014 | Dec. 29, 2013 | |||
Restructuring Reserve [Roll Forward] | |||||||||||||
Beginning balance | $ 23,830 | $ 35,535 | $ 23,830 | $ 35,535 | $ 27,747 | ||||||||
Restructuring Charges and Changes in Estimates | 13,590 | 13,390 | 33,892 | ||||||||||
Amounts paid and foreign currency translation | (15,223) | (25,095) | (26,104) | ||||||||||
Ending balance | $ 22,197 | $ 23,830 | 22,197 | 23,830 | 35,535 | ||||||||
Restructuring and contract termination charges, net | 8,752 | $ (118) | $ 4,956 | 0 | (579) | $ 11,092 | $ 742 | 2,135 | 13,590 | 13,390 | 33,892 | ||
Employee Severance and Facility Closing [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Beginning balance | 23,526 | 35,235 | 23,526 | 35,235 | 27,151 | ||||||||
Restructuring Charges and Changes in Estimates | 13,507 | 11,845 | 33,196 | ||||||||||
Amounts paid and foreign currency translation | (14,968) | (23,554) | (25,112) | ||||||||||
Ending balance | 22,065 | 23,526 | 22,065 | 23,526 | 35,235 | ||||||||
Contract Termination [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Beginning balance | 304 | 300 | 304 | 300 | 596 | ||||||||
Restructuring Charges and Changes in Estimates | 83 | 1,545 | 696 | ||||||||||
Amounts paid and foreign currency translation | (255) | (1,541) | (992) | ||||||||||
Ending balance | 132 | 304 | 132 | 304 | 300 | ||||||||
Q4 2015 Restructuring Plan [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | 11,580 | ||||||||||||
Q4 2015 Restructuring Plan [Member] | Severance [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Beginning balance | 0 | 0 | 0 | 0 | 0 | ||||||||
Restructuring Charges and Changes in Estimates | 11,295 | 0 | 0 | ||||||||||
Amounts paid and foreign currency translation | (925) | 0 | 0 | ||||||||||
Ending balance | 10,370 | 0 | 10,370 | 0 | 0 | ||||||||
Q4 2015 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Beginning balance | 0 | 0 | 0 | 0 | 0 | ||||||||
Restructuring Charges and Changes in Estimates | 285 | 0 | 0 | ||||||||||
Amounts paid and foreign currency translation | (26) | 0 | 0 | ||||||||||
Ending balance | 259 | 0 | 259 | 0 | 0 | ||||||||
Q2 2015 Restructuring Plan [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | 6,010 | ||||||||||||
Q2 2015 Restructuring Plan [Member] | Severance [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Beginning balance | 0 | 0 | 0 | 0 | 0 | ||||||||
Restructuring Charges and Changes in Estimates | 5,471 | [1] | 0 | 0 | |||||||||
Amounts paid and foreign currency translation | (4,322) | 0 | 0 | ||||||||||
Ending balance | 1,149 | 0 | 1,149 | 0 | 0 | ||||||||
Q3 2014 Restructuring Plan [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | 13,051 | ||||||||||||
Q3 2014 Restructuring Plan [Member] | Severance [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Beginning balance | 10,059 | 0 | 10,059 | 0 | 0 | ||||||||
Restructuring Charges and Changes in Estimates | (3,064) | [2] | 13,051 | 0 | |||||||||
Amounts paid and foreign currency translation | (5,460) | (2,992) | 0 | ||||||||||
Ending balance | 1,535 | 10,059 | 1,535 | 10,059 | 0 | ||||||||
Q2 2014 Restructuring Plan [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | 735 | ||||||||||||
Q2 2014 Restructuring Plan [Member] | Severance [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Beginning balance | 251 | 0 | 251 | 0 | 0 | ||||||||
Restructuring Charges and Changes in Estimates | (179) | [3] | 735 | 0 | |||||||||
Amounts paid and foreign currency translation | (13) | (484) | 0 | ||||||||||
Ending balance | 59 | 251 | 59 | 251 | 0 | ||||||||
Q1 2014 Restructuring Plan [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | 567 | ||||||||||||
Q1 2014 Restructuring Plan [Member] | Severance [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Beginning balance | 92 | 0 | 92 | 0 | 0 | ||||||||
Restructuring Charges and Changes in Estimates | (92) | [4] | 567 | 0 | |||||||||
Amounts paid and foreign currency translation | 0 | (475) | 0 | ||||||||||
Ending balance | 0 | 92 | 0 | 92 | 0 | ||||||||
Previous restructuring and integration plans [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Beginning balance | $ 13,124 | 35,235 | 13,124 | 35,235 | 27,151 | ||||||||
Restructuring Charges and Changes in Estimates | (209) | [5] | (2,508) | [5] | 33,196 | ||||||||
Amounts paid and foreign currency translation | 4,222 | 19,603 | 25,112 | ||||||||||
Ending balance | 8,693 | $ 13,124 | 8,693 | 13,124 | $ 35,235 | ||||||||
Environmental Health [Member] | Q4 2015 Restructuring Plan [Member] | Severance [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | 9,065 | ||||||||||||
Environmental Health [Member] | Q4 2015 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | 0 | ||||||||||||
Environmental Health [Member] | Q2 2015 Restructuring Plan [Member] | Severance [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Change in estimates | (302) | ||||||||||||
Restructuring and contract termination charges, net | 4,160 | ||||||||||||
Environmental Health [Member] | Q2 2015 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | 0 | ||||||||||||
Environmental Health [Member] | Q3 2014 Restructuring Plan [Member] | Severance [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Change in estimates | (1,861) | ||||||||||||
Restructuring and contract termination charges, net | 5,925 | ||||||||||||
Environmental Health [Member] | Q3 2014 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | 0 | ||||||||||||
Environmental Health [Member] | Q2 2014 Restructuring Plan [Member] | Severance [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Change in estimates | (100) | ||||||||||||
Restructuring and contract termination charges, net | 190 | ||||||||||||
Environmental Health [Member] | Q2 2014 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | 0 | ||||||||||||
Environmental Health [Member] | Q1 2014 Restructuring Plan [Member] | Severance [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | 197 | ||||||||||||
Environmental Health [Member] | Q1 2014 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | 0 | ||||||||||||
Environmental Health [Member] | Previous restructuring and integration plans [Member] | Severance [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Change in estimates | (1,600) | (1,700) | |||||||||||
Human Health [Member] | Q4 2015 Restructuring Plan [Member] | Severance [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | 2,230 | ||||||||||||
Human Health [Member] | Q4 2015 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | $ 285 | ||||||||||||
Human Health [Member] | Q2 2015 Restructuring Plan [Member] | Severance [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Change in estimates | (237) | ||||||||||||
Restructuring and contract termination charges, net | 1,850 | ||||||||||||
Human Health [Member] | Q2 2015 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | $ 0 | ||||||||||||
Human Health [Member] | Q3 2014 Restructuring Plan [Member] | Severance [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Change in estimates | (1,203) | ||||||||||||
Restructuring and contract termination charges, net | 7,126 | ||||||||||||
Human Health [Member] | Q3 2014 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | $ 0 | ||||||||||||
Human Health [Member] | Q2 2014 Restructuring Plan [Member] | Severance [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Change in estimates | (100) | ||||||||||||
Restructuring and contract termination charges, net | 545 | ||||||||||||
Human Health [Member] | Q2 2014 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | $ 0 | ||||||||||||
Human Health [Member] | Q1 2014 Restructuring Plan [Member] | Severance [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Change in estimates | (100) | ||||||||||||
Restructuring and contract termination charges, net | 370 | ||||||||||||
Human Health [Member] | Q1 2014 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Restructuring and contract termination charges, net | $ 0 | ||||||||||||
Human Health [Member] | Previous restructuring and integration plans [Member] | Severance [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Change in estimates | $ (800) | ||||||||||||
Human Health [Member] | Previous restructuring and integration plans [Member] | Closure Of Excess Facility Space [Member] | |||||||||||||
Restructuring Reserve [Roll Forward] | |||||||||||||
Change in estimates | $ 1,400 | ||||||||||||
[1] | During fiscal year 2015, the Company recognized pre-tax restructuring reversals of $0.2 million in the Human Health segment and $0.3 million in the Environmental Health segment related to lower than expected costs associated with workforce reductions for the Q2 2015 Plan. | ||||||||||||
[2] | During fiscal year 2015, the Company recognized pre-tax restructuring reversals of $1.2 million in the Human Health segment and $1.9 million in the Environmental Health segment related to lower than expected costs associated with workforce reductions for the Q3 2014 Plan. | ||||||||||||
[3] | During fiscal year 2015, the Company recognized pre-tax restructuring reversals of $0.1 million in each of the Human Health and Environmental Health segments related to lower than expected costs associated with workforce reductions for the Q2 2014 Plan. | ||||||||||||
[4] | During fiscal year 2015, the Company recognized a pre-tax restructuring reversal of $0.1 million in the Human Health segment related to lower than expected costs associated with workforce reductions for the Q1 2014 Plan. | ||||||||||||
[5] | During fiscal year 2015, the Company recognized a pre-tax restructuring charge of $1.4 million in the Human Health segment primarily related to higher than expected costs associated with the closure of the excess facility space, which was offset by a pre-tax restructuring reversal of $1.6 million in the Environmental Health segment primarily related to lower than expected costs associated with workforce reductions for the previous restructuring plans. During fiscal year 2014, the Company recognized pre-tax restructuring reversals of $0.8 million in the Human Health segment and $1.7 million in the Environmental Health segment primarily related to lower than expected costs associated with workforce reductions, which was partially offset by higher than expected costs associated with the closure of the excess facility space for the previous restructuring plans. |
Interest and Other Expense (I60
Interest and Other Expense (Income), Net (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |||
Dec. 29, 2013 | Jan. 03, 2016 | Dec. 28, 2014 | Dec. 29, 2013 | May. 30, 2008 | |
Early Repayment of Senior Debt | $ 0 | $ 0 | $ 150,000 | ||
Payments of Debt Extinguishment Costs | $ 11,100 | 0 | 0 | 11,119 | |
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax | 4,800 | ||||
Write off of Deferred Debt Issuance Cost | 200 | ||||
Foreign Currency Transaction Gain (Loss), before Tax | 25,500 | 5,500 | 4,700 | ||
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments | 20,800 | 200 | 1,400 | ||
Interest income | (673) | (667) | (650) | ||
Interest expense | 37,997 | 36,270 | 49,924 | ||
Other expense, net | 4,795 | 5,536 | 14,836 | ||
Total interest and other expense, net | $ 42,119 | $ 41,139 | 64,110 | ||
2015 Notes [Member] | |||||
Unsecured senior notes, interest rate percent | 6.00% | ||||
Early Repayment of Senior Debt | 150,000 | ||||
Interest Rate Contract [Member] | Interest Expense [Member] | |||||
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax | $ (2,800) | $ (2,000) |
Income Taxes (Details)
Income Taxes (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Jan. 03, 2016 | Dec. 28, 2014 | Dec. 29, 2013 | |
Income Tax Contingency [Line Items] | |||
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | $ 15,000 | ||
Income Tax Holiday, Aggregate Dollar Amount | (8,300) | $ (7,100) | $ (7,400) |
Valuation Allowance, Amount | 67,400 | 55,460 | |
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] | |||
Unrecognized tax benefits, beginning of period | 32,342 | 39,410 | 58,110 |
Gross increases - tax positions in prior period | 325 | 0 | 325 |
Gross decreases - tax positions in prior period | (2,305) | (1,809) | (10,539) |
Gross increases - current-period tax positions | 0 | 239 | 2,222 |
Settlements | (441) | (1,400) | (3,643) |
Lapse of statute of limitations | (1,077) | (4,129) | (6,495) |
Foreign currency translation adjustments | (701) | 31 | (570) |
Unrecognized tax benefits, end of period | 28,143 | 32,342 | 39,410 |
Interest on income taxes accrued | 2,100 | 3,400 | |
Interest on income taxes expense | (1,500) | (700) | (3,900) |
Income tax penalties expense | (100) | (200) | (3,700) |
Income tax penalties accrued | 100 | 200 | |
Uncertain tax benefits if recognized that could affect the continuing operations effective tax rate | 24,300 | ||
Unrecognized Tax Benefits Expected To Be Resolved With In A Year | 5,700 | ||
Foreign earnings invested outside U.S. | $ 859,000 | ||
Open Tax Years by Major Tax Jurisdiction, Begin Date | 2,009 | ||
Tax Adjustments, Settlements, and Unusual Provisions | $ (7,200) | (7,000) | (24,000) |
Current deferred tax assets | 62,000 | ||
Excess tax benefit from exercise of common stock options | 2,435 | $ 0 | $ 0 |
General Business [Member] | |||
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] | |||
Tax Credit Carryforward, Amount | 32,100 | ||
State and Local Jurisdiction [Member] | |||
Income Tax Contingency [Line Items] | |||
Operating Loss Carryforwards | 226,400 | ||
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] | |||
Tax Credit Carryforward, Amount | 10,700 | ||
Foreign Tax Authority [Member] | |||
Income Tax Contingency [Line Items] | |||
Operating Loss Carryforwards | 199,500 | ||
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] | |||
Tax Credit Carryforward, Amount | 13,000 | ||
Internal Revenue Service (IRS) [Member] | |||
Income Tax Contingency [Line Items] | |||
Operating Loss Carryforwards | $ 36,300 | ||
Minimum [Member] | |||
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] | |||
Income Tax Holiday, Termination Date | 12/31/2017 | ||
Maximum [Member] | |||
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] | |||
Income Tax Holiday, Termination Date | 12/31/2018 |
Income Taxes Income Before Inco
Income Taxes Income Before Income taxes (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | ||||||||||
Jan. 03, 2016 | [1] | Oct. 04, 2015 | Jun. 28, 2015 | Mar. 29, 2015 | Dec. 28, 2014 | Sep. 28, 2014 | Jun. 29, 2014 | Mar. 30, 2014 | Jan. 03, 2016 | Dec. 28, 2014 | Dec. 29, 2013 | |
Income Tax Contingency [Line Items] | ||||||||||||
U.S. | $ 3,160 | $ (37,758) | $ (71,901) | |||||||||
Non-U.S. | 240,855 | 207,361 | 235,585 | |||||||||
Income from continuing operations before income taxes | $ 74,813 | $ 63,954 | $ 57,288 | $ 47,960 | $ 20,647 | $ 47,810 | $ 60,673 | $ 40,473 | $ 244,015 | $ 169,603 | $ 163,684 | |
[1] | The fourth quarter of fiscal year 2015 includes a pre-tax loss of $12.4 million as a result of the mark-to-market adjustment on postretirement benefit plans. The fourth quarter of fiscal year 2014 includes a pre-tax loss of $75.9 million as a result of the mark-to-market adjustment on postretirement benefit plans. See Note 1 for a discussion of this accounting policy. |
Income Taxes Components of the
Income Taxes Components of the Provision (Benefits from) Income Tax (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Jan. 03, 2016 | Dec. 28, 2014 | Dec. 29, 2013 | |
Income Tax Contingency [Line Items] | |||
Federal current | $ (5,532) | $ (262) | $ 2,331 |
Federal deferred expense (benefit) | (1,799) | (19,169) | (29,961) |
Federal total | (7,331) | (19,431) | (27,630) |
State current | 3,112 | 2,416 | 1,968 |
State deferred expense (benefit) | (2,492) | (3,842) | (2,147) |
State total | 620 | (1,426) | (179) |
Non-U.S. current | 40,318 | 39,634 | 15,025 |
Non-U.S.deferred expense benefit | (2,280) | (10,340) | 2,201 |
Non-U.S. total | 38,038 | 29,294 | 17,226 |
Total current | 37,898 | 41,788 | 19,324 |
Total deferred expense (benefit) | (6,571) | (33,351) | (29,907) |
Total | 31,327 | 8,437 | (10,583) |
Discontinued operations | 232 | (1,831) | (5,107) |
Total provision for income taxes | $ 31,559 | $ 6,606 | $ (15,690) |
Income Taxes Reconciliation of
Income Taxes Reconciliation of Income Tax Expense (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Jan. 03, 2016 | Dec. 28, 2014 | Dec. 29, 2013 | |
Income Tax Contingency [Line Items] | |||
Tax at statutory rate | $ 85,405 | $ 59,361 | $ 57,289 |
Non-U.S. rate differential, net | (51,814) | (36,616) | (36,377) |
U.S. taxation of multinational operations | 1,732 | 2,367 | 3,658 |
State income taxes, net | 649 | 1,970 | (1,762) |
Prior year tax matters | (7,202) | (7,009) | (23,534) |
Federal tax credits | (2,295) | (3,399) | (5,452) |
Change in valuation allowance | 2,593 | (7,679) | (4,675) |
Other, net | 2,259 | (558) | 270 |
Total | $ 31,327 | $ 8,437 | $ (10,583) |
Income Taxes Components of Defe
Income Taxes Components of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands | Jan. 03, 2016 | Dec. 28, 2014 |
Income Tax Contingency [Line Items] | ||
Inventory | $ 9,887 | $ 9,041 |
Reserves and accruals | 29,137 | 30,641 |
Accrued compensation | 23,620 | 22,915 |
Net operating loss and credit carryforwards | 100,336 | 106,020 |
Accrued pension | 34,736 | 44,342 |
Restructuring reserve | 6,362 | 7,522 |
Deferred revenue | 40,065 | 46,413 |
All other, net | 0 | 824 |
Total deferred tax assets | 244,143 | 267,718 |
Postretirement health benefits | (4,202) | (4,472) |
Depreciation and amortization | (140,091) | (176,043) |
Total deferred tax liabilities | (144,293) | (180,515) |
Valuation allowance | (67,400) | (55,460) |
Net deferred tax liabilities | 32,450 | 31,743 |
Domestic Country [Member] | ||
Income Tax Contingency [Line Items] | ||
Net deferred tax liabilities | 54,411 | 44,073 |
Foreign Tax Authority [Member] | ||
Income Tax Contingency [Line Items] | ||
Total deferred tax liabilities | $ (21,961) | $ (12,330) |
Income Taxes Summary of Loss an
Income Taxes Summary of Loss and Tax Credit Carryforwards (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Jan. 03, 2016 | Dec. 28, 2014 | |
Income Tax Contingency [Line Items] | ||
Valuation Allowance, Amount | $ 67,400 | $ 55,460 |
State and Local Jurisdiction [Member] | ||
Income Tax Contingency [Line Items] | ||
Operating Loss Carryforwards | 226,400 | |
Tax Credit Carryforward, Amount | 10,700 | |
Foreign Tax Authority [Member] | ||
Income Tax Contingency [Line Items] | ||
Operating Loss Carryforwards | 199,500 | |
Tax Credit Carryforward, Amount | 13,000 | |
Internal Revenue Service (IRS) [Member] | ||
Income Tax Contingency [Line Items] | ||
Operating Loss Carryforwards | 36,300 | |
General Business [Member] | ||
Income Tax Contingency [Line Items] | ||
Tax Credit Carryforward, Amount | $ 32,100 | |
Minimum [Member] | Foreign Tax Authority [Member] | ||
Income Tax Contingency [Line Items] | ||
Tax Credit Carryforward, Expiration Date | Jan. 1, 2016 | |
Maximum [Member] | Foreign Tax Authority [Member] | ||
Income Tax Contingency [Line Items] | ||
Tax Credit Carryforward, Expiration Date | Dec. 31, 2034 |
Earnings Per Share (Schedule of
Earnings Per Share (Schedule of Reconciliation of Number of Shares Utilized in Earnings Per Share Calculations) (Details) - shares shares in Thousands | 12 Months Ended | ||
Jan. 03, 2016 | Dec. 28, 2014 | Dec. 29, 2013 | |
Earnings Per Share [Abstract] | |||
Number of common shares-basic | 112,507 | 112,593 | 112,254 |
Effect of dilutive securities, Stock options | 621 | 922 | 982 |
Effect of dilutive securities, Restricted stock | 187 | 224 | 267 |
Number of common shares-diluted | 113,315 | 113,739 | 113,503 |
Number of potentially dilutive securities excluded from calculation due to antidilutive impact | 607 | 475 | 485 |
Accounts Receivable, Net (Detai
Accounts Receivable, Net (Details) - USD ($) $ in Millions | Jan. 03, 2016 | Dec. 28, 2014 |
Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract] | ||
Reserves for doubtful accounts | $ 29.9 | $ 32.9 |
Inventories, Net (Details)
Inventories, Net (Details) - USD ($) $ in Thousands | Jan. 03, 2016 | Dec. 28, 2014 |
Inventory Disclosure [Abstract] | ||
Raw materials | $ 98,984 | $ 96,169 |
Work in progress | 17,858 | 18,783 |
Finished goods | 171,186 | 170,505 |
Total inventories | $ 288,028 | $ 285,457 |
Property, Plant and Equipment70
Property, Plant and Equipment, Net (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Jan. 03, 2016 | Dec. 28, 2014 | Dec. 29, 2013 | |
Property, Plant and Equipment [Line Items] | |||
Property, plant and equipment, gross | $ 494,956 | $ 492,814 | |
Accumulated depreciation | (327,927) | (316,620) | |
Total property, plant and equipment, net | 167,029 | 176,194 | |
Depreciation expense | 33,400 | 33,300 | $ 37,600 |
Land [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property, plant and equipment, gross | 802 | 906 | |
Building and leasehold Improvements [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property, plant and equipment, gross | 177,587 | 175,040 | |
Machinery and Equipment [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property, plant and equipment, gross | $ 316,567 | $ 316,868 |
Marketable Securities and Inv71
Marketable Securities and Investments (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Jan. 03, 2016 | Dec. 28, 2014 | Dec. 29, 2013 | |
Schedule of Available-for-sale Securities [Line Items] | |||
Unrealized (losses) gains on securities, net of tax | $ (262) | $ 14 | $ 8 |
Marketable securities | 1,586 | 1,568 | |
Marketable securities and investments | 1,586 | 1,568 | |
Equity Securities [Member] | |||
Schedule of Available-for-sale Securities [Line Items] | |||
Cost | 1,299 | 1,110 | |
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax | 0 | 7 | |
Market value | 908 | 1,002 | |
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax | (391) | (115) | |
Fixed Income Securities [Member] | |||
Schedule of Available-for-sale Securities [Line Items] | |||
Cost | 57 | 88 | |
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax | 0 | 0 | |
Market value | 57 | 88 | |
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax | 0 | 0 | |
Available-for-sale Securities, Other [Member] | |||
Schedule of Available-for-sale Securities [Line Items] | |||
Cost | 822 | 541 | |
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax | 0 | 0 | |
Market value | 621 | 478 | |
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax | (201) | (63) | |
Available-for-sale Securities [Member] | |||
Schedule of Available-for-sale Securities [Line Items] | |||
Cost | 2,178 | 1,739 | |
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax | 0 | 7 | |
Market value | 1,586 | 1,568 | |
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax | $ (592) | $ (178) |
Goodwill and Intangible Asset72
Goodwill and Intangible Assets, Net (Narrative) (Details) - USD ($) $ in Thousands | 12 Months Ended | |||
Jan. 03, 2016 | Dec. 28, 2014 | Dec. 29, 2013 | Dec. 30, 2012 | |
Goodwill and Intangible Assets Net [Line Items] | ||||
Reallocation of Goodwill Resulting from Realignment Within Operating Segments | $ 41,200 | |||
Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount | 20.00% | |||
Long-term terminal growth rates for reporting units | 3.00% | |||
Change in any one of the input assumptions for the various reporting units | 10.00% | |||
Total amortization expense related to finite-lived intangible assets | $ 78,600 | 83,400 | $ 89,300 | |
Future Amortization Expense, Year One | 71,800 | |||
Future Amortization Expense, Year Two | 62,500 | |||
Future Amortization Expense, Year Three | 60,700 | |||
Future Amortization Expense, Year Four | 48,700 | |||
Future Amortization Expense, Year Five | 40,100 | |||
Finite-Lived Intangible Assets, Net | 420,227 | 419,681 | ||
Asset impairment | $ 0 | 0 | 158 | |
Minimum [Member] | ||||
Goodwill and Intangible Assets Net [Line Items] | ||||
Discount rates for reporting units | 9.50% | |||
Maximum [Member] | ||||
Goodwill and Intangible Assets Net [Line Items] | ||||
Discount rates for reporting units | 12.50% | |||
Trade Names And Trademarks [Member] | ||||
Goodwill and Intangible Assets Net [Line Items] | ||||
Finite-Lived Intangible Assets, Net | $ 19,563 | 23,133 | ||
Licenses [Member] | ||||
Goodwill and Intangible Assets Net [Line Items] | ||||
Finite-Lived Intangible Assets, Net | 13,683 | 17,839 | ||
Human Health [Member] | ||||
Goodwill and Intangible Assets Net [Line Items] | ||||
Finite-Lived Intangible Assets, Net | 297,568 | 272,813 | ||
Human Health [Member] | Trade Names And Trademarks [Member] | ||||
Goodwill and Intangible Assets Net [Line Items] | ||||
Finite-Lived Intangible Assets, Net | 13,077 | 16,191 | ||
Human Health [Member] | Customer Lists [Member] | ||||
Goodwill and Intangible Assets Net [Line Items] | ||||
Impairment of Intangible Assets (Excluding Goodwill) | 200 | |||
Asset impairment | 200 | |||
Human Health [Member] | Licenses [Member] | ||||
Goodwill and Intangible Assets Net [Line Items] | ||||
Finite-Lived Intangible Assets, Net | 13,683 | 17,839 | ||
Environmental Health [Member] | ||||
Goodwill and Intangible Assets Net [Line Items] | ||||
Finite-Lived Intangible Assets, Net | 122,659 | 146,868 | ||
Environmental Health [Member] | Trade Names And Trademarks [Member] | ||||
Goodwill and Intangible Assets Net [Line Items] | ||||
Finite-Lived Intangible Assets, Net | 6,486 | 6,942 | ||
Environmental Health [Member] | Licenses [Member] | ||||
Goodwill and Intangible Assets Net [Line Items] | ||||
Finite-Lived Intangible Assets, Net | 0 | $ 0 | ||
Other Asset Acquisitions [Member] | ||||
Goodwill and Intangible Assets Net [Line Items] | ||||
Finite-Lived Intangible Assets, Net | 7,000 | $ 6,800 | ||
Prepaid Royalties | 9,800 | $ 40,300 | $ 25,000 | |
Prepaid Royalties To Be Paid Within One Year | $ 10,000 |
Goodwill and Intangible Asset73
Goodwill and Intangible Assets, Net (Changes in the Carrying Amount of Goodwill) (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Jan. 03, 2016 | Dec. 28, 2014 | |
Changes in the carrying amount of goodwill | ||
Foreign currency translation | $ (55,434) | $ (37,886) |
Acquisitions, earn outs and other | 47,506 | 178,843 |
Ending balance | 2,276,149 | 2,284,077 |
Human Health [Member] | ||
Changes in the carrying amount of goodwill | ||
Foreign currency translation | (28,368) | (29,145) |
Acquisitions, earn outs and other | 38,104 | 2,408 |
Ending balance | 1,672,491 | 1,662,755 |
Environmental Health [Member] | ||
Changes in the carrying amount of goodwill | ||
Foreign currency translation | (27,066) | (8,741) |
Acquisitions, earn outs and other | 9,402 | 176,435 |
Ending balance | $ 603,658 | $ 621,322 |
Goodwill and Intangible Asset74
Goodwill and Intangible Assets, Net (Identifiable Intangible Asset Balances) (Details) - USD ($) $ in Thousands | Jan. 03, 2016 | Dec. 28, 2014 |
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Net amortizable intangible assets | $ 420,227 | $ 419,681 |
Totals | 490,811 | 490,265 |
Patents [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Gross amortizable intangible assets | 39,911 | 39,953 |
Less: Accumulated amortization | (29,788) | (27,200) |
Net amortizable intangible assets | 10,123 | 12,753 |
Trade Names And Trademarks [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Gross amortizable intangible assets | 40,249 | 40,069 |
Less: Accumulated amortization | (20,686) | (16,936) |
Net amortizable intangible assets | 19,563 | 23,133 |
Non-amortizing intangible assets | 70,584 | 70,584 |
Licenses [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Gross amortizable intangible assets | 58,969 | 59,631 |
Less: Accumulated amortization | (45,286) | (41,792) |
Net amortizable intangible assets | 13,683 | 17,839 |
Core Technology [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Gross amortizable intangible assets | 307,242 | 298,491 |
Less: Accumulated amortization | (211,829) | (184,697) |
Net amortizable intangible assets | 95,413 | 113,794 |
Customer Relationships [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Gross amortizable intangible assets | 391,566 | 402,185 |
Less: Accumulated amortization | (191,655) | (156,994) |
Net amortizable intangible assets | 199,911 | 245,191 |
In Process Research and Development [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Gross amortizable intangible assets | 85,679 | 10,103 |
Less: Accumulated amortization | (4,145) | (3,132) |
Net amortizable intangible assets | 81,534 | 6,971 |
Human Health [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Net amortizable intangible assets | 297,568 | 272,813 |
Totals | 297,568 | 272,813 |
Human Health [Member] | Patents [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Gross amortizable intangible assets | 37,111 | 37,153 |
Less: Accumulated amortization | (27,466) | (25,018) |
Net amortizable intangible assets | 9,645 | 12,135 |
Human Health [Member] | Trade Names And Trademarks [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Gross amortizable intangible assets | 32,887 | 33,069 |
Less: Accumulated amortization | (19,810) | (16,878) |
Net amortizable intangible assets | 13,077 | 16,191 |
Non-amortizing intangible assets | 0 | 0 |
Human Health [Member] | Licenses [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Gross amortizable intangible assets | 58,969 | 59,631 |
Less: Accumulated amortization | (45,286) | (41,792) |
Net amortizable intangible assets | 13,683 | 17,839 |
Human Health [Member] | Core Technology [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Gross amortizable intangible assets | 181,807 | 171,163 |
Less: Accumulated amortization | (121,262) | (100,050) |
Net amortizable intangible assets | 60,545 | 71,113 |
Human Health [Member] | Customer Relationships [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Gross amortizable intangible assets | 298,978 | 301,371 |
Less: Accumulated amortization | (177,730) | (149,917) |
Net amortizable intangible assets | 121,248 | 151,454 |
Human Health [Member] | In Process Research and Development [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Gross amortizable intangible assets | 80,748 | 5,079 |
Less: Accumulated amortization | (1,378) | (998) |
Net amortizable intangible assets | 79,370 | 4,081 |
Environmental Health [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Net amortizable intangible assets | 122,659 | 146,868 |
Totals | 193,243 | 217,452 |
Environmental Health [Member] | Patents [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Gross amortizable intangible assets | 2,800 | 2,800 |
Less: Accumulated amortization | (2,322) | (2,182) |
Net amortizable intangible assets | 478 | 618 |
Environmental Health [Member] | Trade Names And Trademarks [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Gross amortizable intangible assets | 7,362 | 7,000 |
Less: Accumulated amortization | (876) | (58) |
Net amortizable intangible assets | 6,486 | 6,942 |
Non-amortizing intangible assets | 70,584 | 70,584 |
Environmental Health [Member] | Licenses [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Gross amortizable intangible assets | 0 | 0 |
Less: Accumulated amortization | 0 | 0 |
Net amortizable intangible assets | 0 | 0 |
Environmental Health [Member] | Core Technology [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Gross amortizable intangible assets | 125,435 | 127,328 |
Less: Accumulated amortization | (90,567) | (84,647) |
Net amortizable intangible assets | 34,868 | 42,681 |
Environmental Health [Member] | Customer Relationships [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Gross amortizable intangible assets | 92,588 | 100,814 |
Less: Accumulated amortization | (13,925) | (7,077) |
Net amortizable intangible assets | 78,663 | 93,737 |
Environmental Health [Member] | In Process Research and Development [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Gross amortizable intangible assets | 4,931 | 5,024 |
Less: Accumulated amortization | (2,767) | (2,134) |
Net amortizable intangible assets | $ 2,164 | $ 2,890 |
Debt (Details)
Debt (Details) - USD ($) $ in Thousands | 1 Months Ended | 12 Months Ended | |||
Oct. 25, 2011 | Jan. 03, 2016 | Dec. 30, 2012 | Dec. 28, 2014 | Sep. 30, 2012 | |
Unamortized discount and debt issuance costs | $ (7,312) | ||||
Unamortized Debt Issuance Expense | $ 6,500 | ||||
Maturities of Long-term Debt [Abstract] | |||||
2,016 | 1,123 | ||||
2,017 | 1,169 | ||||
2,018 | 1,367 | ||||
2,019 | 483,532 | ||||
2,020 | 1,597 | ||||
Thereafter | 531,409 | ||||
Long-term Debt Before Unamortized Discount | 1,020,197 | ||||
Total | 1,012,885 | ||||
Other Long-term Debt, Current | 1,123 | 1,075 | |||
Line of Credit, Maturing January 8, 2019 [Member] | |||||
Long-term Debt | 479,600 | 512,800 | |||
Unsecured revolving credit facility, amount | $ 700,000 | ||||
Unsecured revolving credit facility, expiry date | Jan. 8, 2019 | ||||
Line of Credit Facility, Remaining Borrowing Capacity | $ 206,500 | ||||
Letters of credit issued and outstanding | $ 11,500 | ||||
Interest rate terms under amended senior unsecured revolving credit facility | The interest rates under the senior unsecured revolving credit facility are based on the Eurocurrency rate or the base rate at the time of borrowing plus a margin. The base rate is the higher of (i) the rate of interest in effect for such day as publicly announced from time to time by JP Morgan Chase Bank, N.A. as its "prime rate," (ii) the Federal Funds rate plus 50 basis points or (iii) one-month Libor plus 1.00%. | ||||
Weighted average interest rates under amended senior unsecured revolving credit facility | The Eurocurrency margin as of January 3, 2016 was 108 basis points. The weighted average Eurocurrency interest rate as of January 3, 2016 was 0.36%, resulting in a weighted average effective Eurocurrency rate, including the margin, of 1.44%. | ||||
Aggregate borrowings under the amended facility | $ 482,000 | 516,000 | |||
Unamortized discount and debt issuance costs | (2,384) | ||||
Unamortized Debt Issuance Expense | 2,400 | 3,200 | |||
Maturities of Long-term Debt [Abstract] | |||||
2,016 | 0 | ||||
2,017 | 0 | ||||
2,018 | 0 | ||||
2,019 | 482,000 | ||||
2,020 | 0 | ||||
Thereafter | 0 | ||||
Long-term Debt Before Unamortized Discount | 482,000 | ||||
Total | $ 479,616 | ||||
Line of Credit, Maturing January 8, 2019 [Member] | Base Rate Option Three [Member] | |||||
Basis spread on variable rate | 1.00% | ||||
Line of Credit, Maturing January 8, 2019 [Member] | Eurocurrency Rate [Member] | |||||
Basis spread on variable rate | 1.08% | ||||
Weighted average Eurocurrency interest rate | 0.36% | ||||
Weighted average effective Eurocurrency rate, including the margin | 1.44% | ||||
Line of Credit, Maturing January 8, 2019 [Member] | Base Rate Option Two [Member] | |||||
Basis spread on variable rate | 0.50% | ||||
Line of Credit, Maturing December 16, 2016 [Member] | Eurocurrency Rate [Member] | |||||
Description of variable rate basis | Eurocurrency | ||||
Line of Credit, Maturing December 16, 2016 [Member] | Base Rate Option Two [Member] | |||||
Description of variable rate basis | Federal Funds | ||||
2021 Notes [Member] | |||||
Long-term Debt | $ 495,100 | 494,400 | |||
Unsecured senior notes, interest rate percent | 5.00% | ||||
Unsecured senior notes, face value | $ 500,000 | 500,000 | |||
Gross proceeds from the issuance of debt instrument | $ 496,900 | ||||
Senior unsecured notes issuance as percentage of principal amount | 99.372% | ||||
Debt Instrument, Unamortized Discount | $ 3,100 | 2,017 | 2,300 | ||
Unamortized discount and debt issuance costs | (4,928) | ||||
Unamortized Debt Issuance Expense | 2,900 | 3,300 | |||
Debt instrument maturity date | Nov. 25, 2021 | ||||
Percentage of redemption of senior notes on or after August 15, 2021 | 100.00% | ||||
Percentage of redemption upon a change of control and a contemporaneous downgrade of the Notes | 101.00% | ||||
Maturities of Long-term Debt [Abstract] | |||||
2,016 | 0 | ||||
2,017 | 0 | ||||
2,018 | 0 | ||||
2,019 | 0 | ||||
2,020 | 0 | ||||
Thereafter | 500,000 | ||||
Long-term Debt Before Unamortized Discount | 500,000 | ||||
Total | $ 495,072 | ||||
2021 Notes [Member] | Treasury Rate [Member] | |||||
Basis spread on variable rate | 0.45% | ||||
Financing Lease Obligations [Member] | |||||
Additional Financing Lease Obligations | $ 11,500 | ||||
Unamortized discount and debt issuance costs | $ 0 | ||||
Maturities of Long-term Debt [Abstract] | |||||
2,016 | 1,123 | ||||
2,017 | 1,169 | ||||
2,018 | 1,367 | ||||
2,019 | 1,532 | ||||
2,020 | 1,597 | ||||
Thereafter | 31,409 | ||||
Long-term Debt Before Unamortized Discount | 38,197 | ||||
Total | 38,197 | ||||
Other Long-term Debt | 38,200 | 39,300 | $ 29,300 | ||
Other Long-term Debt, Current | 1,100 | 1,100 | |||
Other Long-term Debt, Noncurrent | $ 37,100 | $ 38,200 |
Accrued Expenses and Other Cu76
Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands | Jan. 03, 2016 | Dec. 28, 2014 |
Accounts Payable and Accrued Liabilities, Current [Abstract] | ||
Payroll and incentives | $ 62,813 | $ 61,018 |
Employee benefits | 33,446 | 40,318 |
Deferred revenue | 163,167 | 168,928 |
Federal, non-U.S. and state income taxes | 2,882 | 9,801 |
Other accrued operating expenses | 126,138 | 122,956 |
Total accrued expenses and other current liabilities | $ 388,446 | $ 403,021 |
Employee Benefit Plans (Schedul
Employee Benefit Plans (Schedule of Net Benefit Costs, Pension Plans) (Details) - USD ($) $ in Thousands | 6 Months Ended | 12 Months Ended | ||
Jun. 28, 2015 | Jan. 03, 2016 | Dec. 28, 2014 | Dec. 29, 2013 | |
Defined Benefit Plan Disclosure [Line Items] | ||||
Net periodic benefit cost | $ 10,815 | $ 73,957 | $ (16,839) | |
Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Defined Benefit Plan, Curtailments | $ (816) | |||
Service cost | 4,332 | 4,070 | 3,664 | |
Interest cost | 20,696 | 23,475 | 21,334 | |
Expected return on plan assets | (26,021) | (25,007) | (25,106) | |
Actuarial loss (gain) | $ 821 | 12,953 | 71,700 | (16,464) |
Amortization of prior service cost | $ (238) | $ (281) | $ (267) |
Employee Benefit Plans (Sched78
Employee Benefit Plans (Schedule of Net Funded Status, Pension Plans) (Details) - USD ($) $ in Thousands | 12 Months Ended | |||
Jan. 03, 2016 | Dec. 28, 2014 | Dec. 29, 2013 | Dec. 30, 2012 | |
Defined Benefit Plan Disclosure [Line Items] | ||||
Defined Benefit Plan, Plans with Benefit Obligations in Excess of Plan Assets, Aggregate Benefit Obligation | $ 138,201 | $ 156,867 | ||
Change in benefit obligations: | ||||
Defined Benefit Plan, Other Changes | 6,800 | 32,100 | ||
Change in plan assets: | ||||
Employer's contributions | 14,900 | |||
Actuarial assumptions as of the year-end measurement date: | ||||
Defined Benefit Plan, Plans with Benefit Obligations in Excess of Plan Assets, Aggregate Fair Value of Plan Assets | 0 | 0 | ||
Defined Benefit Plan, Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets, Aggregate Projected Benefit Obligation | 134,858 | 153,239 | ||
Defined Benefit Plan, Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets, Aggregate Fair Value of Plan Assets | 0 | 0 | ||
Foreign Pension Plans, Defined Benefit [Member] | ||||
Actuarial present value of benefit obligations: [Abstract] | ||||
Accumulated benefit obligations | 267,862 | 291,640 | ||
Change in benefit obligations: | ||||
Projected benefit obligations at beginning of year | 303,809 | 288,216 | ||
Service cost | 2,532 | 2,670 | ||
Interest cost | 7,695 | 10,575 | ||
Benefits paid and plan expenses | (11,100) | (12,280) | ||
Participant's contributions | 343 | 394 | ||
Defined Benefit Plan, Curtailments | (759) | 0 | ||
Defined Benefit Plan, Other Changes | (1,401) | 0 | ||
Actuarial loss (gain) | 131 | 42,095 | ||
Effect of exchange rate changes | (24,290) | (27,861) | ||
Projected benefit obligations at end of year | 276,960 | 303,809 | $ 288,216 | |
Change in plan assets: | ||||
Fair value of plan assets at beginning of year | 156,767 | 143,704 | ||
Actual return on plan assets | 3,745 | 22,939 | ||
Benefits paid and plan expenses | (11,100) | (12,280) | ||
Employer's contributions | 10,908 | 11,195 | 20,200 | |
Defined Benefit Plan, Settlements, Plan Assets | (1,401) | 0 | ||
Participant's contributions | 343 | 394 | ||
Effect of exchange rate changes | (8,368) | (9,185) | ||
Fair value of plan assets at end of year | 150,894 | 156,767 | $ 143,704 | |
Net amounts recognized in the consolidated balance sheets consist of: | ||||
Net amounts recognized in the consolidated balance sheets | (126,066) | (147,042) | ||
Defined Benefit Plan, Assets for Plan Benefits, Noncurrent | 12,135 | 9,825 | ||
Current liabilities | (6,261) | (6,786) | ||
Noncurrent liabilities | (131,940) | (150,081) | ||
Net amounts recognized in accumulated other comprehensive income consist of: | ||||
Prior service cost | (932) | (1,371) | ||
Net amounts recognized in accumulated other comprehensive income | $ (932) | $ (1,371) | ||
Actuarial assumptions as of the year-end measurement date: | ||||
Discount rate | 2.88% | 2.75% | 3.77% | 3.62% |
Rate of compensation increase | 3.26% | 3.28% | 3.23% | 2.88% |
Expected rate of return on assets | 4.60% | 5.30% | 5.50% | |
United States Pension Plans of US Entity, Defined Benefit [Member] | ||||
Actuarial present value of benefit obligations: [Abstract] | ||||
Accumulated benefit obligations | $ 301,416 | $ 327,632 | ||
Change in benefit obligations: | ||||
Projected benefit obligations at beginning of year | 327,632 | 279,299 | ||
Service cost | 1,800 | 1,400 | ||
Interest cost | 13,001 | 12,900 | ||
Benefits paid and plan expenses | (24,127) | (19,282) | ||
Participant's contributions | 0 | 0 | ||
Defined Benefit Plan, Curtailments | 0 | 0 | ||
Defined Benefit Plan, Other Changes | 0 | 0 | ||
Actuarial loss (gain) | (16,890) | 53,315 | ||
Effect of exchange rate changes | 0 | 0 | ||
Projected benefit obligations at end of year | 301,416 | 327,632 | $ 279,299 | |
Change in plan assets: | ||||
Fair value of plan assets at beginning of year | 256,254 | 249,756 | ||
Actual return on plan assets | (7,434) | 25,780 | ||
Benefits paid and plan expenses | (24,127) | (19,282) | ||
Employer's contributions | 20,000 | 0 | 37,000 | |
Defined Benefit Plan, Settlements, Plan Assets | 0 | 0 | ||
Participant's contributions | 0 | 0 | ||
Effect of exchange rate changes | 0 | 0 | ||
Fair value of plan assets at end of year | 244,693 | 256,254 | $ 249,756 | |
Net amounts recognized in the consolidated balance sheets consist of: | ||||
Net amounts recognized in the consolidated balance sheets | (56,723) | (71,378) | ||
Defined Benefit Plan, Assets for Plan Benefits, Noncurrent | 0 | 0 | ||
Current liabilities | 0 | 0 | ||
Noncurrent liabilities | (56,723) | (71,378) | ||
Net amounts recognized in accumulated other comprehensive income consist of: | ||||
Prior service cost | 0 | 0 | ||
Net amounts recognized in accumulated other comprehensive income | $ 0 | $ 0 | ||
Actuarial assumptions as of the year-end measurement date: | ||||
Discount rate | 4.25% | 4.08% | 4.77% | 3.92% |
Rate of compensation increase | 0.00% | 0.00% | 0.00% | 0.00% |
Expected rate of return on assets | 7.25% | 7.25% | 7.50% | |
Other Pension Plan [Member] | ||||
Actuarial assumptions as of the year-end measurement date: | ||||
Rate of compensation increase | 3.07% |
Employee Benefit Plans (Sched79
Employee Benefit Plans (Schedule of Allocation of Plan Assets, Pension Plans) (Details) | 12 Months Ended | ||
Jan. 01, 2017 | Jan. 03, 2016 | Dec. 28, 2014 | |
Foreign Pension Plans, Defined Benefit [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit Plan, Equity Securities | 100.00% | 100.00% | |
United States Pension Plans of US Entity, Defined Benefit [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit Plan, Equity Securities | 100.00% | 100.00% | |
Minimum [Member] | Equity Securities [Member] | Foreign Pension Plans, Defined Benefit [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit, Target Asset Allocation Percentage | 45.00% | ||
Minimum [Member] | Equity Securities [Member] | United States Pension Plans of US Entity, Defined Benefit [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit, Target Asset Allocation Percentage | 40.00% | ||
Minimum [Member] | Debt Securities [Member] | Foreign Pension Plans, Defined Benefit [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit, Target Asset Allocation Percentage | 45.00% | ||
Minimum [Member] | Debt Securities [Member] | United States Pension Plans of US Entity, Defined Benefit [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit, Target Asset Allocation Percentage | 50.00% | ||
Minimum [Member] | Trading Assets, Excluding Debt and Equity Securities [Member] | Foreign Pension Plans, Defined Benefit [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit, Target Asset Allocation Percentage | 0.00% | ||
Minimum [Member] | Trading Assets, Excluding Debt and Equity Securities [Member] | United States Pension Plans of US Entity, Defined Benefit [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit, Target Asset Allocation Percentage | 0.00% | ||
Maximum [Member] | Equity Securities [Member] | Foreign Pension Plans, Defined Benefit [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit, Target Asset Allocation Percentage | 55.00% | ||
Maximum [Member] | Equity Securities [Member] | United States Pension Plans of US Entity, Defined Benefit [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit, Target Asset Allocation Percentage | 50.00% | ||
Maximum [Member] | Debt Securities [Member] | Foreign Pension Plans, Defined Benefit [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit, Target Asset Allocation Percentage | 55.00% | ||
Maximum [Member] | Debt Securities [Member] | United States Pension Plans of US Entity, Defined Benefit [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit, Target Asset Allocation Percentage | 60.00% | ||
Maximum [Member] | Trading Assets, Excluding Debt and Equity Securities [Member] | Foreign Pension Plans, Defined Benefit [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit, Target Asset Allocation Percentage | 5.00% | ||
Maximum [Member] | Trading Assets, Excluding Debt and Equity Securities [Member] | United States Pension Plans of US Entity, Defined Benefit [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit, Target Asset Allocation Percentage | 5.00% | ||
Other Securities [Member] | Foreign Pension Plans, Defined Benefit [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit Plan, Equity Securities | 1.00% | 1.00% | |
Other Securities [Member] | United States Pension Plans of US Entity, Defined Benefit [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit Plan, Equity Securities | 0.00% | 0.00% | |
Debt Securities [Member] | Foreign Pension Plans, Defined Benefit [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit Plan, Equity Securities | 50.00% | 50.00% | |
Debt Securities [Member] | United States Pension Plans of US Entity, Defined Benefit [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit Plan, Equity Securities | 58.00% | 61.00% | |
Equity Securities [Member] | Foreign Pension Plans, Defined Benefit [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit Plan, Equity Securities | 49.00% | 49.00% | |
Equity Securities [Member] | United States Pension Plans of US Entity, Defined Benefit [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit Plan, Equity Securities | 42.00% | 39.00% | |
Scenario, Forecast [Member] | Foreign Pension Plans, Defined Benefit [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit Plan, Target Allocation Percentage | 1 | ||
Scenario, Forecast [Member] | United States Pension Plans of US Entity, Defined Benefit [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit Plan, Target Allocation Percentage | 1 |
Employee Benefit Plans (Sched80
Employee Benefit Plans (Schedule of Changes in Fair Value of Plan Assets, Pension Plans) (Details) - Pension Plans, Defined Benefit - USD ($) $ in Thousands | Jan. 03, 2016 | Dec. 28, 2014 | Dec. 29, 2013 | Dec. 30, 2012 |
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | $ 395,587 | $ 413,021 | ||
Cash [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 2,890 | 4,971 | ||
Equity Securities, U.S. Large-cap [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 30,357 | 28,602 | ||
Equity Securities, International large-cap value[Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 26,686 | 25,202 | ||
Equity Securities, Emerging Markets Growth [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 10,600 | 13,010 | ||
Equity Securities, Equity Index Funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 74,974 | 77,432 | ||
Equity Securities, Domestic Real Estate Funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 2,735 | 2,860 | ||
Equity Securities, Commodity Funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 8,128 | 7,423 | ||
Foreign Government Debt Securities [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 21,531 | 22,025 | ||
Fixed Income Funds, Corporate Debt Instruments [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 137,117 | 147,834 | ||
Fixed Income Funds, Corporate Bonds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 23,871 | 25,164 | ||
Fixed Income Funds, High Yield Bonds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 3,324 | 3,614 | ||
Other Types of Investments, Multi-strategy hedge funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 23,415 | 23,332 | ||
Other Types of Investments, Venture Capital Funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 1 | 1 | ||
Other Types of Investments, Non U.S. Government Index Linked Bonds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 29,958 | 31,551 | ||
Fair Value, Inputs, Level 1 [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 113,466 | 139,495 | ||
Fair Value, Inputs, Level 1 [Member] | Cash [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 2,890 | 4,971 | ||
Fair Value, Inputs, Level 1 [Member] | Equity Securities, U.S. Large-cap [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 30,357 | 28,602 | ||
Fair Value, Inputs, Level 1 [Member] | Equity Securities, International large-cap value[Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 26,686 | 25,202 | ||
Fair Value, Inputs, Level 1 [Member] | Equity Securities, Emerging Markets Growth [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 10,600 | 13,010 | ||
Fair Value, Inputs, Level 1 [Member] | Equity Securities, Equity Index Funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 1 [Member] | Equity Securities, Domestic Real Estate Funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 2,735 | 2,860 | ||
Fair Value, Inputs, Level 1 [Member] | Equity Securities, Commodity Funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 8,128 | 7,423 | ||
Fair Value, Inputs, Level 1 [Member] | Foreign Government Debt Securities [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 1 [Member] | Fixed Income Funds, Corporate Debt Instruments [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 28,746 | 53,813 | ||
Fair Value, Inputs, Level 1 [Member] | Fixed Income Funds, Corporate Bonds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 1 [Member] | Fixed Income Funds, High Yield Bonds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 3,324 | 3,614 | ||
Fair Value, Inputs, Level 1 [Member] | Other Types of Investments, Multi-strategy hedge funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 1 [Member] | Other Types of Investments, Venture Capital Funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 1 [Member] | Other Types of Investments, Non U.S. Government Index Linked Bonds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 2 [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 258,705 | 250,193 | ||
Fair Value, Inputs, Level 2 [Member] | Cash [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 2 [Member] | Equity Securities, U.S. Large-cap [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 2 [Member] | Equity Securities, International large-cap value[Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 2 [Member] | Equity Securities, Emerging Markets Growth [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 2 [Member] | Equity Securities, Equity Index Funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 74,974 | 77,432 | ||
Fair Value, Inputs, Level 2 [Member] | Equity Securities, Domestic Real Estate Funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 2 [Member] | Equity Securities, Commodity Funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 2 [Member] | Foreign Government Debt Securities [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 21,531 | 22,025 | ||
Fair Value, Inputs, Level 2 [Member] | Fixed Income Funds, Corporate Debt Instruments [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 108,371 | 94,021 | ||
Fair Value, Inputs, Level 2 [Member] | Fixed Income Funds, Corporate Bonds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 23,871 | 25,164 | ||
Fair Value, Inputs, Level 2 [Member] | Fixed Income Funds, High Yield Bonds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 2 [Member] | Other Types of Investments, Multi-strategy hedge funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 2 [Member] | Other Types of Investments, Venture Capital Funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 2 [Member] | Other Types of Investments, Non U.S. Government Index Linked Bonds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 29,958 | 31,551 | ||
Fair Value, Inputs, Level 3 [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 23,416 | 23,333 | $ 22,697 | $ 20,431 |
Fair Value, Inputs, Level 3 [Member] | Cash [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 3 [Member] | Equity Securities, U.S. Large-cap [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 3 [Member] | Equity Securities, International large-cap value[Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 3 [Member] | Equity Securities, Emerging Markets Growth [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 3 [Member] | Equity Securities, Equity Index Funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 3 [Member] | Equity Securities, Domestic Real Estate Funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 3 [Member] | Equity Securities, Commodity Funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 3 [Member] | Foreign Government Debt Securities [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 3 [Member] | Fixed Income Funds, Corporate Debt Instruments [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 3 [Member] | Fixed Income Funds, Corporate Bonds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 3 [Member] | Fixed Income Funds, High Yield Bonds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fair Value, Inputs, Level 3 [Member] | Other Types of Investments, Multi-strategy hedge funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 23,415 | 23,332 | 22,689 | 20,262 |
Fair Value, Inputs, Level 3 [Member] | Other Types of Investments, Venture Capital Funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 1 | 1 | $ 8 | $ 7 |
Fair Value, Inputs, Level 3 [Member] | Other Types of Investments, Non U.S. Government Index Linked Bonds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | $ 0 | $ 0 |
Employee Benefit Plans (Sched81
Employee Benefit Plans (Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets, Pension Plans) (Details) - Pension Plans, Defined Benefit - USD ($) $ in Thousands | 12 Months Ended | ||
Jan. 03, 2016 | Dec. 28, 2014 | Dec. 29, 2013 | |
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] | |||
Fair value of plan assets at beginning of year | $ 413,021 | ||
Fair value of plan assets at end of year | 395,587 | $ 413,021 | |
Venture Capital Funds [Member] | |||
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] | |||
Fair value of plan assets at beginning of year | 1 | ||
Fair value of plan assets at end of year | 1 | 1 | |
Multi-strategy hedge funds [Member] | |||
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] | |||
Fair value of plan assets at beginning of year | 23,332 | ||
Fair value of plan assets at end of year | 23,415 | 23,332 | |
Fair Value, Inputs, Level 3 [Member] | |||
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] | |||
Fair value of plan assets at beginning of year | 23,333 | 22,697 | $ 20,431 |
Realized gains (losses) | 7 | ||
Unrealized gains (losses) | 83 | 636 | 2,409 |
Fair value of plan assets at end of year | 23,416 | 23,333 | 22,697 |
Fair Value, Inputs, Level 3 [Member] | Common Collective Trusts [Member] | |||
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] | |||
Fair value of plan assets at beginning of year | 0 | 0 | 162 |
Realized gains (losses) | 7 | ||
Unrealized gains (losses) | 0 | 0 | (19) |
Fair value of plan assets at end of year | 0 | 0 | 0 |
Fair Value, Inputs, Level 3 [Member] | Venture Capital Funds [Member] | |||
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] | |||
Fair value of plan assets at beginning of year | 1 | 8 | 7 |
Realized gains (losses) | 0 | ||
Unrealized gains (losses) | 0 | (7) | 1 |
Fair value of plan assets at end of year | 1 | 1 | 8 |
Fair Value, Inputs, Level 3 [Member] | Multi-strategy hedge funds [Member] | |||
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] | |||
Fair value of plan assets at beginning of year | 23,332 | 22,689 | 20,262 |
Realized gains (losses) | 0 | ||
Unrealized gains (losses) | 83 | 643 | 2,427 |
Fair value of plan assets at end of year | $ 23,415 | $ 23,332 | 22,689 |
Defined Benefit Plans, Sales and Settlements [Member] | Fair Value, Inputs, Level 3 [Member] | |||
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] | |||
Purchases, issuances, and settlements | (150) | ||
Defined Benefit Plans, Sales and Settlements [Member] | Fair Value, Inputs, Level 3 [Member] | Common Collective Trusts [Member] | |||
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] | |||
Purchases, issuances, and settlements | 150 | ||
Defined Benefit Plans, Sales and Settlements [Member] | Fair Value, Inputs, Level 3 [Member] | Venture Capital Funds [Member] | |||
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] | |||
Purchases, issuances, and settlements | 0 | ||
Defined Benefit Plans, Sales and Settlements [Member] | Fair Value, Inputs, Level 3 [Member] | Multi-strategy hedge funds [Member] | |||
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] | |||
Purchases, issuances, and settlements | $ 0 |
Employee Benefit Plans (Sched82
Employee Benefit Plans (Schedule of Expected Benefit Payments, Pension Plans) (Details) - USD ($) $ in Thousands | 12 Months Ended | |||
Jan. 01, 2017 | Jan. 03, 2016 | Dec. 28, 2014 | Dec. 29, 2013 | |
Defined Benefit Plan Disclosure [Line Items] | ||||
Defined Benefit Plan, Contributions by Employer | $ 14,900 | |||
United States Pension Plans of US Entity, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
2,016 | 17,950 | |||
2,017 | 18,018 | |||
2,018 | 18,289 | |||
2,019 | 18,469 | |||
2,020 | 18,683 | |||
2021-2025 | 95,733 | |||
Defined Benefit Plan, Contributions by Employer | 20,000 | $ 0 | $ 37,000 | |
Foreign Pension Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
2,016 | 10,490 | |||
2,017 | 11,051 | |||
2,018 | 11,466 | |||
2,019 | 11,855 | |||
2,020 | 12,473 | |||
2021-2025 | 67,253 | |||
Defined Benefit Plan, Contributions by Employer | $ 10,908 | $ 11,195 | 20,200 | |
UNITED KINGDOM | Foreign Pension Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Defined Benefit Plan, Contributions by Employer | $ 10,000 | |||
Scenario, Forecast [Member] | Foreign Pension Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Expected contributions in next fiscal year | $ 9,300 |
Employee Benefit Plans (Sched83
Employee Benefit Plans (Schedule of Net Benefit Costs, Other Postretirement Benefits) (Details) - USD ($) $ in Thousands | 6 Months Ended | 12 Months Ended | ||
Jun. 28, 2015 | Jan. 03, 2016 | Dec. 28, 2014 | Dec. 29, 2013 | |
Defined Benefit Plan Disclosure [Line Items] | ||||
Net periodic benefit cost | $ 10,815 | $ 73,957 | $ (16,839) | |
Pension Plans, Defined Benefit | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Service cost | 4,332 | 4,070 | 3,664 | |
Interest cost | 20,696 | 23,475 | 21,334 | |
Expected return on plan assets | (26,021) | (25,007) | (25,106) | |
Defined Benefit Plan, Recognized Net Gain (Loss) Due to Curtailments | 907 | 0 | 0 | |
Actuarial loss (gain) | $ (821) | (12,953) | (71,700) | 16,464 |
Amortization of prior service cost | 238 | 281 | 267 | |
Other Postretirement Benefit Plans, Defined Benefit [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Service cost | 108 | 95 | 106 | |
Interest cost | 143 | 155 | 135 | |
Expected return on plan assets | (1,062) | (964) | (965) | |
Defined Benefit Plan, Amortization of Gains (Losses) | 971 | (384) | (182) | |
Actuarial loss (gain) | (308) | 141 | ||
Net periodic benefit cost | $ 160 | $ (1,098) | $ (906) |
Employee Benefit Plans (Sched84
Employee Benefit Plans (Schedule of Net Funded Status, Other Postretirement Benefit Plans) (Details) - Other Postretirement Benefit Plans, Defined Benefit [Member] - USD ($) $ in Thousands | 12 Months Ended | ||
Jan. 03, 2016 | Dec. 28, 2014 | Dec. 29, 2013 | |
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate | 4.10% | 4.77% | 3.86% |
Change in benefit obligations: | |||
Projected benefit obligations at beginning of year | $ 3,576 | $ 3,342 | |
Service cost | 108 | 95 | $ 106 |
Interest cost | 143 | 155 | 135 |
Benefits Paid | (158) | (157) | |
Actuarial loss (gain) | (308) | 141 | |
Change in accumulated benefit obligations during the year | (215) | 234 | |
Projected benefit obligations at end of year | 3,361 | 3,576 | 3,342 |
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] | |||
Fair value of plan assets at beginning of year | 14,728 | 13,396 | |
Actual return on plan assets | (375) | 1,332 | |
Benefits Paid | (158) | (157) | |
Fair value of plan assets at end of year | 14,353 | 14,728 | $ 13,396 |
Net amounts recognized in the consolidated balance sheets | 10,992 | 11,152 | |
Defined Benefit Plan, Assets for Plan Benefits, Noncurrent | 10,992 | 11,152 | |
Prior service cost | 0 | 0 | |
Net amounts recognized in accumulated other comprehensive income | $ 0 | $ 0 | |
Discount rate | 4.34% | 4.10% | |
Expected rate of return on assets | 7.25% | 7.25% | 7.50% |
Retirees [Member] | |||
Change in benefit obligations: | |||
Projected benefit obligations at beginning of year | $ 1,033 | $ 1,159 | |
Projected benefit obligations at end of year | 907 | 1,033 | $ 1,159 |
Active Employees Eligible to Retire [Member] | |||
Change in benefit obligations: | |||
Projected benefit obligations at beginning of year | 424 | 388 | |
Projected benefit obligations at end of year | 423 | 424 | 388 |
Other Active Employees [Member] | |||
Change in benefit obligations: | |||
Projected benefit obligations at beginning of year | 2,119 | 1,795 | |
Projected benefit obligations at end of year | $ 2,031 | $ 2,119 | $ 1,795 |
Employee Benefit Plans (Sched85
Employee Benefit Plans (Schedule of Changes in Fair Value of Plan Assets, Other Postretirement Benefit Plans) (Details) - Other Postretirement Benefit Plans, Defined Benefit [Member] - USD ($) $ in Thousands | Jan. 03, 2016 | Dec. 28, 2014 | Dec. 29, 2013 | Dec. 30, 2012 |
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | $ 14,353 | $ 14,728 | $ 13,396 | |
Fair Value, Inputs, Level 1 [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 6,621 | 7,982 | ||
Fair Value, Inputs, Level 2 [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 6,358 | 5,405 | ||
Fair Value, Inputs, Level 3 [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 1,374 | 1,341 | 1,217 | $ 1,194 |
Cash [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 133 | 248 | ||
Cash [Member] | Fair Value, Inputs, Level 1 [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 133 | 248 | ||
Cash [Member] | Fair Value, Inputs, Level 2 [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Cash [Member] | Fair Value, Inputs, Level 3 [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Equity Securities, U.S. Large-cap [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 1,781 | 1,644 | ||
Equity Securities, U.S. Large-cap [Member] | Fair Value, Inputs, Level 1 [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 1,781 | 1,644 | ||
Equity Securities, U.S. Large-cap [Member] | Fair Value, Inputs, Level 2 [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Equity Securities, U.S. Large-cap [Member] | Fair Value, Inputs, Level 3 [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Equity Securities, International large-cap value[Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 1,566 | 1,449 | ||
Equity Securities, International large-cap value[Member] | Fair Value, Inputs, Level 1 [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 1,566 | 1,449 | ||
Equity Securities, International large-cap value[Member] | Fair Value, Inputs, Level 2 [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Equity Securities, International large-cap value[Member] | Fair Value, Inputs, Level 3 [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Equity Securities, Equity Index Funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 622 | 748 | ||
Equity Securities, Equity Index Funds [Member] | Fair Value, Inputs, Level 1 [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 622 | 748 | ||
Equity Securities, Equity Index Funds [Member] | Fair Value, Inputs, Level 2 [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Equity Securities, Equity Index Funds [Member] | Fair Value, Inputs, Level 3 [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Equity Securities, Domestic Real Estate Funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 160 | 164 | ||
Equity Securities, Domestic Real Estate Funds [Member] | Fair Value, Inputs, Level 1 [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 160 | 164 | ||
Equity Securities, Domestic Real Estate Funds [Member] | Fair Value, Inputs, Level 2 [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Equity Securities, Domestic Real Estate Funds [Member] | Fair Value, Inputs, Level 3 [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Equity Securities, Commodity Funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 477 | 427 | ||
Equity Securities, Commodity Funds [Member] | Fair Value, Inputs, Level 1 [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 477 | 427 | ||
Equity Securities, Commodity Funds [Member] | Fair Value, Inputs, Level 2 [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Equity Securities, Commodity Funds [Member] | Fair Value, Inputs, Level 3 [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fixed Income Funds, Corporate Debt Instruments [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 8,045 | 8,499 | ||
Fixed Income Funds, Corporate Debt Instruments [Member] | Fair Value, Inputs, Level 1 [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 1,687 | 3,094 | ||
Fixed Income Funds, Corporate Debt Instruments [Member] | Fair Value, Inputs, Level 2 [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 6,358 | 5,405 | ||
Fixed Income Funds, Corporate Debt Instruments [Member] | Fair Value, Inputs, Level 3 [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fixed Income Funds, High Yield Bonds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 195 | 208 | ||
Fixed Income Funds, High Yield Bonds [Member] | Fair Value, Inputs, Level 1 [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 195 | 208 | ||
Fixed Income Funds, High Yield Bonds [Member] | Fair Value, Inputs, Level 2 [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Fixed Income Funds, High Yield Bonds [Member] | Fair Value, Inputs, Level 3 [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Other Types of Investments, Multi-strategy hedge funds [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 1,374 | 1,341 | ||
Other Types of Investments, Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 1 [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Other Types of Investments, Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 2 [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 0 | 0 | ||
Other Types of Investments, Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 3 [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | 1,374 | 1,341 | 1,217 | 1,184 |
Other Types of Investments, Venture Capital Funds [Member] | Fair Value, Inputs, Level 3 [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Fair value of plan assets | $ 0 | $ 0 | $ 0 | $ 1 |
Employee Benefit Plans (Sched86
Employee Benefit Plans (Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets, Other Postretirement Benefit Plans) (Details) - Other Postretirement Benefit Plan [Member] - USD ($) $ in Thousands | 12 Months Ended | ||
Jan. 03, 2016 | Dec. 28, 2014 | Dec. 29, 2013 | |
Defined Benefit Plan Disclosure [Line Items] | |||
Fair value of plan assets at beginning of year | $ 14,728 | $ 13,396 | |
Realized gains (losses) | (971) | 384 | $ 182 |
Fair value of plan assets at end of year | 14,353 | 14,728 | 13,396 |
Fair Value, Inputs, Level 3 [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Fair value of plan assets at beginning of year | 1,341 | 1,217 | 1,194 |
Unrealized gains (losses) | 33 | 124 | 31 |
Fair value of plan assets at end of year | 1,374 | 1,341 | 1,217 |
Common Collective Trusts [Member] | Fair Value, Inputs, Level 3 [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Fair value of plan assets at beginning of year | 0 | 0 | 9 |
Unrealized gains (losses) | 0 | 0 | (1) |
Fair value of plan assets at end of year | 0 | 0 | 0 |
Venture Capital Funds [Member] | Fair Value, Inputs, Level 3 [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Fair value of plan assets at beginning of year | 0 | 0 | 1 |
Unrealized gains (losses) | 0 | 0 | (1) |
Fair value of plan assets at end of year | 0 | 0 | 0 |
Multi-strategy hedge funds [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Fair value of plan assets at beginning of year | 1,341 | ||
Fair value of plan assets at end of year | 1,374 | 1,341 | |
Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 3 [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Fair value of plan assets at beginning of year | 1,341 | 1,217 | 1,184 |
Unrealized gains (losses) | 33 | 124 | 33 |
Fair value of plan assets at end of year | $ 1,374 | $ 1,341 | 1,217 |
Defined Benefit Plans, Sales and Settlements [Member] | Fair Value, Inputs, Level 3 [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Purchases, issuances, and settlements | (8) | ||
Defined Benefit Plans, Sales and Settlements [Member] | Common Collective Trusts [Member] | Fair Value, Inputs, Level 3 [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Purchases, issuances, and settlements | (8) | ||
Defined Benefit Plans, Sales and Settlements [Member] | Venture Capital Funds [Member] | Fair Value, Inputs, Level 3 [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Purchases, issuances, and settlements | 0 | ||
Defined Benefit Plans, Sales and Settlements [Member] | Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 3 [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Purchases, issuances, and settlements | $ 0 |
Employee Benefit Plans (Sched87
Employee Benefit Plans (Schedule of Expected Benefit Payments, Other Postretirement Benefits) (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Jan. 01, 2017 | Jan. 03, 2016 | |
United States Pension Plan of US Entity, Defined Benefit [Member] | ||
Defined Benefit Plan Disclosure [Line Items] | ||
2,016 | $ 17,950 | |
2,017 | 18,018 | |
2,018 | 18,289 | |
2,019 | 18,469 | |
2,020 | 18,683 | |
2021-2025 | 95,733 | |
Other Postretirement Benefit Plans, Defined Benefit [Member] | ||
Defined Benefit Plan Disclosure [Line Items] | ||
2,016 | 162 | |
2,017 | 171 | |
2,018 | 179 | |
2,019 | 189 | |
2,020 | 197 | |
2021-2025 | 1,154 | |
Foreign Pension Plan, Defined Benefit [Member] | ||
Defined Benefit Plan Disclosure [Line Items] | ||
2,016 | 10,490 | |
2,017 | 11,051 | |
2,018 | 11,466 | |
2,019 | 11,855 | |
2,020 | 12,473 | |
2021-2025 | $ 67,253 | |
Scenario, Forecast [Member] | Foreign Pension Plan, Defined Benefit [Member] | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Defined Benefit Plans, Estimated Future Employer Contributions in Next Fiscal Year | $ 9,300 |
Employee Benefit Plans (Savings
Employee Benefit Plans (Savings Plan) (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Jan. 03, 2016 | Dec. 28, 2014 | Dec. 29, 2013 | |
Defined Benefit Plan Disclosure [Line Items] | |||
Defined Benefit Plan, 401(k) Savings Plan, Employer Contribution Match of Employees Eligible Compensation | 100.00% | ||
Defined Benefit Plan, 401(k) Savings Plan, Maximum Employee Match Percent for Employer Match | 5.00% | ||
Defined Benefit, 401(k) Savings Plan Expense | $ 12.8 | $ 12.2 | $ 12.8 |
Employee Benefit Plans (Supplem
Employee Benefit Plans (Supplemental Executive Retirement Plan) (Details) - Supplemental Employee Retirement Plans, Defined Benefit [Member] - USD ($) $ in Millions | 12 Months Ended | ||
Jan. 03, 2016 | Dec. 28, 2014 | Dec. 29, 2013 | |
Defined Benefit Plan Disclosure [Line Items] | |||
Projected benefit obligation | $ 21.5 | $ 24.5 | |
Fair value of plan assets | 0.6 | 0.5 | |
Pension expense | $ (1.6) | $ 4.8 | $ (0.4) |
Employee Benefit Plans (Nonqual
Employee Benefit Plans (Nonqualified Deferred Compensation Plans) (Details) - USD ($) $ in Millions | Jan. 03, 2016 | Dec. 28, 2014 |
Management [Member] | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Deferred Compensation Arrangement with Individual, Recorded Liability | $ 1.2 | $ 1 |
Contingencies (Details)
Contingencies (Details) $ in Millions | 12 Months Ended | ||
Jan. 03, 2016USD ($)years | Dec. 28, 2014USD ($) | Dec. 29, 2013USD ($) | |
Commitments and Contingencies Disclosure [Abstract] | |||
Accrual for Environmental Loss Contingencies, Component Amount | $ (2.3) | $ 5.7 | |
Management's estimate of total cost of ultimate disposition of known environmental matters | $ 11.8 | $ 12.3 | |
Number of years over which estimated environmental cost will be paid | years | 10 |
Warranty Reserves (Details)
Warranty Reserves (Details) $ in Thousands | 12 Months Ended | ||
Jan. 03, 2016USD ($)years | Dec. 28, 2014USD ($) | Dec. 29, 2013USD ($) | |
Warranty reserve activity | |||
Period of warranty protection beyond date of sale (in years) | years | 1 | ||
Balance beginning of period | $ 10,783 | $ 10,534 | $ 11,003 |
Provision charged to income | 16,904 | 17,447 | 17,291 |
Payments | (16,204) | (16,750) | (17,116) |
Adjustments to previously provided warranties, net | (60) | 73 | (693) |
Foreign currency and acquisitions | (501) | (521) | 49 |
Balance end of period | $ 10,922 | $ 10,783 | $ 10,534 |
Stock Plans (Narrative) (Detail
Stock Plans (Narrative) (Details) | 3 Months Ended | 12 Months Ended | |||
Mar. 29, 2015shares | Jan. 03, 2016USD ($)plan$ / sharesshares | Dec. 28, 2014USD ($)$ / sharesshares | Dec. 29, 2013USD ($)$ / sharesshares | Dec. 30, 2012shares | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Number of Stock-based Compensation Plans | plan | 1 | ||||
Total income tax benefit recognized for stock-based compensation | $ 5,800,000 | $ 5,400,000 | $ 4,400,000 | ||
Stock-based compensation costs capitalized as part of inventory | 200,000 | 300,000 | |||
Options related excess tax benefit, classified as a financing cash activity | 2,435,000 | 0 | 0 | ||
Aggregate intrinsic value for stock options outstanding | $ 42,700,000 | ||||
Weighted average remaining contractual term of options (in years) | 3 years 7 months | ||||
Aggregate intrinsic value for stock options exercisable | $ 36,200,000 | ||||
Weighted average remaining contractual term of options exercisable (in years) | 2 years 6 months | ||||
Number of shares vested and expected to vest in the future | shares | 2,300,000 | ||||
Aggregate intrinsic value of vested and expected to vest stock options | $ 42,100,000 | ||||
Weighted average remaining contractual term for options vested and expected to vest | 3 years 7 months | ||||
Total pre-tax stock-based compensation expense | $ 17,719,000 | $ 14,464,000 | $ 14,053,000 | ||
Deferred compensation liability | $ 5,900,000 | ||||
Performance Units [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Weighted-average grant-date fair value of stock granted (per share) | $ / shares | $ 46.83 | $ 42.84 | $ 34.06 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period | shares | 8,860 | 35,954 | 28,515 | ||
Total pre-tax stock-based compensation expense | $ 4,000,000 | $ 1,600,000 | $ 1,400,000 | ||
Shares/units granted | shares | 66,509 | 79,463 | 98,056 | ||
Awards/units outstanding | shares | 201,415 | ||||
Stock Awards [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Weighted-average grant-date fair value of stock granted (per share) | $ / shares | $ 51.01 | $ 42.14 | $ 30.65 | ||
Total pre-tax stock-based compensation expense | $ 700,000 | $ 700,000 | $ 700,000 | ||
Shares/units granted | shares | 544 | 1,953 | 2,373 | 3,263 | |
Stock award program for non-employees Directors, fair market value | $ 100,000 | $ 100,000 | $ 100,000 | ||
Restricted Stock Awards [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Weighted-average grant-date fair value of stock granted (per share) | $ / shares | $ 46.86 | $ 42.61 | $ 33.87 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period | shares | 52,000 | 94,000 | 75,000 | ||
Fair value of restricted stock awards vested | $ 7,800,000 | $ 7,100,000 | $ 8,000,000 | ||
Total pre-tax stock-based compensation expense | 8,700,000 | $ 7,100,000 | $ 7,500,000 | ||
Total unrecognized compensation cost, net of estimated forfeitures, related to nonvested stock, granted | $ 10,800,000 | ||||
Shares/units granted | shares | 245,000 | 261,000 | 289,000 | ||
Awards/units outstanding | shares | 502,000 | 558,000 | 649,000 | 781,000 | |
Weighted-average period for recognition of unrecognized compensation cost, years | 1 year 3 months | ||||
Option vesting period (in years) | 3 years | ||||
Employee Stock Purchase Plan [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Shares authorized under plan | shares | 5,000,000 | ||||
Weighted-average grant-date fair value of stock granted (per share) | $ / shares | $ 47.08 | $ 41.71 | $ 30.51 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date | 95.00% | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate | 10.00% | ||||
Shares/units granted | shares | 78,294 | 60,870 | 89,521 | ||
Shares available for grant under employee stock purchase plan | shares | 1,000,000 | ||||
Stock Options [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Weighted-average grant-date fair value of options | $ / shares | $ 11.02 | $ 11.86 | $ 10.82 | ||
Total intrinsic value of options exercised | $ 25,900,000 | $ 22,000,000 | $ 13,800,000 | ||
Cash received from option exercises | 14,900,000 | 24,500,000 | 20,300,000 | ||
Total pre-tax stock-based compensation expense | 4,200,000 | $ 5,000,000 | $ 4,400,000 | ||
Total unrecognized compensation cost, net of estimated forfeitures, related to nonvested stock, granted | $ 5,700,000 | ||||
Weighted-average period for recognition of unrecognized compensation cost, years | 1 year 9 months | ||||
Option vesting period (in years) | 3 years | ||||
Stock Options Expiration Period After Date of Grant | 7 years | ||||
Two Thousand Nine Incentive Plan [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Shares authorized under plan | shares | 10,700,000 |
Stock Plans (Summary of Total C
Stock Plans (Summary of Total Compensation Recognized Related to Outstanding Stock Options) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Jan. 03, 2016 | Dec. 28, 2014 | Dec. 29, 2013 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total stock-based compensation expense | $ 17,719 | $ 14,464 | $ 14,053 |
Cost of sales [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total stock-based compensation expense | 1,339 | 1,456 | 1,304 |
Research and development expenses [Member ] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total stock-based compensation expense | 600 | 546 | 853 |
Selling, general and administrative and other expenses [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total stock-based compensation expense | $ 15,780 | $ 12,462 | $ 11,896 |
Stock Plans (Weighted-Average A
Stock Plans (Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model) (Details) | 12 Months Ended | ||
Jan. 03, 2016 | Dec. 28, 2014 | Dec. 29, 2013 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |||
Risk-free interest rate | 1.30% | 1.50% | 0.90% |
Expected dividend yield | 0.60% | 0.70% | 0.80% |
Expected lives, years | 5 years | 5 years | 5 years |
Expected stock volatility | 26.50% | 30.90% | 38.50% |
Stock Plans (Summary of Stock O
Stock Plans (Summary of Stock Option Activity) (Details) - $ / shares shares in Thousands | 12 Months Ended | ||
Jan. 03, 2016 | Dec. 28, 2014 | Dec. 29, 2013 | |
Stock option activity | |||
Shares outstanding at beginning of the year | 2,828 | 3,494 | 4,266 |
Shares granted | 502 | 520 | 518 |
Shares exercised | (849) | (1,024) | (947) |
Shares canceled | (4) | (4) | (8) |
Shares forfeited | (105) | (158) | (335) |
Shares outstanding at end of year | 2,372 | 2,828 | 3,494 |
Shares exercisable at end of year | 1,500 | 1,900 | 2,392 |
Number of shares vested and expected to vest in the future | 2,300 | ||
Weighted-average price, outstanding at beginning of year (per share) | $ 26.11 | $ 23.34 | $ 21.64 |
Weighted-average price, granted (per share) | 46.36 | 43.12 | 33.62 |
Weighted-average price, exercised (per share) | 17.56 | 23.89 | 21.45 |
Weighted-average price, canceled (per share) | 20.20 | 20.97 | 22.88 |
Weighted-average price, forfeited (per share) | 33.90 | 35.33 | 23.04 |
Weighted-average price, outstanding at end of year (per share) | 33.12 | 26.11 | 23.34 |
Weighted-average price, exercisable at end of year (per share) | $ 27.01 | $ 21.13 | $ 20.66 |
Stock Plans (Summary of Restric
Stock Plans (Summary of Restricted Stock Award Activity) (Details) - $ / shares shares in Thousands | 12 Months Ended | ||
Jan. 03, 2016 | Dec. 28, 2014 | Dec. 29, 2013 | |
Restricted Stock Units (RSUs) [Member] | |||
Restricted stock award activity | |||
Performance factor percentage minimum | 0.00% | ||
Performance factor percentage maximum | 200.00% | ||
Restricted Stock Awards [Member] | |||
Restricted stock award activity | |||
Nonvested at beginning of year | 558 | 649 | 781 |
Shares, granted | 245 | 261 | 289 |
Shares, vested | (249) | (258) | (346) |
Shares, forfeited | (52) | (94) | (75) |
Nonvested at end of year | 502 | 558 | 649 |
Weighted-average grant-date fair value, nonvested at beginning of year (per share) | $ 35.51 | $ 29.24 | $ 24.71 |
Weighted-average grant-date fair value of stock granted (per share) | 46.86 | 42.61 | 33.87 |
Weighted-average grant-date fair value, vested (per share) | 31.11 | 27.64 | 22.98 |
Weighted-average grant-date fair value, forfeited (per share) | 40.71 | 33.58 | 28.76 |
Weighted-average grant-date fair value, nonvested at end of year (per share) | $ 42.61 | $ 35.51 | $ 29.24 |
Stockholders' Equity (Narrative
Stockholders' Equity (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 12 Months Ended | |||||||||||||
Apr. 03, 2016 | Jan. 03, 2016 | Oct. 04, 2015 | Jun. 28, 2015 | Mar. 29, 2015 | Dec. 28, 2014 | Sep. 28, 2014 | Jun. 29, 2014 | Mar. 30, 2014 | Dec. 29, 2013 | Jan. 03, 2016 | Dec. 28, 2014 | Dec. 29, 2013 | Oct. 23, 2014 | Oct. 24, 2012 | |
Schedule of Stockholders' Equity [Line Items] | |||||||||||||||
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax | $ 4,800 | ||||||||||||||
Stock repurchase program, number of shares authorized to be repurchased | 8,000,000 | 6,000,000 | |||||||||||||
Cash dividends (per share) | $ 0.07 | $ 0.07 | $ 0.07 | $ 0.07 | $ 0.07 | $ 0.07 | $ 0.07 | $ 0.07 | $ 0.28 | $ 0.28 | |||||
Aggregate cost of repurchased common stock to satisfy statutory tax withholding obligation requirements | $ 4,400 | $ 4,300 | $ 4,400 | ||||||||||||
Number of common stock repurchased in open market | 1,500,000 | 1,400,000 | 3,600,000 | ||||||||||||
Stock repurchase program, number of shares remained available for repurchase | 5,900,000 | 5,900,000 | |||||||||||||
Repurchases of common stock | $ 72,000 | $ 61,300 | $ 123,000 | ||||||||||||
Repurchased shares of common stock to satisfy statutory tax withholding obligation requirements | 95,129 | 98,269 | 127,544 | ||||||||||||
Dividends accrued | $ 7,800 | $ 7,800 | |||||||||||||
Other Comprehensive Loss (Income), Reclassification Adjustment from AOCI on Derivatives, Tax | $ 1,900 | ||||||||||||||
Unrecognized prior service costs, net of tax | $ (316) | $ 146 | (658) | ||||||||||||
Interest Rate Contract [Member] | Interest Expense [Member] | |||||||||||||||
Schedule of Stockholders' Equity [Line Items] | |||||||||||||||
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax | $ (2,800) | $ (2,000) | |||||||||||||
Subsequent Event [Member] | |||||||||||||||
Schedule of Stockholders' Equity [Line Items] | |||||||||||||||
Cash dividends (per share) | $ 0.07 | ||||||||||||||
Number of common stock repurchased in open market | 2,400,000 | ||||||||||||||
Repurchases of common stock | $ 109,700 |
Stockholders' Equity (Component
Stockholders' Equity (Components Of Accumulated Other Comprehensive Loss) (Details) - USD ($) $ in Thousands | 12 Months Ended | |||
Jan. 03, 2016 | Dec. 28, 2014 | Dec. 29, 2013 | Dec. 30, 2012 | |
Cumulative Translation Adjustment Summary [Roll Forward] | ||||
Foreign currency translation adjustment, net of tax, beginning of year | $ 23,332 | $ 76,283 | $ 67,527 | |
Current year change | (70,178) | (52,951) | 8,756 | |
Foreign currency translation adjustment, net of tax, end of year | (46,846) | 23,332 | 76,283 | |
Unrecognized prior service costs, net of tax | 1,259 | 1,575 | 1,429 | $ 2,087 |
Unrecognized prior service costs, net of tax, current year change | (316) | 146 | (658) | |
Unrealized (losses) gains on securities, net of tax | (369) | (107) | (121) | (129) |
Unrealized (losses) gains on securities, net of tax, current year change | (262) | 14 | 8 | |
Reclassification adjustments for losses on derivatives included in net income, net of tax | 0 | 0 | 2,892 | |
Unrealized and realized (losses) gains on derivatives, net of income tax | 0 | 0 | 0 | (2,892) |
Other comprehensive (loss) income | (70,756) | (52,791) | 10,998 | |
Accumulated other comprehensive income (loss) | $ (45,956) | $ 24,800 | $ 77,591 | $ 66,593 |
Derivatives And Hedging Acti100
Derivatives And Hedging Activities (Details) $ in Thousands, € in Millions | 1 Months Ended | 3 Months Ended | 12 Months Ended | ||||||
May. 31, 2008USD ($) | Dec. 29, 2013USD ($) | Jan. 03, 2016USD ($) | Dec. 28, 2014USD ($) | Dec. 29, 2013USD ($) | Jan. 03, 2016EUR (€) | Mar. 29, 2015USD ($) | Dec. 28, 2014EUR (€) | Dec. 30, 2012USD ($) | |
Derivative [Line Items] | |||||||||
Company's business conducted outside United States | 60.00% | ||||||||
Payments for (Proceeds from) Hedge, Financing Activities | $ (18,706) | $ 0 | $ (1,363) | ||||||
Settlement of forward interest rate contracts with notional amounts | $ 150,000 | ||||||||
Accumulated derivative losses in other comprehensive (loss) income, net of taxes | 8,400 | ||||||||
Accumulated derivative losses in other comprehensive (loss) income, tax | $ 5,400 | ||||||||
Accumulated derivative losses related to effective cash flow hedges in accumulated other comprehensive loss, net of taxes | $ 0 | $ 0 | $ 0 | 0 | $ (2,892) | ||||
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax | $ 4,800 | ||||||||
Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months | $ 0 | ||||||||
European And Asian Currencies [Member] | |||||||||
Derivative [Line Items] | |||||||||
Maximum maturity period for foreign exchange contracts, in months | 12 months | ||||||||
Duration of foreign currency derivative contract, days | 30 days | 30 days | 30 days | ||||||
Fair Value Hedging [Member] | |||||||||
Derivative [Line Items] | |||||||||
Derivative, Notional Amount | 138,400 | $ 127,300 | $ 95,000 | $ 138,400 | |||||
Cash Flow Hedging [Member] | |||||||||
Derivative [Line Items] | |||||||||
Derivative, Number of Instruments Held | 5 | 5 | |||||||
Derivative, Notional Amount | € | € 107.4 | € 238.2 | |||||||
Interest Rate Contract [Member] | Interest Expense [Member] | |||||||||
Derivative [Line Items] | |||||||||
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax | $ (2,800) | $ (2,000) | |||||||
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | |||||||||
Derivative [Line Items] | |||||||||
Foreign Currency Contract, Asset, Fair Value Disclosure | $ (2,659) | $ (3,205) |
Fair Value Measurements (Narrat
Fair Value Measurements (Narrative) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||||
Jan. 03, 2016 | Dec. 28, 2014 | Dec. 29, 2013 | Dec. 30, 2012 | Oct. 25, 2011 | |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||||
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High | $ 95,400 | ||||
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value | 57,350 | $ 91 | $ 4,926 | $ 3,017 | |
Asset impairment | $ 0 | 0 | $ 158 | ||
Unamortized Debt Issuance Expense | 6,500 | ||||
Business Combination, Contingent Consideration Arrangements, Maximum Period | 6 years | ||||
Business Combination, Contingent Consideration Arrangements, Weighted Average Period | 2 years | ||||
Line of Credit, Maturing January 8, 2019 [Member] | |||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||||
Unsecured revolving credit facility, amount | $ 700,000 | ||||
Revolving credit facility outstanding balance | 482,000 | 516,000 | |||
Unsecured senior notes, carrying value | 479,600 | 512,800 | |||
Long-term Debt | 479,600 | 512,800 | |||
Unamortized Debt Issuance Expense | 2,400 | 3,200 | |||
2021 Notes [Member] | |||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||||
Unsecured senior notes, face value | 500,000 | $ 500,000 | |||
Unsecured senior notes, carrying value | 495,100 | 494,400 | |||
Long-term Debt | 495,100 | 494,400 | |||
Discount on senior unsecured notes | (2,017) | (2,300) | $ (3,100) | ||
Unamortized Debt Issuance Expense | 2,900 | 3,300 | |||
Unsecured senior notes, fair value | 518,900 | 542,700 | |||
Financing Lease Obligations [Member] | |||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||||
Unsecured senior notes, fair value | 38,200 | $ 39,300 | |||
Vanadis Diagnostics AB [Member] | |||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||||
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High | $ 93,000 | ||||
Vanadis Diagnostics AB [Member] | Minimum [Member] | |||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||||
Projected milestone date | 2,016 | ||||
Fair Value Inputs, Discount Rate | 3.10% | ||||
Conditional probability of success | 85.00% | ||||
Cumulative probability of success | 53.00% | ||||
Vanadis Diagnostics AB [Member] | Maximum [Member] | |||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||||
Projected milestone date | 2,019 | ||||
Fair Value Inputs, Discount Rate | 11.30% | ||||
Conditional probability of success | 95.00% | ||||
Cumulative probability of success | 90.00% |
Fair Value Measurements (Assets
Fair Value Measurements (Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis) (Details) - USD ($) $ in Thousands | Jan. 03, 2016 | Dec. 28, 2014 | Dec. 29, 2013 | Dec. 30, 2012 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value | $ 57,350 | $ 91 | $ 4,926 | $ 3,017 |
Fair Value, Measurements, Recurring [Member] | Carrying Value [Member] | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Marketable securities | (1,586) | (1,568) | ||
Foreign Currency Contract, Asset, Fair Value Disclosure | 2,659 | 3,205 | ||
Foreign exchange derivative liabilities, net | (442) | (302) | ||
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value | 57,350 | 91 | ||
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Marketable securities | (1,586) | (1,568) | ||
Foreign Currency Contract, Asset, Fair Value Disclosure | 0 | 0 | ||
Foreign exchange derivative liabilities, net | 0 | 0 | ||
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value | 0 | 0 | ||
Fair Value, Measurements, Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member] | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Marketable securities | 0 | 0 | ||
Foreign Currency Contract, Asset, Fair Value Disclosure | 2,659 | 3,205 | ||
Foreign exchange derivative liabilities, net | (442) | (302) | ||
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value | 0 | 0 | ||
Fair Value, Measurements, Recurring [Member] | Significant Unobservable Inputs (Level 3) [Member] | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Marketable securities | 0 | 0 | ||
Foreign Currency Contract, Asset, Fair Value Disclosure | 0 | 0 | ||
Foreign exchange derivative liabilities, net | 0 | 0 | ||
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value | $ 57,350 | $ 91 |
Fair Value Measurements (Reconc
Fair Value Measurements (Reconciliation of Beginning and Ending Level 3 Net Liabilities) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Jan. 03, 2016 | Dec. 28, 2014 | Dec. 29, 2013 | |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | |||
Balance beginning of period | $ (91) | $ (4,926) | $ (3,017) |
Additions | (57,353) | 0 | (1,100) |
Payments | (113) | (2,074) | (135) |
Change in fair value (included within selling, general and administrative expenses) | (19) | 2,761 | (944) |
Balance end of period | $ (57,350) | $ (91) | $ (4,926) |
Leases (Details)
Leases (Details) - USD ($) $ in Millions | 12 Months Ended | |||
Jan. 03, 2016 | Dec. 28, 2014 | Dec. 29, 2013 | Aug. 22, 2013 | |
Sale Leaseback Transaction [Line Items] | ||||
Sale Leaseback Transaction, Description of Accounting for Leaseback | The lease is accounted for as an operating lease and the excess of the net proceeds over the net carrying amount of the property are being amortized on a straight-line basis over the initial lease term of 15 years. | |||
Sale Leaseback Transaction, Date | 8/22/2013 | |||
Sale Leaseback Transaction, Gross Proceeds | $ 47.6 | |||
Sale Leaseback Transaction, Lease Terms | 15 years | |||
Sale Leaseback Transaction, Current Period Gain Recognized | $ 1.8 | $ 1.8 | $ 0.6 | |
Sale Leaseback Transaction, Deferred Gain, Gross | $ 26.5 | |||
Sale Leaseback Transaction, Deferred Gain, Net | 22.3 | 24.1 | ||
Sales Leaseback Transaction, Short-Term Deferred Gain | 1.8 | 1.8 | ||
Sales Leaseback Transaction, Long-Term Deferred Gain | 20.5 | 22.3 | ||
Rental expense charged to continiuing operations | 54.4 | $ 54.8 | $ 52.6 | |
Minimum rental commitments in next fiscal year | 51 | |||
Minimum rental commitments due in two years | 34.1 | |||
Minimum rental commitments due in three year | 25.9 | |||
Minimum rental commitments due in four years | 20.2 | |||
Minimum rental commitments due in five years | 16.4 | |||
Minimum rental commitments due in six years and thereafter | $ 48.7 |
Schedule of Sales and Operating
Schedule of Sales and Operating Income from Continuing Operations by Operating Segment (Details) $ in Thousands | 3 Months Ended | 12 Months Ended | |||||||||||
Jan. 03, 2016USD ($) | [1] | Oct. 04, 2015USD ($) | Jun. 28, 2015USD ($) | Mar. 29, 2015USD ($) | Dec. 28, 2014USD ($) | Sep. 28, 2014USD ($) | Jun. 29, 2014USD ($) | Mar. 30, 2014USD ($) | Jan. 03, 2016USD ($)segments | Dec. 28, 2014USD ($) | Dec. 29, 2013USD ($) | ||
Schedule of Segment Reporting Information, by Segment [Line Items] | |||||||||||||
Number of Operating Segments | segments | 2 | ||||||||||||
Sales Revenue, Goods, Net | $ 1,552,638 | $ 1,540,075 | $ 1,498,070 | ||||||||||
Service revenue | 709,721 | 697,144 | 659,516 | ||||||||||
Total revenue | 2,262,359 | 2,237,219 | 2,157,586 | ||||||||||
Operating income from continuing operations | $ 84,724 | $ 75,898 | $ 68,131 | $ 57,381 | $ 30,567 | $ 58,776 | $ 69,637 | $ 51,762 | 286,134 | 210,742 | 227,794 | ||
Interest and other expense (income), net | 42,119 | 41,139 | 64,110 | ||||||||||
Income from continuing operations before income taxes | $ 74,813 | $ 63,954 | $ 57,288 | $ 47,960 | $ 20,647 | $ 47,810 | $ 60,673 | $ 40,473 | 244,015 | 169,603 | 163,684 | ||
Defined Benefit Plan, Recognized Net Gain (Loss) on Mark-to-Market | 12,400 | 75,900 | (17,600) | ||||||||||
Payments for Legal Settlements | 7,000 | ||||||||||||
Loss Contingency Accrual | 3,700 | ||||||||||||
Human Health [Member] | |||||||||||||
Schedule of Segment Reporting Information, by Segment [Line Items] | |||||||||||||
Sales Revenue, Goods, Net | 976,451 | 996,767 | 957,022 | ||||||||||
Service revenue | 400,193 | 387,456 | 368,872 | ||||||||||
Total revenue | 1,376,644 | 1,384,223 | 1,325,894 | ||||||||||
Operating income from continuing operations | [2] | 251,743 | 233,689 | 168,794 | |||||||||
Human Health [Member] | Customer Lists [Member] | |||||||||||||
Schedule of Segment Reporting Information, by Segment [Line Items] | |||||||||||||
Impairment of Intangible Assets (Excluding Goodwill) | 200 | ||||||||||||
Environmental Health [Member] | |||||||||||||
Schedule of Segment Reporting Information, by Segment [Line Items] | |||||||||||||
Sales Revenue, Goods, Net | 576,187 | 543,308 | 541,048 | ||||||||||
Service revenue | 309,528 | 309,688 | 290,644 | ||||||||||
Total revenue | 885,715 | 852,996 | 831,692 | ||||||||||
Operating income from continuing operations | 89,544 | 95,605 | 84,710 | ||||||||||
Corporate [Member] | |||||||||||||
Schedule of Segment Reporting Information, by Segment [Line Items] | |||||||||||||
Operating income from continuing operations | [3],[4] | (55,153) | (118,552) | $ (25,710) | |||||||||
Particular Human Health Case [Member] | |||||||||||||
Schedule of Segment Reporting Information, by Segment [Line Items] | |||||||||||||
Legal Fees | $ 800 | ||||||||||||
Enzo Biochem, Inc. Complaint [Member] | |||||||||||||
Schedule of Segment Reporting Information, by Segment [Line Items] | |||||||||||||
Loss Contingency Accrual, Period Increase (Decrease) | 3,300 | ||||||||||||
Litigation Settlement, Expense | $ 3,400 | ||||||||||||
[1] | The fourth quarter of fiscal year 2015 includes a pre-tax loss of $12.4 million as a result of the mark-to-market adjustment on postretirement benefit plans. The fourth quarter of fiscal year 2014 includes a pre-tax loss of $75.9 million as a result of the mark-to-market adjustment on postretirement benefit plans. See Note 1 for a discussion of this accounting policy. | ||||||||||||
[2] | Legal costs for a particular case in the Human Health segment were $0.8 million for fiscal year 2015. The Company also recognized a $0.2 million pre-tax impairment charge in the Human Health segment in fiscal year 2013. Both of these items have been included in operating income from continuing operations in the Human Health segment. | ||||||||||||
[3] | Activity related to the mark-to-market adjustment on postretirement benefit plans has been included in the Corporate operating loss from continuing operations, and in the aggregate constituted a pre-tax loss of $12.4 million in fiscal year 2015, a pre-tax loss of $75.9 million in fiscal year 2014, and pre-tax income of $17.6 million in fiscal year 2013. | ||||||||||||
[4] | Includes expenses related to litigation with Enzo Biochem, Inc. and Enzo Life Sciences, Inc. (collectively, “Enzo”). Enzo filed a complaint in 2002 that alleged that the Company separately and together with other defendants breached distributorship and settlement agreements with Enzo, infringed Enzo's patents, engaged in unfair competition and fraud, and committed torts against Enzo by, among other things, engaging in commercial development and exploitation of Enzo's patented products and technology. The Company entered into a settlement agreement with Enzo dated June 20, 2014 and during fiscal year 2014 paid $7.0 million into a designated escrow account to resolve this matter, of which $3.7 million had been accrued in previous years and $3.3 million was recorded during fiscal year 2014. In addition, $3.4 million of expenses were incurred and recorded in preparation for the trial during fiscal year 2014. |
Industry Segment and Geograp106
Industry Segment and Geographic Area Information Schedule of Depreciation, Amortization and Capital Expenditures (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Jan. 03, 2016 | Dec. 28, 2014 | Dec. 29, 2013 | |
Segment Reporting Information [Line Items] | |||
Depreciation and amortization expense | $ 112,007 | $ 116,736 | $ 126,879 |
Human Health [Member] | |||
Segment Reporting Information [Line Items] | |||
Depreciation and amortization expense | 81,335 | 92,604 | 100,941 |
Capital expenditures | 16,091 | 16,922 | 22,999 |
Environmental Health [Member] | |||
Segment Reporting Information [Line Items] | |||
Depreciation and amortization expense | 29,213 | 22,101 | 23,556 |
Capital expenditures | 10,352 | 10,428 | 14,433 |
Corporate [Member] | |||
Segment Reporting Information [Line Items] | |||
Depreciation and amortization expense | 1,459 | 2,031 | 2,382 |
Capital expenditures | 3,189 | 1,722 | 1,549 |
Continuing Operations [Member] | |||
Segment Reporting Information [Line Items] | |||
Depreciation and amortization expense | 112,007 | 116,736 | 126,879 |
Capital expenditures | 29,632 | 29,072 | 38,981 |
Discontinued Operations [Member] | |||
Segment Reporting Information [Line Items] | |||
Depreciation and amortization expense | 0 | 339 | 1,590 |
Capital expenditures | $ 0 | $ 213 | $ 10 |
Industry Segment and Geograp107
Industry Segment and Geographic Area Information Schedule of Total Assets by Segment (Details) - USD ($) $ in Thousands | Jan. 03, 2016 | Dec. 28, 2014 | Dec. 29, 2013 |
Schedule of Total Assets, by segment [Line Items] | |||
Assets | $ 4,166,295 | $ 4,127,576 | |
Human Health [Member] | |||
Schedule of Total Assets, by segment [Line Items] | |||
Assets | 2,778,835 | 2,737,824 | $ 2,724,254 |
Environmental Health [Member] | |||
Schedule of Total Assets, by segment [Line Items] | |||
Assets | 1,358,963 | 1,361,270 | 1,182,356 |
Corporate [Member] | |||
Schedule of Total Assets, by segment [Line Items] | |||
Assets | 28,497 | 28,482 | 28,441 |
Net current and long-term assets of discontinued operations [Member] | |||
Schedule of Total Assets, by segment [Line Items] | |||
Assets | 0 | 0 | 5,831 |
Total assets [Member] | |||
Schedule of Total Assets, by segment [Line Items] | |||
Assets | $ 4,166,295 | $ 4,127,576 | $ 3,940,882 |
Industry Segment and Geograp108
Industry Segment and Geographic Area Information Schedule of Revenue by Geographic Area (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Jan. 03, 2016 | Dec. 28, 2014 | Dec. 29, 2013 | |
Sales by Geographic Area [Line Items] | |||
Total sales | $ 2,262,359 | $ 2,237,219 | $ 2,157,586 |
UNITED STATES | |||
Sales by Geographic Area [Line Items] | |||
Total sales | 916,314 | 849,356 | 826,991 |
CHINA | |||
Sales by Geographic Area [Line Items] | |||
Total sales | 312,915 | 276,230 | 254,838 |
UNITED KINGDOM | |||
Sales by Geographic Area [Line Items] | |||
Total sales | 112,763 | 134,614 | 133,611 |
GERMANY | |||
Sales by Geographic Area [Line Items] | |||
Total sales | 105,421 | 107,081 | 99,153 |
ITALY | |||
Sales by Geographic Area [Line Items] | |||
Total sales | 74,744 | 85,433 | 78,120 |
FRANCE | |||
Sales by Geographic Area [Line Items] | |||
Total sales | 74,651 | 84,946 | 81,719 |
JAPAN | |||
Sales by Geographic Area [Line Items] | |||
Total sales | 72,624 | 93,811 | 95,676 |
Other International [Member] | |||
Sales by Geographic Area [Line Items] | |||
Total sales | 592,927 | 605,748 | 587,478 |
Total international [Member] | |||
Sales by Geographic Area [Line Items] | |||
Total sales | $ 1,346,045 | $ 1,387,863 | $ 1,330,595 |
Industry Segment and Geograp109
Industry Segment and Geographic Area Information Schedule of Long-Lived Assets by Geographic Location (Details) - USD ($) $ in Thousands | Jan. 03, 2016 | Dec. 28, 2014 | Dec. 29, 2013 |
Long-lived assets by Geographic Area [Line Items] | |||
Total net long-lived assets | $ 281,370 | $ 284,683 | $ 290,310 |
UNITED STATES | |||
Long-lived assets by Geographic Area [Line Items] | |||
Total net long-lived assets | 192,681 | 192,176 | 208,891 |
CHINA | |||
Long-lived assets by Geographic Area [Line Items] | |||
Total net long-lived assets | 34,494 | 36,797 | 30,682 |
UNITED KINGDOM | |||
Long-lived assets by Geographic Area [Line Items] | |||
Total net long-lived assets | 14,751 | 13,033 | 9,882 |
FINLAND | |||
Long-lived assets by Geographic Area [Line Items] | |||
Total net long-lived assets | 12,203 | 12,758 | 13,635 |
SINGAPORE | |||
Long-lived assets by Geographic Area [Line Items] | |||
Total net long-lived assets | 7,679 | 7,041 | 6,812 |
NETHERLANDS | |||
Long-lived assets by Geographic Area [Line Items] | |||
Total net long-lived assets | 3,835 | 3,614 | 4,037 |
ITALY | |||
Long-lived assets by Geographic Area [Line Items] | |||
Total net long-lived assets | 2,958 | 4,107 | 2,735 |
GERMANY | |||
Long-lived assets by Geographic Area [Line Items] | |||
Total net long-lived assets | 2,171 | 2,493 | 2,591 |
Other International [Member] | |||
Long-lived assets by Geographic Area [Line Items] | |||
Total net long-lived assets | 10,598 | 12,664 | 11,045 |
Total international [Member] | |||
Long-lived assets by Geographic Area [Line Items] | |||
Total net long-lived assets | $ 88,689 | $ 92,507 | $ 81,419 |
Quarterly Financial Informat110
Quarterly Financial Information (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 12 Months Ended | |||||||||||
Jan. 03, 2016 | Oct. 04, 2015 | Jun. 28, 2015 | Mar. 29, 2015 | Dec. 28, 2014 | Sep. 28, 2014 | Jun. 29, 2014 | Mar. 30, 2014 | Jan. 03, 2016 | Dec. 28, 2014 | Dec. 29, 2013 | |||
Quarterly Financial Data [Abstract] | |||||||||||||
Revenue | $ 608,116 | $ 563,436 | $ 563,906 | $ 526,901 | $ 608,390 | $ 542,049 | $ 556,170 | $ 530,610 | $ 2,262,359 | $ 2,237,219 | |||
Gross profit | 282,011 | 254,603 | 252,512 | 235,374 | 277,602 | 243,309 | 247,984 | 235,713 | 1,024,500 | 1,004,608 | |||
Restructuring and contract termination charges, net | 8,752 | (118) | 4,956 | 0 | (579) | 11,092 | 742 | 2,135 | 13,590 | 13,390 | $ 33,892 | ||
Operating income from continuing operations | 84,724 | [1] | 75,898 | 68,131 | 57,381 | 30,567 | 58,776 | 69,637 | 51,762 | 286,134 | 210,742 | 227,794 | |
Income from continuing operations before income taxes | 74,813 | [1] | 63,954 | 57,288 | 47,960 | 20,647 | 47,810 | 60,673 | 40,473 | 244,015 | 169,603 | 163,684 | |
Operating income from continuing operations | 68,484 | [1] | 54,897 | 48,996 | 40,311 | 31,314 | 42,898 | 52,003 | 34,951 | 212,688 | 161,166 | 174,267 | |
Net income | $ 68,254 | [1] | $ 54,863 | $ 48,974 | $ 40,334 | $ 30,787 | $ 42,277 | $ 50,490 | $ 34,224 | $ 212,425 | $ 157,778 | $ 167,212 | |
Basic earnings per share: | |||||||||||||
Income from continuing operations | $ 0.61 | [1] | $ 0.49 | $ 0.43 | $ 0.36 | $ 0.28 | $ 0.38 | $ 0.46 | $ 0.31 | $ 1.89 | $ 1.43 | $ 1.55 | |
Net income | 0.61 | [1] | 0.49 | 0.43 | 0.36 | 0.27 | 0.38 | 0.45 | 0.30 | 1.89 | 1.40 | 1.49 | |
Diluted earnings per share: | |||||||||||||
Income from continuing operations | 0.61 | [1] | 0.48 | 0.43 | 0.36 | 0.28 | 0.38 | 0.46 | 0.31 | 1.88 | 1.42 | 1.54 | |
Net income | 0.61 | [1] | 0.48 | 0.43 | 0.36 | 0.27 | 0.37 | 0.44 | 0.30 | 1.87 | 1.39 | $ 1.47 | |
Cash dividends per common share | $ 0.07 | $ 0.07 | $ 0.07 | $ 0.07 | $ 0.07 | $ 0.07 | $ 0.07 | $ 0.07 | $ 0.28 | $ 0.28 | |||
Defined Benefit Plan, Recognized Net Gain (Loss) on Mark-to-Market | $ 12,400 | $ 75,900 | $ (17,600) | ||||||||||
Tax Adjustments, Settlements, and Unusual Provisions | (7,200) | (7,000) | (24,000) | ||||||||||
Human Health [Member] | |||||||||||||
Quarterly Financial Data [Abstract] | |||||||||||||
Operating income from continuing operations | [2] | $ 251,743 | $ 233,689 | $ 168,794 | |||||||||
[1] | The fourth quarter of fiscal year 2015 includes a pre-tax loss of $12.4 million as a result of the mark-to-market adjustment on postretirement benefit plans. The fourth quarter of fiscal year 2014 includes a pre-tax loss of $75.9 million as a result of the mark-to-market adjustment on postretirement benefit plans. See Note 1 for a discussion of this accounting policy. | ||||||||||||
[2] | Legal costs for a particular case in the Human Health segment were $0.8 million for fiscal year 2015. The Company also recognized a $0.2 million pre-tax impairment charge in the Human Health segment in fiscal year 2013. Both of these items have been included in operating income from continuing operations in the Human Health segment. |